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 Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, 
liver cirrhosis and hepatocellular carcinoma (HCC).  Although the molecular 
mechanisms of HCV pathogenesis remain unclear, HCV proteins are known to 
interact with various host factors and modulate diverse cellular pathways 
including apoptosis.  Modulation of host cell apoptosis contributes to HCV-
associated liver injury.  However, the mechanisms underlying HCV-mediated 
modulation of apoptosis are poorly understood. 
 In this study, we have identified a Bcl-2 homology 3 (BH3) domain in 
the HCV core protein that is essential for its proapoptotic property and for 
specific interaction with the human myeloid cell factor 1 (Mcl-1), a 
prosurvival member of the Bcl-2 family.  Moreover, the overexpression of 
Mcl-1 and the absence of proapoptotic Bax, protected cells against core 
protein-induced apoptosis.  By using peptide mimetics as well as protein 
coexpression, the core protein was found to functionally complement the 
proapoptotic activity of Bad.  Thus, the core protein is a bona fide BH3-only 
protein having properties similar to those of Noxa, a BH3-only member of the 
Bcl-2 family that binds preferentially to Mcl-1.  The BH3 domain of the core 
protein contains three hydrophobic residues that are essential for its 
proapoptotic activity.  Furthermore, the genotype 1b core protein is more 
effective than the genotype 2a core protein in inducing apoptosis due to a 
difference in one of these hydrophobic residues (residue 119).  Substituting 
this residue in the J6/JFH-1 infectious clone (genotype 2a) with the 
corresponding amino acid in the genotype 1b core protein produced a mutant 
X 
virus, J6/JFH-1(V119L), which induced significantly higher levels of 
apoptosis in infected cells than the parental virus.  In addition, the core protein 
of the mutant virus, but not that of the parental J6/JFH-1 virus, interacted with 
endogenous Mcl-1 in infected cells.  Taken together, our findings show that 
the core protein is a novel BH3-only viral homologue that contributes to 
apoptosis induction during HCV infection. 
 Induction of apoptosis by the J6/JFH-1 virus, which lacks a functional 
BH3 domain in the core protein, indicates the presence of alternative pathways 
of HCV-induced apoptosis.  Gene expression profiling of cells infected with a 
cell culture adapted variant of the J6/JFH-1 virus revealed upregulation of 
primarily proapoptotic genes (BIK, FAS, GADD45A and HRK) and 
downregulation of BNIP3 expression.  Interestingly, the expression of Bcl-XL, 
a prosurvival Bcl-2 protein, was also enhanced by HCV infection.  When the 
level of Bcl-XL in infected cells was further increased by stable transfection, 
there was a reduction in HCV-induced apoptosis, viral RNA replication and 
progeny virus release.  When the upregulation of Bcl-XL in infected cells was 
prevented by RNA interference, HCV-infected cells displayed higher levels of 
apoptosis and an initial spike in progeny virus release.  However, enhanced 
apoptosis also resulted in a reduction in viable cell number and lower viral 
RNA replication was observed.  Taken together, our results show that HCV 
can modulate host cell apoptosis via diverse pathways in order to maintain a 
fine balance between cell survival and apoptosis which maximises both viral 
replication and apoptosis-dependent virus release.  
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CHAPTER 1:  INTRODUCTION 
1.1 Hepatitis C virus (HCV) 
1.1.1 Epidemiology 
 HCV infection is a leading cause of chronic hepatitis, liver cirrhosis 
and hepatocellular carcinoma (HCC).  Approximately 2 – 3% of the world’s 
population, or about 130 – 170 million people, are chronically infected with 
HCV and 3 – 4 million new infections are estimated to occur each year 
(WHO, 2011).  Diagnosis of acute HCV infection is difficult as most of the 
cases are asymptomatic (McCaughan et al., 1992).  Only 15 – 25% of infected 
individuals manage to clear the virus within 6 months after onset of acute 
infection while the rest progress to chronic active hepatitis (Alter and Seeff, 
2000; Chen and Morgan, 2006; Thimme et al., 2001).  Liver cirrhosis slowly 
develops in about 10 – 20% of individuals with chronic HCV infection and 
appears to be closely associated with the development of HCC in 1 – 5% of 
chronic HCV patients (Chen and Morgan, 2006; Colombo, 1999; Degos et al., 
2000; NIH, 2002a). 
 HCV has been shown to have a worldwide distribution with high 
prevalence rates of chronic infection in Egypt, Pakistan and China (Lavanchy, 
2011; WHO, 1997, 2000, 2011).  In the United States and Europe, end-stage 
liver disease due to HCV infection is the most common indication for liver 
transplantation (Charlton, 2001).  Hence, hepatitis C presents a major global 
health burden.  To date, there is no vaccine available for the prevention of 
HCV infection and the current standard therapy, a combination of pegylated 
2 
interferon-α and ribavirin (Peg-IFNα-ribavirin), is often poorly tolerated and 
only effective in about 50% of patients (Feld and Hoofnagle, 2005; Houghton 
and Abrignani, 2005; Leroux-Roels, 2005; Zeuzem, 2004).  Recent clinical 
trials have demonstrated that the use of viral protease inhibitors in 
combination with Peg-IFNα-ribavirin may have promising therapeutic 
applications against HCV (Kwo et al., 2010; McHutchison et al., 2010).  
Together with other direct acting antiviral drugs currently in development, 
they may offer major advances in HCV therapy (Ciesek and Manns, 2011). 
1.1.2 Classification 
 Post-transfusion non-A, non-B hepatitis (NANBH) cases were first 
reported in the mid-1970s (Alter et al., 1975; Feinstone et al., 1975; Prince et 
al., 1974).  However, the search for the causative agent of NANBH was 
greatly hampered by the lack of suitable cell culture or animal models for the 
propagation of the unidentified agent.  A breakthrough was achieved through 
the successful transmission of the NANBH agent into chimpanzees and 
subsequent findings suggested that the etiological agent of NANBH would be 
a small, enveloped virus (Bradley et al., 1985; Feinstone et al., 1983; He et al., 
1987; Tabor et al., 1978).  In 1989, immunoscreening of an expression library 
derived from nucleic acids in the plasma of NANBH-infected chimpanzees led 
to the identification of the HCV genome (Choo et al., 1989). 
 Following its discovery, HCV was classified as the prototype member 
of the Hepacivirus genus within the Flaviviridae family (Choo et al., 1991).  
This virus family includes the classical flaviviruses (for example, dengue, 
 3 
yellow fever and tick-borne encephalitis viruses), the animal pestivirus (for 
example, bovine viral diarrhoea virus) and GB viruses A (GBV-A), GBV-B 
and GBV-C (Thiel, 2005).  HCV displays extensive sequence variability 
between different isolates, as well as a diverse population of quasispecies 
within each infected individual (Bukh et al., 1995; Kato et al., 1990; 
Simmonds, 2004).  The high replication rate of HCV together with the lack of 
proofreading capacity by the viral RNA polymerase are responsible for this 
genetic diversity (Neumann et al., 1998). 
 There are six major HCV genotypes (numbered 1 through 6) and more 
than 50 subtypes (designated a, b, c and so on) within these genotypes 
(Simmonds et al., 2005; Simmonds et al., 1993).  The sequence divergence of 
genotypes and subtypes are 30 – 35% and 20 – 25% respectively.  The HCV 
genotypes exhibit differences in their geographical distribution, prevalence, 
pathobiology and response to therapy.  Genotypes 1, 2 and 3 are globally 
distributed while genotypes 4, 5 and 6 are found in more distinct geographical 
locations (WHO, 2009).  A close relationship between hepatic steatosis and 
HCV genotype 3 infection has been described and host genetic factors have 
also been shown to influence the degree of steatosis in patients infected with 
genotype 3 (Mihm et al., 1997; Rubbia-Brandt et al., 2000; Zampino et al., 
2008).  A clinically important difference among HCV genotypes is their 
susceptibility to IFNα-based therapy.  The highly prevalent HCV genotype 1 
has been shown to be more resistant to therapy compared to genotypes 2 and 3 
(Kanai et al., 1992; NIH, 2002b). 
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1.1.3 Genome organization 
 The HCV genome is well characterized as a 9.6 kb single-stranded, 
positive-sense RNA molecule that encodes a large precursor polyprotein of 
approximately 3000 amino acids.  It is composed of a single open reading 
frame (ORF) flanked by highly structured 5’ and 3’ untranslated regions 
(UTRs) (Figure 1.1).  Like other positive-stranded RNA viruses, the HCV 
genome serves as a template for both translation of viral proteins and RNA 
replication.  The 5’ UTR is highly conserved across HCV genotypes and 
possesses a complex secondary structure made up of four distinct domains (I – 
IV) (Honda et al., 1999).  Domains II-IV forms an internal ribosome entry site 
(IRES) that mediates cap-independent translation of the viral RNA (Friebe et 
al., 2001).  Although domain I is not required for IRES activity, domains I and 
II are critical for HCV RNA replication (Kim et al., 2002).  Interaction of an 
abundant liver-specific microRNA (miRNA), miR-122, with binding sites in 
the 5’ UTR has been shown to facilitate viral RNA replication (Jopling et al., 
2006).  HCV RNA replication is also regulated by the 3’ UTR which is 
composed of a variable region, a poly(U/UC) tract and an extremely conserved 
98 nucleotide X-tail at the 3’ end of the HCV genome (Blight and Rice, 1997; 
Friebe and Bartenschlager, 2002; Tanaka et al., 1996).  In addition, the X-tail 
interacts with a cis-acting replication element (CRE) in the NS5B-encoding 
region to form a tertiary RNA structure that is required for RNA replication 
(Friebe et al., 2005; You et al., 2004).  Another long range RNA-RNA 
interaction involving the 5’ and 3’ UTRs is also essential for replication and 




Fig. 1.1.  Genome organization and polyprotein processing of HCV.  The HCV genome is composed of a 5’ untranslated region (UTR), a 
long open reading frame (ORF) and a 3’ UTR (top).  The conserved RNA elements in the 2 UTRs essential for replication and translation 
are shown.  IRES, internal ribosome entry site; C, cytidine; U, uridine.  The translated polyprotein is cleaved co- and post-translationally by 
cellular and viral proteases into ten different products (bottom).  The structural proteins are represented by yellow boxes while the non-
structural (NS) proteins are represented by pink boxes.  Amino acid numbers are shown below each protein and arrows indicate the cleavage 
sites on the HCV polyprotein.  Figure adapted from Rehermann, B. J. Clin. Invest. 119:1745 – 1754 (2009). 
Autoproteolytic
cleavage by HCV 
NS2-NS3 protease
Cleavage by cellular 
signal peptidases
Cleavage by HCV 
NS3-NS4A protease
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1.1.4 Viral proteins 
 The translated polyprotein is processed through a series of co- and 
post-translational cleavage events catalyzed by cellular and viral proteases 
(Figure 1.1).  Cleavage by the endoplasmic reticulum (ER) signal peptidase 
liberates the N-terminal structural (core, E1 and E2) and p7 proteins (Hijikata 
et al., 1991).  Maturation of the core protein is achieved through further 
processing by a signal peptide peptidase to remove the E1 signal peptide 
(McLauchlan et al., 2002).  The C-terminus of the mature core protein is not 
precisely known but lies between residues 170 and 179 (Lai and Ware, 2000; 
McLauchlan, 2000; Ray and Ray, 2001).  Using mass spectrometry analysis, 
the C-terminal end of the mature core protein expressed in Sf9 insect cells or 
293T cells has been identified as Phe177 or Leu179 (Hussy et al., 1996; Ogino 
et al., 2004; Okamoto et al., 2008).  The non-structural (NS) proteins are 
processed by two virally encoded enzymes, the NS2-3 cysteine protease and 
the NS3-4A serine protease.  The NS2-3 protease cleaves at the junction of 
NS2 and NS3 while the NS3-4A protease processes the remaining proteins, 
namely NS4A, NS4B, NS5A and NS5B (Bartenschlager et al., 1993; Eckart et 
al., 1993; Grakoui et al., 1993).  The HCV genome also contains a functional 
alternative reading frame that overlaps with the core protein gene and encodes 
an ARFP/F/core+1 protein (Walewski et al., 2001).  To date, little is known of 
the biological role of the ARFP/F/core+1 protein (Vassilaki and Mavromara, 
2009).  The focus of our study is the nucleocapsid core protein and the 
properties and functions of this protein will be discussed in detail in section 
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1.1.4.2.  The characteristics and roles of the other structural and non-structural 




1.1.4.1   Structural and non-structural proteins 
Table 1.1  Summary of HCV structural and non-structural proteins 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
E1 (192 aa) 
and 
E2 (363 aa) 
The E1 and E2 proteins are Type I 
transmembrane proteins with a large hydrophilic 
N-terminal ectodomain and a short C-terminal 
transmembrane domain (TMD) (Op De Beeck et 
al., 2004).  The envelope proteins are mainly 
retained in the ER and ER retention signals have 
been mapped to the TMDs of E1 and E2 
(Cocquerel et al., 1999; Cocquerel et al., 1998; 
Rouille et al., 2006).  Virion-associated E1 and 
E2 proteins form large covalent heterodimers 
which are stabilized by disulfide bridges 
(Vieyres et al., 2010). 
The ectodomains of both envelope proteins 
undergo extensive post-translational N-linked 
glycosylation in the ER lumen.  The E1 and E2 
proteins harbour up to 6 and 11 putative 
glycosylation sites, respectively (Goffard and 
Dubuisson, 2003). 
Two hypervariable regions (HVR) have been 
identified in the E2 protein sequence.  The first 
27 residues of the E2 ectodomain represent 
HVR1 while amino acid residues 91 to 97 define 
HVR2 (Kato et al., 1992; Weiner et al., 1991). 
The E1-E2 complex plays critical roles in virus 
adsorption, entry and assembly (Bartosch and 
Cosset, 2006).  The E2 protein directly interacts 
with putative HCV receptors including CD81 
and SR-BI (Pileri et al., 1998; Scarselli et al., 
2002).  The N-linked glycans and variable 
regions of the E2 protein have been shown to 
contribute to glycoprotein folding and virus entry 
(Callens et al., 2005; Goffard et al., 2005; 
McCaffrey et al., 2007). 
Based on sequence analysis and computational 
modelling, the E1 protein has been proposed to 
be a truncated class II fusion protein, possibly 
involved in the membrane fusion step (Garry and 
Dash, 2003). 
The E2 protein elicits a neutralizing immune 
response and HVR1 has been shown to be a 
major target of neutralizing antibodies (Farci et 
al., 1996; Schofield et al., 2005).  A recent study 
using antibodies against HVR1 revealed that the 
region plays an important role in virus entry at a 
post-attachment step (Vieyres et al., 2011). 
In vitro studies have shown that the E2 protein 
can interact with and inhibit the activity of 
interferon-inducible protein kinase PKR, thus 
possibly interfering with the antiviral effects of 
interferon (Pavio et al., 2002; Taylor et al., 
1999).  The envelope glycoproteins have been 
shown to induce ER stress and the unfolded 
protein response (Chan and Egan, 2005; 
Liberman et al., 1999).  This may be related to 
the observation that E1 and E2 induce apoptosis 
when transiently expressed (Chiou et al., 2006; 
Ciccaglione et al., 2004).  However, E2 
displayed prosurvival activity when stably 
expressed and a recent study showed that E2-
CD81 interaction protects B cells against 
apoptosis (Chen et al., 2011; Lee et al., 2005). 
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Table 1.1 − Continued 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
p7 (63 aa) The p7 protein is an integral membrane protein 
consisting of two transmembrane segments 
linked by a short cytoplasmic loop with its N- 
and C-termini oriented towards the ER lumen 
(Carrere-Kremer et al., 2002).  When expressed 
from a replication-competent genome, the full 
length p7 protein displayed ER localisation 
(Haqshenas et al., 2007). 
The p7 protein is essential for infectivity of HCV 
in vivo but is not required for RNA replication, 
suggesting a role in virus particle assembly and 
release (Lohmann et al., 1999; Sakai et al., 
2003).  The interactions of p7 with HCV 
structural proteins and/or NS2 may be crucial for 
these processes (Steinmann et al., 2007; Yi et al., 
2007).  The p7 protein may function as a 
viroporin since it has been shown to form 
oligomers with ion channel activity (Montserret 
et al., 2010).  The p7 protein may also be 
required to direct insertion of NS2 into the ER 
membrane (Tedbury et al., 2011). 
It has been proposed that p7 may modulate host 
cell apoptosis by altering mitochondrial 
membrane permeability in a similar manner to 
other viroporins (D'Agostino et al., 2002; Jacotot 
et al., 2001; Rahmani et al., 2000).  Moreover, p7 
and other viroporins have been shown to induce 
caspase-dependent apoptosis in baby hamster 
kidney cells (Madan et al., 2008).  Using a yeast 
two-hybrid system, p7 has been shown to bind 
many human liver proteins including tetraspanins 
and nucleoporin 214ku (NUP14) (Huang et al., 
2005b).  However, the significance of these 
interactions needs to be further investigated. 
NS2 (217 aa) The highly hydrophobic N-terminal domain of 
NS2 is proposed to contain multiple 
transmembrane segments that anchor the protein 
to the ER (Santolini et al., 1995; Yamaga and 
Ou, 2002).  The C-terminal portion of NS2 
contributes to the catalytic activity of the NS2-3 
protease (Pallaoro et al., 2001).  A crystal 
structure of the catalytic domain of the NS2-3 
protease reveals that NS2 forms a dimeric 
cysteine protease with two composite active sites 
(Lorenz et al., 2006). 
Together with the N-terminus of NS3, NS2 
forms the NS2-3 protease responsible for the 
intramolecular cleavage of NS2 from NS3 
(Grakoui et al., 1993).  NS2 is dispensable for 
viral RNA replication in vitro but is essential for 
the production of infectious virus in vivo, 
possibly acting at an early stage of virion 
morphogenesis (Jones et al., 2007; Pietschmann 
et al., 2006). 
NS2 potentially regulates cellular protein levels 
by interfering with transcription or translation.  
Two different studies have described inhibitory 
effects of NS2 on a variety of viral and cellular 
promoters including those involved in cytokine 
production (Dumoulin et al., 2003; Kaukinen et 
al., 2006).  NS2 has been shown to inhibit CIDE-
B-induced apoptosis through direct interaction 
and possibly by preventing CIDE-B dimerization 
or mitochondrial localization (Erdtmann et al., 
2003).  In addition, transient and stable 
expression of NS2 has been shown to inhibit cell 
proliferation (Yang et al., 2006). 
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Table 1.1 − Continued 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
NS3 (631 aa) 
and 
NS4A (54 aa) 
The N-terminal domain of NS3 contains serine 
protease activity (Gallinari et al., 1998).  The 
NS3 serine protease domain adopts a 
chymotrypsin-like fold with two β-barrel 
subdomains (Love et al., 1996).  The C-terminal 
domain of NS3 contains RNA helicase/NTPase 
activity (Gallinari et al., 1998).  The NS3 
helicase couples unwinding of RNA to ATP 
hydrolysis and belongs to the DExH/D-box 
helicase superfamily 2 (Tai et al., 1996).  Crystal 
structures of the helicase domain revealed that it 
is composed of three subdomains of similar size 
(Kim et al., 1998; Yao et al., 1997).  The NS3 
helicase can function as a monomer or oligomer 
depending on the concentrations of substrate and 
enzyme available (Jennings et al., 2009). 
The central portion of NS4A contributes one β-
strand to the NS3 protease domain while the 
hydrophobic N-terminal portion of NS4A forms 
a transmembrane α-helix that targets the NS3-4A 
complex to the ER (Kim et al., 1996; Lin et al., 
1995; Wolk et al., 2000). 
 
The NS3-4A protease is responsible for the 
polyprotein processing of the non-structural 
proteins downstream of NS3 (Bartenschlager et 
al., 1995; Failla et al., 1994).  NS4A functions as 
a cofactor for the protease and enhances the 
protease activity of the NS3-4A complex in 
polyprotein processing (Tanji et al., 1995). 
The NS3 helicase may function to unwind stem-
loop structures and replicative double-stranded 
RNA products, eliminate stable RNA secondary 
structures and/or remove nucleic acid binding 
proteins during viral RNA replication.  The NS3 
helicase activity is positively regulated by 
interactions between the serine protease and 
helicase domains as well as by the presence of 
NS4A (Frick et al., 2004; Pang et al., 2002).  
Recently, modulation of NS3 helicase activity by 
NS5B has also been described (Jennings et al., 
2008). 
The C-terminus of NS4A plays a role in viral 
RNA replication and virus assembly through 
interactions with other replicase components 
(Lindenbach et al., 2007; Phan et al., 2011). 
 
The NS3-4A protease has been shown to 
interfere with innate immune sensing in the host 
cell.  It disrupts the retinoic acid-inducible gene I 
(RIG-I) viral RNA-sensing pathway by cleaving 
and inactivating a crucial adaptor protein of the 
pathway, MAVS/Cardif/IPS-1/VISA (Bellecave 
et al., 2010; Li et al., 2005b; Meylan et al., 
2005).  In addition, it cleaves TRIF/TICAM-1, a 
key adaptor protein of the Toll-like receptor 3 
(TLR3) double-stranded RNA-sensing pathway 
(Li et al., 2005a).  Inhibition of RIG-I and TLR3 
signalling blocks the cellular interferon antiviral 
response.  The NS3-4A also cleaves T-cell 
protein tyrosine phosphatase which results in 
enhanced epithelial growth factor-induced 
signalling (Brenndorfer et al., 2009). 
Cleavage of MAVS by the NS3-4A protease also 
results in inhibition of MAVS-induced apoptosis 
(Lei et al., 2009).  Moreover, NS3 may suppress 
host cell apoptosis by interacting with p53 and 
inhibiting p53-mediated transcriptional 
activation (Deng et al., 2006; Tanaka et al., 
2006).  On the other hand, several other studies 
have described proapoptotic activities for both 
NS3 and NS4A (Nomura-Takigawa et al., 2006; 
Prikhod'ko et al., 2004; Thoren et al., 2004). 
 11 
Table 1.1 − Continued 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
NS4B 
(261 aa) 
NS4B is a small hydrophobic protein which is 
predicted to contain four transmembrane 
segments, a cytosolic C-terminus and an N-
terminus with dual topology (Lundin et al., 
2003).  Different studies have shown that the N- 
or C-terminus may be involved in targeting 
NS4B to the ER (Elazar et al., 2004; Gouttenoire 
et al., 2009; Liefhebber et al., 2009).  NS4B has 
been reported to be palmitoylated at two C-
terminal cysteine residues and to form oligomers 
(Yu et al., 2006).  A nucleotide-binding motif 
has been identified in NS4B (Einav et al., 2004). 
NS4B induces the formation of a membranous 
web that may serve as a scaffold for the 
replication complex (Egger et al., 2002).  NS4B 
is essential for HCV RNA replication and may 
also have a role in virus assembly (Blight, 2007; 
Jones et al., 2009).  In relation to its nucleotide-
binding motif, NS4B has been shown to possess 
both adenylate kinase and nucleotide hydrolase 
activities (Einav et al., 2004; Thompson et al., 
2009).  However, the functions of these 
enzymatic activities in HCV replication are still 
unclear. 
NS4B has been shown to induce ER stress and 
the unfolded protein response (Li et al., 2009; 
Zheng et al., 2005).  Furthermore, direct 
interaction between NS4B and ATF6, an ER 
membrane transducer, has been reported (Tong 
et al., 2002).  NS4B also enhances the expression 
of sterol regulatory element-binding proteins via 
the phosphatidylinositol-3 kinase (PI3K) 
pathway, leading to cellular lipid accumulation 
(Park et al., 2009).  The nucleotide-binding motif 
of NS4B has been shown to contribute to cellular 
transformation (Einav et al., 2008).  NS4B also 
has been implicated in the suppression of RIG-I-
mediated interferon antiviral response (Tasaka et 




Table 1.1 − Continued 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
NS5A 
(448 aa) 
NS5A is predominantly hydrophilic and contains 
an N-terminal amphipathic helix which serves as 
an in-plane anchor in the cytosolic leaflet of the 
membrane bilayer (Penin et al., 2004).  NS5A 
has been reported to localise to the perinuclear 
regions of ER and lipid droplets (Brass et al., 
2002; Shi et al., 2002).  Besides the N-terminal 
helix, NS5A can be defined by three distinct 
domains, of which domain I is best characterized 
(Tellinghuisen et al., 2004).  A crystal structure 
of domain I revealed that it is composed of a 
basic N-terminal subdomain IA containing four 
conserved cysteine residues that coordinate a 
zinc ion, and an acidic C-terminal subdomain IB 
(Tellinghuisen et al., 2005).  Dimerization of 
domain I results in the formation of a cytosolic-
facing basic groove.  NS5A exists in basally 
phosphorylated (p56) and hyperphosphorylated 
forms (p58).  Hyperphosphorylation is dependent 
on the presence of other NS proteins (Kaneko et 
al., 1994; Koch and Bartenschlager, 1999; Liu et 
al., 1999; Neddermann et al., 1999).   
NS5A is essential for HCV replication and forms 
part of the viral replicase complex (Mottola et 
al., 2002; Shimakami et al., 2004).  The groove 
formed by the NS5A dimer is proposed to 
accommodate and protect the viral RNA during 
replication and consistent with this, NS5A has 
been shown to bind HCV RNA (Huang et al., 
2005a).  The phosphorylation state of NS5A 
modulates the efficiency of viral RNA 
replication and the hyperphosphorylated form 
correlates with reduced replication, probably 
through inhibition of NS5A-hVAP-A interaction 
(Appel et al., 2005; Evans et al., 2004; 
Neddermann et al., 2004). 
 
The central portion of NS5A contains the 
interferon-α sensitivity-determining region 
(ISDR) which has been shown to mediate 
interaction with the cellular interferon-induced 
double-stranded RNA-activated protein kinase 
PKR (Enomoto et al., 1995; Gale et al., 1997).  
Thus, NS5A possibly modulates the host 
interferon response.  Numerous studies have 
shown that NS5A can interact with various 
cellular proteins and modulate diverse cell 
signalling pathways (He et al., 2006).  These 
include the MAPK mitogenic, Src kinase and 
PI3K-AKT cell survival pathways.  In addition, 
NS5A has been reported to modulate cell 
proliferation and apoptosis through PKR and 
p53-dependent or -independent mechanisms 
(Gale et al., 1999; Lan et al., 2002; Siavoshian et 
al., 2004).  Inhibition of TNF-induced apoptosis 
by NS5A is mediated by its interaction with 
adaptor proteins of the TNF receptor (Majumder 
et al., 2002; Park et al., 2003).  NS5A may also 
function as a prosurvival Bcl-2 homologue that 
sequesters Bax and thus, inhibits apoptosis 
induction (Chung et al., 2003).  A recent study 
showed that NS5A can activate a calpain 
cysteine protease that degrades Bid, leading to 
apoptosis inhibition (Simonin et al., 2009). 
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Table 1.1 − Continued 
Protein Protein characteristic(s) Protein function(s) Effect(s) on host cellular processes 
NS5B 
(591 aa) 
NS5B contains a C-terminal hydrophobic (21 aa) 
domain that mediates post-translational 
membrane association and ER localisation 
(Ivashkina et al., 2002; Schmidt-Mende et al., 
2001).  The catalytic domain of NS5B is located 
in the cytoplasm and forms a typical right-
handed polymerase structure with fingers, palm 
and thumb subdomains and a fully enclosed 
active site (Ago et al., 1999; Bressanelli et al., 
1999; Lesburg et al., 1999).  NS5B contains the 
hallmark GDD sequence motif that is essential 
for polymerase activity (Yamashita et al., 1998).  
Evidence suggests that NS5B functions as an 
oligomer with cooperative RNA synthesis 
activity (Qin et al., 2002; Wang et al., 2002).  
NS5B serves as the RNA-dependent RNA 
polymerase (RdRp) of HCV (Behrens et al., 
1996).  Viral RNA replication proceeds via the 
synthesis of a complementary negative-sense 
RNA which then serves as the template for 
synthesis of genomic positive-sense RNA.  
NS5B is an error-prone enzyme and lacks 
proofreading capacity, thus contributing to a high 
rate of misincorporation and genetic diversity.  
The membrane anchor of NS5B is dispensable 
for polymerase activity in vitro but required for 
RNA replication in cells (Moradpour et al., 
2004).  In addition to modulation by other viral 
factors, the polymerase activity of NS5B has 
been shown to be enhanced by cyclophilin B 
interaction (Piccininni et al., 2002; Shirota et al., 
2002; Watashi et al., 2005). 
NS5B has been shown to interact with cellular 
IκB kinase and prevent TNF-α-induced 
activation of NF-κB.  In addition, TNF-α-
mediated JNK activity was observed to be 
synergistically enhanced by NS5B (Choi et al., 
2006).  It was reported that NS5B interacts with 
retinoblastoma tumour suppressor protein and 
targets it for degradation, resulting in activation 
of E2F-responsive promoters and cell 
proliferation (Munakata et al., 2005). 
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1.1.4.2   Core protein 
 The 21 kDa mature core protein is thought to constitute the HCV 
nucleocapsid and is the predominant form detected in virus particles purified 
from the sera of patients with chronic HCV infection (McLauchlan, 2000; 
Yasui et al., 1998).  It has also been reported that the maturation of the core 
protein is required for the production of HCV using the Japanese fulminant 
hepatitis-1 (JFH-1) infectious clone (Targett-Adams et al., 2008).  The highly 
conserved core protein is composed of two distinct domains of varying 
hydrophobicity (Bukh et al., 1994).  The N-terminal two-third of the protein 
constitutes domain 1 (D1) which contains a high proportion of basic residues 
together with two short hydrophobic regions.  The core protein has been 
shown to interact with viral RNA through the first 75 residues of D1 (Santolini 
et al., 1994).  More recently, the in vivo interaction between the core protein 
and both the 5’ and 3’ UTRs has been described (Yu et al., 2009).  D1 has also 
been implicated in the oligomerization of the core protein (Matsumoto et al., 
1996).  The ability to bind viral RNA and homo-oligomerization of the core 
protein are consistent with its perceived role as the viral nucleocapsid, as is its 
interaction with viral envelope glycoprotein E1 (Lo et al., 1996).  Moreover, 
the core protein-E1 interaction has been shown to be dependent on the 
oligomerization of the core protein (Nakai et al., 2006).  Recently, mutational 
analysis using the HCV cell culture (HCVcc) infection system has led to the 
identification of four basic residues (R50, K51, R59 and R62) in D1 that are 
essential for the production of infectious virus at a post-nucleocapsid assembly 
step (Alsaleh et al., 2010). 
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 In contrast to D1, the C-terminal domain 2 (D2) of the core protein is 
less basic and more hydrophobic (Bukh et al., 1994).  The core protein shows 
a cytoplasmic distribution through association with ER, lipid droplets and 
membranous webs possibly derived from ER membranes (Barba et al., 1997; 
Moradpour et al., 1996).  Boulant and colleagues demonstrated that D2 
mediates the core protein-lipid droplet interaction and that this interaction is 
critical for the production of infectious particles (Boulant et al., 2006; Boulant 
et al., 2007).  It has been suggested that lipid droplets provide a platform for 
virus assembly following core protein-mediated recruitment of non-structural 
proteins and replication complexes to these sites (Miyanari et al., 2007).  
However, recent research using infectious clones of different infectivities 
suggested that p7- and NS2-mediated ER localization of the core protein is 
required for efficient virus assembly (Boson et al., 2011). 
 Besides its role in the encapsidation of viral RNA, the core protein has 
been shown to interact with numerous host proteins and interfere with various 
cellular pathways, including apoptosis, cell signalling, transcriptional 
activation, carcinogenesis, lipid metabolism and immune modulation.  
However, due to the lack of cell culture infection systems and suitable small 
animal models, most of the early studies on the core protein (and other viral 
proteins) relied heavily on heterologous expression systems that produce 
unphysiologically high levels of protein.  Thus, in some cases, conflicting data 
have been reported and more importantly, it remains to be seen if these 
interactions occur in the course of a natural infection. 
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 The core protein has been reported to inhibit as well as promote 
apoptosis via diverse pathways, depending on the death stimuli and types of 
cells used.  For instance, several studies have demonstrated that the core 
protein acts as a positive regulator of Fas-mediated apoptosis in different cell 
lines (Hahn et al., 2000; Moorman et al., 2003; Ruggieri et al., 1997).  
Interestingly, the C-terminal of the core protein has been shown to induce Fas 
ligand-independent apoptosis in Jurkat cells by directly facilitating Fas 
receptor aggregation (Moorman et al., 2003).  In addition to the Fas signalling 
pathway, the core protein also enhanced tumour necrosis factor (TNF)-induced 
apoptosis through direct interaction with the death domains of TNF receptor-1 
and Fas-associated death domain (FADD) protein (Zhu et al., 1998; Zhu et al., 
2001).  Furthermore, interaction of the core protein with two other members of 
the TNF- and TNF receptor-like family, lymphotoxin-β receptor and TRAIL, 
have been shown to sensitize cells to apoptosis (Chen et al., 1997; Chou et al., 
2005).  However, contrary to these findings, several other studies have 
demonstrated core protein-mediated inhibition of Fas- and TNF-induced 
apoptosis via NF-κB activation, STAT3 activation or regulation of cellular 
FLICE inhibitory protein levels (Kawamura et al., 2006; Marusawa et al., 
1999; Saito et al., 2006).  Apoptotic signalling via the transforming growth 
factor-β (TGF-β) pathway was also inhibited through direct interaction of the 
core protein with Smad3, an important apoptosis modulator acting 
downstream of TGF-β-receptor-I/II (Pavio et al., 2005). 
 Modulation of the intrinsic or mitochondrial apoptotic pathway by the 
core protein has also been demonstrated.  Expression of the core protein has 
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been reported to be associated with the induction of oxidative and ER stress, 
which then leads to apoptosis (Benali-Furet et al., 2005; Kang et al., 2009).  
For instance, binding of the core protein to Hsp60, a mitochondrial 
chaperonin, has been shown to trigger production of reactive oxygen species 
(ROS), which then enhanced sensitization to TNF-induced apoptosis (Kang et 
al., 2009).  Interaction between the core protein and the 14-3-3ε protein also 
promoted apoptosis induction through indirect activation of Bax, a 
proapoptotic member of the Bcl-2 family (Lee et al., 2007).  On the other 
hand, the core protein was shown to protect cells against apoptosis by 
upregulating the expression of prosurvival Bcl-XL (Hara et al., 2006; Otsuka et 
al., 2002; Yoshida et al., 2002).  Also, binding of the core protein to p53 or its 
interacting partners may lead to the induction or inhibition of p53-mediated 
apoptosis (Cao et al., 2004; Herzer et al., 2005; Kao et al., 2004; Otsuka et al., 
2000).  For example, the core protein was reported to bind to and interfere 
with the coactivator function of promyelocytic leukemia (PML)-IV, thus 
inhibiting the expression of downstream proapoptotic p53 target genes (Herzer 
et al., 2005).  Overall, although the resultant effect of the core protein on host 
cell apoptosis is still unclear, these studies have highlighted several signalling 
pathways that are possibly regulated by the core protein. 
 The modulation of apoptosis by the core protein may contribute to 
hepatocarcinogenesis (Yoshida et al., 2002).  Consistent with this, several 
studies proposed that the core protein may function as a cofactor in the 
development of HCC (Chang et al., 1998; Kamegaya et al., 2005; Ray et al., 
1996).  Furthermore, the core protein has been shown to induce HCC in 
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transgenic mice and promote immortalization and malignant transformation of 
primary human liver cells (Moriya et al., 1998; Ray et al., 2000; Shan et al., 
2005).  Aside from the inhibition of apoptosis, the core protein has been 
reported to promote cellular transformation through interaction with 
transcription factors and other proteins that regulate cell proliferation and 
growth arrest.  Using a yeast two-hybrid system, heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) was identified as a core protein-interacting 
partner (Hsieh et al., 1998).  HnRNP K is a multifunctional protein that is 
involved in signal transduction, chromation remodelling, transcription, 
splicing and translation processes (Bomsztyk et al., 2004).  It has been 
proposed that specific binding of the core protein to hnRNP K disrupts its 
many functions, including its suppressive effect on transcription, which may 
have implications for carcinogenesis (Hsieh et al., 1998).  Another study 
demonstrated that the core protein inactivated transcription factor leucine-
zipper protein (LZIP) through sequestration in the cytoplasm and the loss of 
LZIP function was associated with cellular transformation (Jin et al., 2000).  
The core protein has also been found to modulate the expression of cyclin-
dependent kinase inhibitor p21, an important regulator of cell cycle 
progression (Kwun and Jang, 2003; Lee et al., 2002).  Lee et. al. suggested 
that the core protein suppresses p21 transcription through inhibition of a TGF-
β pathway, thus promoting cell proliferation (Lee et al., 2002).  Consistent 
with this, a recent study demonstrated that the core protein may switch TGF-β 
growth inhibitory effects to tumour promoting responses in hepatocytes by 
decreasing Smad3 activation (Battaglia et al., 2009).  Nuclear translocation of 
the core protein was observed through its interaction with isoforms of p73, a 
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member of the p53 tumour suppressor family (Alisi et al., 2003).  This 
interaction prevents cell growth arrest mediated by p73α, but not by p73β, in a 
p53-dependent manner. 
 There is increasing evidence suggesting that HCV-related hepatic 
steatosis may contribute to the development of HCC (Moriya et al., 1998; 
Ohata et al., 2003).  The close association of the core protein with lipid 
droplets suggests that this viral protein might induce changes in lipid 
metabolism that result in intrahepatic accumulation of triglycerides.  In 
agreement with this, the core protein has been shown to induce steatosis in 
transgenic mice (Moriya et al., 1997).  Gene expression analysis of core 
protein-expressing cells and mice revealed that the core protein downregulated 
lipid metabolism-associated gene expression and also reduced the expression 
of peroxisome proliferator-activated receptor α (PPARα), a major regulator of 
fatty acid degradation in hepatocytes (Yamaguchi et al., 2005).  Furthermore, 
the direct interaction of the core protein with the nuclear proteasome activator 
PA28γ in transgenic mice has been shown to upregulate genes involved in 
fatty acid biosynthesis (Moriishi et al., 2007).  The core protein also binds to 
and activates retinoid X receptor-α (RXR-α), a transcription factor that 
regulates many cellular functions, including lipid synthesis (Tsutsumi et al., 
2002).  As mentioned earlier, the core protein has been shown to induce 
oxidative stress and it was suggested that ROS production leads to the 
accumulation of intrahepatic lipid peroxidation products which impair very-
low-density lipoprotein (VLDL) secretion (Lerat et al., 2002). 
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 The core protein has been proposed to play an immunomodulatory role 
through its interaction with the complement receptor gC1qR (Kittlesen et al., 
2000).  Proliferation of T lymphocytes and the production of IL-2 and IFN-γ 
were shown to be inhibited by core protein-gC1qR interaction, thus leading to 
the suppression of T cell responsiveness which in turn ensures viral 
persistence (Soguero et al., 2002; Yao et al., 2001).  Interestingly, the core 
protein has been reported to be secreted from cultured cells and free 
circulating core protein has also been detected in the plasma of HCV-infected 
individuals (Maillard et al., 2001; Sabile et al., 1999).  This suggests that prior 
to the production of anti-core antibodies during the early acute phase of HCV 
infection, the circulating core protein could inhibit T cell responses by 
interacting with gC1qR on peripheral T lymphocytes.   
 The N-terminal of the core protein has been demonstrated to interact 
with a cellular DEAD-box RNA helicase DDX3 (Mamiya and Worman, 1999; 
Owsianka and Patel, 1999; You et al., 1999).  Using the HCVcc infection 
system, DDX3 was shown to be essential for HCV replication (Ariumi et al., 
2007).  However, it was recently reported that the requirement of DDX3 for 
HCV replication is unrelated to its interaction with the core protein (Angus et 
al., 2010).  Therefore, the biological function(s) of the core protein-DDX3 
interaction remains to be determined.  
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1.1.5 HCV life cycle 
 HCV derived from patients, infected animals and tissue culture exists 
in various forms.  This heterogeneity arises due to the association of HCV 
with low-density lipoproteins (LDL) and VLDL and the presence of 
immunocomplexed and free virions (Andre et al., 2002; Hijikata et al., 1993; 
Lindenbach et al., 2005; Thomssen et al., 1993).  In both animal models and 
tissue culture systems, low density virion fractions were observed to be more 
infectious, suggesting a possible role for plasma lipoproteins in virus entry 
(Bradley et al., 1991; Lindenbach et al., 2005).  HCV displays a distinct host 
species specificity and tissue tropism, naturally infecting only humans and 
chimpanzees with hepatocytes being the main target cells.  The restricted 
tropism of HCV probably reflects a requirement for specific host factors at one 
or more stages of its life cycle, which comprises viral entry, translation and 
RNA replication, virion assembly and release of progeny virus (Figure 1.2). 
 HCV entry is a complex multistep process which is initiated by the 
adsorption of HCV to the target cell.  The current model of HCV entry 
involves the initial interaction of HCV with the highly sulfated 
glycosaminoglycan (GAG) heparan sulfate and/or the LDL receptor on the 
surface of host cells (Barth et al., 2003; Molina et al., 2007).  The latter may 
be mediated by HCV-associated LDL and VLDL (Thomssen et al., 1992).  
Inhibition of these interactions through enzymatic treatment, antibody 
blocking or host gene silencing resulted in reduced HCV attachment and/or 
infection (Germi et al., 2002; Owen et al., 2009).  However, these two host 
factors have yet to be conclusively proven to be essential for HCV entry. 
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Fig. 1.2.  Current model of the HCV life cycle. 
Figure adapted from Joyce, M. A. Microb. Infect. 12(4): 263 – 271 (2010). 
 Following initial attachment, the HCV E2 glycoprotein interacts with 
scavenger receptor B type 1 (SR-B1), which also acts as a receptor for LDL 
(Acton et al., 1994; Scarselli et al., 2002).  Some studies have shown that this 
interaction is required for subsequent binding of HCV to tetraspanin CD81, 
the first putative HCV receptor identified (Kapadia et al., 2007; Pileri et al., 
1998; Zeisel et al., 2007).  Numerous studies have confirmed the relevance of 
CD81 in HCV entry as a co-receptor and it appears to function in a post-HCV 
binding step (Cormier et al., 2004; Evans et al., 2007).  It has been proposed 
that the binding of HCV E2 to CD81 activates Rho GTPases and results in 




virus encounters two other co-receptors, claudin-1 (CLDN1) and occludin 
(OCLN) (Evans et al., 2007; Ploss et al., 2009; Schwarz et al., 2009).  The 
virus is then internalized via pH-dependent, clathrin-mediated endocytosis 
(Blanchard et al., 2006).  Although the mechanisms underlying viral-host 
membrane fusion are still poorly understood, the acidic environment within 
the early endosome is thought to trigger E1-E2 glycoprotein-mediated fusion 
of virus envelope and endosomal membrane, thereby releasing the viral 
genome into the cytoplasm (Haid et al., 2009; Lavillette et al., 2007).  In 
addition, CD81-independent cell-to-cell transmission of HCV has also been 
described and this poorly understood process may be mediated by tight 
junction proteins (Timpe et al., 2008; Valli et al., 2007). 
 As discussed earlier, translation of the viral RNA is initiated by 
ribosome-binding of the 5’ UTR IRES (Friebe et al., 2001).  This process is 
positively regulated by the 3’ UTR and negatively regulated by NS4A 
(Bradrick et al., 2006; Kou et al., 2006; Song et al., 2006).  In addition, viral 
protein synthesis has been shown to be regulated by several host cell factors.  
The liver-specific miRNA, miR-122, interacts with the 5’ UTR and promotes 
initiation of translation by facilitating the binding of ribosomes to the viral 
RNA (Henke et al., 2008; Jopling et al., 2005).  Recently, it was reported that 
autophagy proteins are required for the translation of HCV RNA (Dreux et al., 
2009).  Following precursor polyprotein processing, the E1 and E2 proteins 
are glycosylated and retained in the ER (Duvet et al., 2002). 
 Formation of the HCV replication complex induces extensive 
rearrangement of intracellular membranes.  This includes generation of an ER-
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derived membranous web, reorganization of cellular endosomal components 
and enhanced formation and localization of lipid droplets (Berger et al., 2009; 
Egger et al., 2002; Piodi et al., 2008).  The N-terminal domain of NS4B 
appears to play a dominant role in membranous web formation and correct 
localization of the replication complex proteins while its C-terminal domain 
induces relocation of Rab-5, a component of early endosomes, to viral 
replication sites (Aligo et al., 2009; Elazar et al., 2004).  As mentioned 
previously, the core protein alters cellular lipid metabolism and it is observed 
to be directly associated with lipid droplets in close proximity to the 
membranous web (Miyanari et al., 2007).  The core protein and ER-associated 
NS5A are proposed to cooperatively recruit viral RNA and other replication 
components to the membranous web which possibly provides a platform for 
the replication complex and protects it from host antiviral responses. 
 Similar to other positive-stranded RNA viruses, HCV RNA replication 
by the RNA-dependent RNA polymerase (RdRp) NS5B occurs via a negative-
stranded RNA intermediate (Behrens et al., 1996).  Prior to this, the NS3 
helicase may function to unwind secondary structures in the template RNA 
(Kim et al., 1995).  It was recently reported that cyclophilin A (Cyp A) is an 
essential host factor for viral RNA replication while cellular Cyp B can 
enhance synthesis of viral RNA through its interaction with NS5B (Heck et 
al., 2009; Kaul et al., 2009; Yang et al., 2008).  Subsequently, the sense viral 
RNA produced may be used for viral protein synthesis or packaged as 
genomic RNA of new virus particles.  Although the precise mechanisms for 
the formation and release of infectious HCV particles are still unknown, 
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Gastaminza et. al. have shown that virus assembly takes place within the ER 
and that HCV possibly utilises the VLDL secretion pathway to exit the cell 
(Gastaminza et al., 2008).  Consistent with this, inhibition of apolipoprotein B 
synthesis and microsomal triglyceride transfer protein activity, both of which 
are important factors for VLDL assembly and secretion, prevented production 
of infectious virus. 
1.1.6 Model systems for studying HCV 
 Aside from the heterologous expression of viral proteins, several 
systems have been developed for studying the different stages of the HCV life 
cycle.  For instance, the HCV tissue culture replicon system is suitable for 
studying viral replication.  This system involves the transfection of bicistronic 
RNA molecules into the human hepatoma cell line Huh7 (Blight et al., 2002; 
Lohmann et al., 1999; Pietschmann et al., 2002).  The first cistron contains the 
HCV 5’ UTR that drives expression of the selectable marker neomycin 
phosphotransferase while the second cistron contains a portion of the HCV 
genome encoding nonstructural protein NS3 to NS5B or the full-length HCV 
genome under the control of the encephalomyocarditis virus (EMCV) IRES.  
The selectable marker allows for the selection of clones which support 
persistent HCV RNA replication.  Enhanced replication was achieved through 
the introduction of cell culture adaptive mutations (Krieger et al., 2001; 
Lohmann et al., 2001).  However, despite robust RNA replication, the full-
length HCV replicons failed to produce infectious virus particles. 
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 Retroviral or lentiviral pseudotypes bearing HCV glycoproteins E1 and 
E2, termed HCV pseudoparticle (HCVpp), can be used to study viral entry.  
HCVpp are generated through cotransfection of two expression plasmids 
encoding HCV E1 and E2 and the retroviral or lentiviral Gag-Pol proteins and 
a third plasmid containing a reporter gene into a packaging cell line.  The 
HCVpp produced can be used to infect primary liver and hepatoma cells and 
HCV E1E2-mediated viral entry can then be assayed through the expression of 
the reporter gene (Bartosch et al., 2003; Hsu et al., 2003).  An advantage of 
this method is the ability to examine the entry and antibody-mediated 
neutralization of various HCV genotypes (Pestka et al., 2007).  However, it is 
important to note that the export pathway of HCVpp and native HCV may 
differ, thus resulting in particles with different characteristics. 
 The isolation of the genotype 2a JFH-1 strain from a patient with 
fulminant hepatitis, later found to be able to replicate efficiently without the 
need for adaptive mutations, provided the breakthrough for the development 
of a system capable of producing infectious HCV in cell culture (Kato et al., 
2001; Wakita et al., 2005).  Subsequently, more robust production of 
infectious particles was achieved using the intragenotypic chimeric J6/JFH-1 
strain and Huh7-derived cell lines, Huh7.5 and Huh7.5.1, which are defective 
in the antiviral RIG-I pathway (Lindenbach et al., 2005; Zhong et al., 2005).  
Following electroporation of transcribed RNA into cultured cells, the J6/JFH-1 
strain encodes the structural proteins, p7 and NS2 of the J6 isolate and the 
remaining non-structural proteins of the JFH-1 isolate and releases newly 
packaged virus particles into the culture medium.  The virus produced in cell 
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culture, termed HCV cell culture (HCVcc), is also infectious in chimpanzees 
and humanised mice (Lindenbach et al., 2006).  A limitation of this system is 
its inability to propagate HCV of other genotypes.  Alternatively, infectious 
HCV particles of various genotypes can be produced in Huh7-derived cell 
lines by expressing full-length HCV-encoding DNA with self-cleaving 
ribozymes (Cai et al., 2005; Kato et al., 2007).  Similar to HCVcc, the culture 
supernatants of these cells were infectious both in vitro and in vivo.  Since 
these systems support viral entry, replication, assembly and egress, they offer 
the best in vitro HCV infection model currently available. 
 A suitable animal model for HCV research is still lacking.  Although 
chimpanzees can be infected experimentally, they are far from ideal due to 
differences in HCV disease and therapy outcomes compared to humans (Major 
et al., 2004).  Furthermore, there are ethical and economic issues relating to 
the use of non-human primates in research.  Transgenic mouse models 
typically employ liver-specific promoters to drive constitutive or inducible 
expression of one or more HCV proteins (Chiyo et al., 2011; Ernst et al., 2007; 
Fimia et al., 2003).  However, studies using these models have reported 
variable phenotypes, probably due to differences in mouse genetic 
backgrounds, transgene integration sites, promoters used to drive transgene 
expression and abundance of HCV protein expressed.  Immunodeficient mice 
harbouring chimeric human-mouse liver which are susceptible to HCV 
infection have been successfully generated.  Chimeric livers are produced by 
destroying mouse hepatocytes and transplanting human ones.  Hepatotoxicity 
can be achieved through expression of the urokinase plasminogen activator 
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 and Il2rγ−/− mice (Bissig et al., 
2010; Mercer et al., 2001).  These humanised mice enable in vivo study of 
HCV infection and can be used for antiviral drug testing.  However, the lack 
of a functional immune system limits the study of immune-mediated 
pathogenesis and immune-based therapies.  
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1.2 An overview of apoptosis 
 Apoptosis, or programmed cell death, plays a fundamental role in 
development, tissue homeostasis and aging through the controlled elimination 
of unwanted, damaged or aberrant cells.  In addition, apoptosis serves as a 
defense strategy against microbial invasion and cytotoxic insults.  However, 
apoptosis may also contribute to disease progression by causing tissue injury.  
Defective apoptotic signalling that results in excessive or insufficient cell 
death is the basis of many pathologic conditions including cancer, 
autoimmune disorders, neurodegenerative diseases and ischemic damage 
(Fadeel and Orrenius, 2005). 
 Apoptosis is generally characterized by a series of morphological and 
nuclear changes (Hacker, 2000).  During the initial stages of apoptosis, cells 
undergo chromatin condensation and exhibit a striking decrease in cell volume 
(Kerr et al., 1972).  Then, extensive plasma membrane blebbing occurs 
followed by nuclear fragmentation.  The subsequent disintegration of dying 
cells into small apoptotic bodies containing dense cytoplasm with or without a 
nuclear fragment is a hallmark of apoptosis.  These bodies are then engulfed 
by neighbouring phagocytes and degraded within phagolysosomes.  This 
entire process is essentially non-inflammatory as cellular constituents are not 
released into the extracellular space and under normal conditions, apoptotic 
bodies are rapidly cleared by phagocytosis without any production of pro- or 
anti-inflammatory cytokines (Kurosaka et al., 2003). 
 Apoptosis can be triggered by a variety of external and intracellular 
stimuli which act via two main apoptotic signalling cascades, namely the 
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extrinsic or death receptor pathway and the intrinsic or mitochondrial 
pathway.  The two pathways will be discussed in sections 1.2.1 and 1.2.2.  A 
common feature of these pathways is the sequential activation of cysteine-
dependent aspartate-specific proteases, also known as caspases (Pop and 
Salvesen, 2009).  Caspases are expressed in most cells as inactive zymogens 
and are themselves activated by proteolytic processing of conserved aspartate 
moieties.  At least 14 members of the caspase family have been identified thus 
far and the ten major caspases can be generally categorized into initiator 
(caspase-2, 8, 9, 10), effector (caspase-3, 6, 7) and inflammatory caspases 
(caspase-1, 4, 5) (Elmore, 2007).  Initiator procaspases undergo autoactivation 
in specialised protein complexes before catalysing the activation of other 
procaspases.  This initiates a caspase cascade that culminates in the activation 
of caspase effectors. 
 Effector or “executioner” caspases induce the degradation of DNA and 
cytoskeletal and nuclear matrix proteins, resulting in the morphological and 
biochemical changes associated with apoptosis.  For example, effector 
caspases cleave inhibitor of caspase-activated DNase (ICAD) and relieve the 
inhibition of CAD endonuclease activity (Sakahira et al., 1998).  CAD then 
induces DNA fragmentation and chromatin condensation.  In addition, effector 
caspases target many cytoskeletal proteins including components of actin 
microfilaments, microtubules and intermediate filaments (Kothakota et al., 
1997; Lane et al., 2001; Morishima, 1999).  Caspase-mediated destruction of 
the cytoskeleton probably contributes to cell shrinkage, membrane blebbing 
and “pinching off” of apoptotic bodies.  Other substrates of effector caspases 
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include signal transduction proteins and chromatin-modifying and DNA repair 
enzymes (Timmer and Salvesen, 2007).  Externalization of phosphatidylserine 
on the cell surface, another feature of apoptosis, may be regulated through 
caspase-dependent or -independent pathways (Ferraro-Peyret et al., 2002; 
Mandal et al., 2005).  Surface exposure of phosphatidylserine facilitates 
recognition of apoptotic cells by phagocytes (Fadok et al., 2001).  Biochemical 
changes such as effector caspase activation, substrate cleavage, DNA 
fragmentation and externalization of phosphatidylserine can be used as 
biomarkers for the detection of apoptosis. 
1.2.1 Extrinsic apoptosis pathway 
 The extrinsic pathway of apoptosis is mediated by death receptors and 
their cognate ligands of the TNF receptor and ligand gene superfamily 
(Tansey and Szymkowski, 2009).  Death receptors are transmembrane proteins 
with a cysteine-rich extracellular domain and a cytoplasmic “death domain” 
(Ashkenazi and Dixit, 1998).  Some of the well-characterized death receptors 
and their ligands include Fas/FasL, TNF-R1/TNF-α and TRAIL-R1 or 
R2/TRAIL.  The extrinsic signalling pathway is triggered by death receptor 
trimerization and binding of the corresponding trimeric ligand.  Ligand 
binding induces recruitment of cytoplasmic death domain-containing adaptor 
proteins to the receptor through homotypic death domain interactions.  
Although death receptors may recruit different adaptors, the eventual 
association with Fas-associated death domain (FADD) protein and procaspase-
8 appears to be common to all death receptors (Chinnaiyan et al., 1995; Harper 
et al., 2003; Sprick et al., 2000).  This promotes the intracellular assembly of a 
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large death-inducing signalling complex (DISC) and the dimerization and 
autoactivation of caspase-8 (Kischkel et al., 1995; Oberst et al., 2010).  Once 
activated, caspase-8 propagates the apoptotic signal by directly activating 
effector caspases or by cleaving the BH3-only protein Bid to initiate the 
intrinsic mitochondrial pathway (Li et al., 1998). 
1.2.2 Intrinsic apoptosis pathway 
 In the intrinsic apoptosis pathway, members of the Bcl-2 family govern 
mitochondrial outer membrane permeability (MOMP) and thus, the 
subsequent activation of caspases (Chipuk and Green, 2008).  Bcl-2 family 
proteins are defined by the presence of one or more Bcl-2 homology (BH) 
domains and can be functionally categorized as prosurvival or proapoptotic 
(Youle and Strasser, 2008).  Major prosurvival Bcl-2 members include Bcl-2, 
Bcl-XL, Bcl-w, Mcl-1 and A1 and they function by directly inhibiting the 
activity of their proapoptotic counterparts.  The proapoptotic Bcl-2 members 
can be further subclassified into effector proteins (Bax and Bak) and BH3-
only proteins (Chipuk et al., 2010). 
 Although the events leading to activation of Bax and/or Bak are still 
unclear, BH3-only proteins have been reported to play a central role in this 
process and two models of Bax/Bak activation have been proposed.  In the 
indirect activation or neutralization model, Bax and Bak are sequestered by 
prosurvival Bcl-2 members until displaced by BH3-only proteins (Uren et al., 
2007; Willis et al., 2007).  Based on this model, some BH3-only members 
(Bim, Bid and Puma) are potent inducers of apoptosis due to their ability to 
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neutralize all the prosurvival Bcl-2 proteins while others (Bad, Noxa and Hrk) 
are weak inducers as they only bind to a subset of prosurvival proteins (Chen 
et al., 2005).  In the direct activation model, certain BH3-only proteins (Bim 
and Bid) function as direct activators of Bax and Bak (Kim et al., 2009; Lovell 
et al., 2008; Wei et al., 2000).  The remaining BH3-only proteins serve as 
sensitizers or de-repressors by binding to prosurvival Bcl-2 proteins, thus 
facilitating Bim/Bid activator function (Kuwana et al., 2005; Letai et al., 
2002).  Interestingly, recent research suggests that both pathways of Bax/Bak 
activation may function in vivo (Merino et al., 2009). 
 Upon activation, Bax and Bak perforate the mitochondrial outer 
membrane by forming large oligomeric channels (Nechushtan et al., 2001; 
Wei et al., 2001).  This results in the release of proapoptotic factors such as 
cytochrome c and DIABLO/Smac from the intermembrane space into the 
cytosol.  Cytochrome c recruits apoptotic protease-activating factor 1 (Apaf-1) 
and procaspase-9 to form the apoptosome, which in turn facilitates the 
autoactivation of caspase-9 and initiation of the caspase cascade (Bao and Shi, 
2007; Riedl and Salvesen, 2007).  
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1.3 Apoptosis in HCV infection 
 Death receptors and ligands are ubiquitously expressed in hepatocytes, 
probably as a result of evolutionary pressure to protect the liver against 
hepatotropic viruses (Faubion and Gores, 1999).  Thus, it is not surprising that 
liver diseases are often associated with activation of the extrinsic apoptosis 
pathway (Akazawa and Gores, 2007; Feldstein et al., 2003; Higuchi et al., 
2002).  In addition, hepatocytes are classified as so-called Type II cells in 
which the extrinsic apoptosis pathway requires amplification via the 
mitochondrial pathway for successful apoptosis induction (Scaffidi et al., 
1998).  This highlights the importance of both apoptosis pathways in liver 
cells.  Massive apoptosis in the liver leads to acute liver failure while 
persistent hepatocyte apoptosis may contribute to chronic liver dysfunction, 
fibrogenesis and even hepatocarcinogenesis (Malhi and Gores, 2008).  
Apoptosis of hepatocytes during HCV infection has been proposed to be a 
direct cause of liver fibrosis (Canbay et al., 2004).  In vitro and in vivo studies 
have shown that phagocytosis of apoptotic bodies by hepatic stellate cells 
induces a profibrogenic response (Canbay et al., 2003; Zhan et al., 2006). 
 Due to the lack of experimental animal models, most of the in vivo 
evidence for apoptosis in HCV infection comes from the analysis of liver 
biopsy samples obtained from patients with chronic hepatitis C.  Early studies 
based on the detection of DNA fragmentation reported that apoptosis was 
slightly elevated (0.54%) in the HCV-infected liver compared to the healthy 
liver (Calabrese et al., 2000; Lau et al., 1998).  However, the extent of 
apoptosis might have been underestimated as not all apoptotic cells display 
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DNA fragmentation and as DNA cleavage occurs at a late stage of apoptosis, 
rapid engulfment by phagocytes would have prevented visualization of this 
morphological change (Grasl-Kraupp et al., 1995; Schulze-Osthoff et al., 
1994).  Using immunohistochemical detection of activated caspases and 
cleaved caspase substrate PARP, another study showed caspase activation in 7 
– 20% of the hepatocytes (Bantel et al., 2001).  This group further compared 
apoptosis induction in HCV-infected patients and control individuals through 
specific detection of cleaved caspase substrate cytokeration-18 (CK-18), the 
major intermediate filament in hepatocytes, in serum (Bantel et al., 2004).  
Consistent with previous findings, the levels of CK-18 cleavage products were 
found to be significantly enhanced in the sera of HCV-infected patients, thus 
indicating caspase activation and apoptosis.  Interestingly, these studies found 
a significant correlation between degree of apoptosis and disease grade, thus 
underlining the role of HCV-induced apoptosis in liver injury.  However, the 
lack of correlation between apoptosis and viral load in these studies suggests 
an indirect mechanism of HCV-induced apoptosis. 
 There is increasing evidence suggesting that both immune-mediated 
processes and direct cytopathic effects of HCV might contribute to apoptosis 
in the HCV-infected liver.  The observation that the onset of acute hepatitis 
coincides precisely with the activation of cytotoxic T lymphocytes (CTLs) 
suggests the involvement of cellular immune responses (Bowen and Walker, 
2005; Lechner et al., 2000; Thimme et al., 2001).  Furthermore, apoptotic 
hepatocytes in HCV-infected liver biopsy specimens were observed to be in 
close physical proximity to infiltrating lymphocytes (Calabrese et al., 2000; 
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Lau et al., 1998).  Cytotoxic lymphocytes such as natural killer cells and virus-
specific CTLs eliminate infected cells by engaging death receptors on the cell 
surface or by delivering toxic granzyme B to the cells (Waterhouse et al., 
2004).  However, virus-infected hepatocytes seem to be resistant to granzyme 
B-mediated cell killing, suggesting that CTLs may preferentially activate the 
extrinsic apoptosis pathway (Kafrouni et al., 2001).  Consistent with this, 
immunohistochemical and gene expression studies have shown that HCV-
infected hepatocytes express elevated levels of Fas while FasL expression is 
upregulated in infiltrating CTLs (Hiramatsu et al., 1994; Mita et al., 1994).  
Moreover, Fas-mediated hepatocyte apoptosis was found to be enhanced in the 
liver tissue of HCV-infected patients (Pianko et al., 2001). 
 The observation that liver injury progresses more rapidly in HCV-
infected patients with defective or suppressed immune systems suggests that 
HCV may also exert direct cytopathic effects (Chen and Morgan, 2006).  In 
addition, recent HCVcc infection studies using cultured hepatoma cells and 
chimeric SCID/Alb-uPA mice have reported induction of apoptosis by HCV in 
the absence of cellular immune responses (Deng et al., 2008; Joyce et al., 
2009; Mateu et al., 2008).  Viral proteins may modulate host cell apoptosis by 
interacting with cellular apoptotic signalling molecules or by inducing 
intracellular stress.  Numerous studies have examined the role of individual 
HCV proteins in apoptosis using cell culture expression systems (Aweya and 
Tan, 2011).  However, these findings may not provide a true reflection of the 
in vivo situation as the viral proteins were expressed at unnaturally high levels 
and the effects of possible viral-viral interactions were not taken into account.  
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Furthermore, studies using transgenic mice conditionally expressing the core, 
E1, E2 and NS2 proteins or only the HCV structural proteins in the liver have 
also shown contradicting results in terms of apoptosis induction (Machida et 
al., 2001; Tumurbaatar et al., 2007).  Thus, the exact mechanisms underlying 
the direct cytopathic effects of HCV are still poorly understood.  Future 
studies using the currently available HCVcc system may provide better 
understanding of HCV-induced apoptosis and its role in pathogenesis.  
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1.4 Project objectives 
 For a virus with only ten gene products, multiple interactions with 
various cellular proteins provide an efficient means of reorganizing host 
processes.  Over the years, much effort have been put into characterizing and 
understanding the complex network of HCV-host interactions and their 
putative roles in the viral life cycle as well as HCV pathogenesis [recently 
reviewed by (Georgel et al., 2010)].  Although many aspects of these 
interactions have yet to be determined, they have been shown to modulate a 
variety of cellular processes including transcription, protein synthesis, 
membrane rearrangement, intracellular trafficking, lipid metabolism, immune 
response, carcinogenesis and apoptosis. 
 In this study, we aim to identify novel HCV-host interactions that 
possibly contribute to the modulation of host cell apoptosis.  Numerous studies 
have reported the involvement of the HCV core protein in apoptosis induction 
and both proapoptotic and prosurvival activities have been described for the 
core protein (Aweya and Tan, 2011; McLauchlan, 2000).  In Chapter 3, we 
used heterologous protein expression and the HCVcc system to investigate 
possible interactions between the core protein and members of the Bcl-2 
family of apoptosis regulators and to identify specific region(s) within the 
viral protein that mediate this interaction.  Following the experimental designs 
used in previous studies, the mature form of the core protein is assumed to be 
constituted by residues 1 to 173 of the HCV precursor polyprotein and this 
shall be referred to as the core protein in this study (Hope and McLauchlan, 
2000; Liu et al., 1997; Yamanaka et al., 2002).  This study may provide 
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further insight into the mechanisms underlying core protein-mediated 
apoptosis. 
 In the subsequent chapters, we focused on the ability of the whole 
virus to induce host cell death post-infection.  Using the JFH-1-based HCVcc 
system, several groups have demonstrated induction of apoptosis in HCV-
infected cells (Deng et al., 2008; Mateu et al., 2008; Walters et al., 2009).  
However, the exact mechanisms and specific host-virus interactions that 
contribute to HCV-induced apoptosis have yet to be identified.  We performed 
protein expression analysis and pathway-focused transcriptional profiling to 
examine changes in the expression of apoptosis-related host factors during 
acute HCV infection.  For two of the host prosurvival factors, Bcl-XL and 
Mcl-1, the impact of overexpression and knockdown of these proteins on 
HCV-induced apoptosis and viral replication was also investigated.  Our goal 
is to identify apoptosis pathways that may be regulated by HCV and the 
accompanying host-virus interactions, if any, in the context of a productive 
infection.  
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CHAPTER 2:  MATERIALS AND METHODS 
2.1 Cell culture 
 The human hepatoma Huh7 cell line and the human embryonic kidney 
293T cell line were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (FBS; HyClone, Logan, Utah), 0.1 mg/ml streptomycin and 100 U/ml 
penicillin.  The Huh7.5 cell line (Blight et al., 2002), a highly HCV permissive 
subclone of Huh7 cells, was kindly provided by C. M. Rice, Center for the 
Study of Hepatitis C, The Rockefeller University, New York, NY, USA and 
cultured in complete DMEM supplemented with 0.1 mM non-essential amino 





) cell lines (Zhang et al., 2000), a kind gift from B. Vogelstein, 
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical 
Institutions, Baltimore, MD, USA, were cultured in McCoy’s 5A medium 
supplemented with 2 mM L-glutamine, 10% FBS, 0.1 mg/ml streptomycin and 
100 U/ml penicillin.  Cells were grown at 37°C with 5% CO2. 
2.2 Antibodies 
 The primary antibodies used for Western blot analysis were anti-myc 
monoclonal, anti-myc and anti-Mcl-1 polyclonal (Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-Mcl-1 and anti-Bax monoclonal (Calbiochem, La Jolla, 
CA), anti-actin monoclonal, anti-Hsp-60 monoclonal, anti-flag monoclonal 
and polyclonal (Sigma, St. Louis, MO), anti-poly (ADP-ribose) polymerase 
(PARP) and anti-Bax polyclonal (Cell Signaling Technology Inc., Beverly, 
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MA), anti-cytochrome c and anti-Bcl-x monoclonal (BD Biosciences, San 
Jose, CA), anti-Bak polyclonal (Upstate, Lake Placid, NY), anti-HRK 
polyclonal (AbD Serotec, Oxford, UK), anti-HCV NS3 monoclonal 
(Chemicon, Temecula, CA) and anti-HCV core monoclonal (Abcam plc, 
Cambridge, UK).  Anti-core protein monoclonal antibody (clone 2H9; a kind 
gift from T. Wakita, Department of Virology II, National Institute of 
Infectious Diseases, Tokyo, Japan) was used to detect the core protein of HCV 
(Wakita et al., 2005).  Horseradish peroxidase (HRP)-conjugated goat anti-
mouse immunoglobulin G (IgG) and HRP-conjugated goat anti-rabbit IgG 
(Pierce, Rockford, IL) were used as secondary antibodies. 
2.3 Construction of plasmids 
Expression plasmids for the wild-type core protein and mutants were 
generated by polymerase chain reaction (PCR) using Titanium Taq DNA 
polymerase (Clontech Laboratories Inc., Palo Alto, CA).  Two plasmids 
containing full-length HCV genomes were used as template.  The first one is a 
1b strain cloned in Singapore (Soo et al., 2002) and the second is the JFH-1 
clone, which is a 2a strain (Wakita et al., 2005).  The PCR products were 
cleaved with restriction enzymes BamHI and XhoI and spliced into the 
pXJ40flag vector.  All sequences were confirmed by sequencing performed by 
the core facilities at the Institute of Molecular and Cell Biology, Singapore.  
The pXJ40flag vector is used so that a flag epitope is fused to the N terminus 
of the core protein and this allows the comparison of protein expression levels 
with an anti-flag antibody.  Epitope-tagged HCV core protein has been shown 
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to be functional in terms of oligomerization and virus-like particle (VLP) 
formation (Acosta-Rivero et al., 2005; Strosberg et al., 2010). 
2.4 Transient transfection of mammalian cells 
 Transient transfection of Huh7, 293T and HCT116 cells were 
performed in 6 cm dishes using Lipofectamine reagent (Invitrogen) according 
to the manufacturer’s protocol.  Typically, 1 to 3 µg of plasmid DNA was 
used per dish.  Transfection was carried out in the absence of antibiotics and 
the cells were replenished with complete medium at 6 h post-transfection.  
Approximately 16 h after transfection, the cells were washed twice with 
phosphate-buffered saline (PBS) and resuspended in 200 µl of 
immunoprecipitation (IP) buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% 
NP-40, 0.5% deoxycholic acid, 0.005% sodium dodecyl sulfate (SDS), 1 mM 
phenylmethylsulfonyl ﬂuoride).  After six freeze-thaw cycles, cell debris was 
removed by centrifugation and the total protein concentration in the lysate was 
determined using the Coomassie Plus protein assay reagent from Pierce. 
2.5 Western blot analysis 
Equal amounts of proteins were prepared in Laemmli’s SDS buffer, 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under 
reducing conditions and electrotransferred onto a nitrocellulose Hybond-C 
(Amersham Pharmacia Biotech, Uppsala, Sweden) or polyvinylidene 
difluoride (Millipore, Bedford, MA) membrane.  The membrane was blocked 
with 5% nonfat milk in PBS containing 0.05% Tween-20 (PBST) for 30 min 
at room temperature and then incubated overnight with the primary antibody 
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at 4°C.  After extensive washes with PBST, the membrane was incubated with 
an appropriate HRP-conjugated secondary antibody for 1 h at room 
temperature, followed by washing and detection by an enhanced 
chemiluminescence method (Pierce).  An imaging densitometer (Bio-Rad, 
Hercules, CA) or the ImageJ software (http://rsbweb.nih.gov/ij/index.html) 
was used for quantification of the intensities of specific bands on 
autoradiographs. 
2.6 Co-immunoprecipitation (Co-IP) 
Anti-flag monoclonal antibody conjugated to sepharose beads (Sigma) 
were added to 150 μl of the cell lysates and the mixture was subjected to end-
over-end mixing at 4°C for 6 h.  Beads were washed four times with cold IP 
buffer, and then 15 μl of Laemmli’s SDS buffer was added and the samples 
were boiled at 100°C for 5 min to release the immunocomplexes.  Samples 
were separated by SDS-PAGE and subjected to Western blot analysis.   
Alternatively, rabbit anti-Mcl-1 polyclonal antibody was used to 
immunoprecipitate endogenous Mcl-1 protein.  In this case, 7 μg of antibody 
(either anti-Mcl-1 or anti-hemagglutinin (HA) polyclonal antibody (Santa 
Cruz Biotechnology)) were added to the lysates obtained from two 6 cm 
dishes of cells and allowed to mix for 1 h at room temperature.  Protein A 
agarose beads (Roche, Indianapolis, IN) were added and the mixture was 
subjected to end-over-end mixing at 4°C overnight.  The co-
immunoprecipitated proteins were then detected as described above.  Co-
immunoprecipitation experiments with HCV-infected cells were performed in 
a similar manner. 
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2.7 Synthesis of peptides 
 A peptide that corresponds to residues 118 to 149 of the genotype 1b 
core protein (NLGKVIDTLTCGFADLMGYIPLVGAPLGGAAR) was 
synthesized and purified to 95% purity (Sigma Genosys, Japan).  Peptides 
containing the BH3 domain of Bad (NLWAAQRYGRELRRMSDE 
FVDSFKK) or Noxa (VPADLKDECAQLRRIGDKVNLRQKL) also were 
synthesized and purified to 95% purity (Mimotopes, Clayton Victoria, 
Australia). 
2.8 In vitro cytochrome c release assay 
 For use in the in vitro cytochrome c release assay, mitochondria were 
isolated from 293T cells as previously described (Fu et al., 2007).  Briefly, 
293T cells were suspended in isolation buffer (320 mM sucrose, 1 mM EDTA, 
50 mM HEPES pH 7.5) and disrupted by 25 expulsions
 
through a 27-gauge 
needle.  The disrupted cells were centrifuged at 1000 × g for 10 min to remove 
cell debris and nuclei.  The supernatant
 
was centrifuged at 7000 × g for 10 min 
and the pellet was retained as the heavy
 
membrane fraction containing the 
mitochondria.  The mitochondrion-containing
 
pellets were then resuspended in 
assay buffer (250 mM sucrose, 2 mM KH2PO4, 5 mM sodium succinate, 25 
mM EGTA, and 10 mM HEPES
 
pH 7.5) at 0.5 mg/ml.  Equal amounts of 
mitochondria were treated
 
with the indicated peptides for 30 min at room 
temperature, followed by centrifugation.  Both the supernatant and pellet were 
then subjected to SDS-PAGE and Western blot analysis to determine the 
amount of cytochrome c released from the mitochondria.  Hsp-60 was used as 
a loading control for the pellet. 
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2.9 Generation of stable cell lines 
 The Bcl-XL and Mcl-1 open reading frames (ORFs) with a myc tag at 
the 5’ end were cloned into the pXJ41neo vector (Zheng et al., 1992).  20 µg 
of plasmid DNA was transfected into approximately 1.0 × 10
7
 Huh7.5 cells by 
means of electroporation (950 µF, 250 V) using a Gene Pulser (Bio-Rad).  The 
transfected cells were plated onto 10 cm dishes and selection medium 
containing 1.5 mg/ml of Geneticin (G418; Invitrogen) was added 48 h post-
transfection.  After 3 to 5 days, single colonies were picked and transferred to 
individual wells in a flat-bottomed 96-well microplate.  Confluent wells were 
expanded into 24-well plates and then 6 cm dishes for screening and freezing 
down.  Stable overexpression of Bcl-XL and Mcl-1 was confirmed by Western 
blot analysis.  Control cells were generated by stably transfecting Huh7.5 cells 
with the empty vector and culturing under G418 selection. 
2.10 Small interfering RNA (siRNA)-mediated gene silencing 
 A 21-nucleotide RNA duplex targeting the coding region of human 
Bcl-XL gene (Zender et al., 2005) was synthesized using the Stealth RNA 
interference (RNAi) technology (Invitrogen).  Pre-designed Silencer Select 
siRNA duplex directed against human Mcl-1 was purchased (Ambion, Austin, 
TX).  The siRNA sequences were as follows: 
 siBcl-XL 
5’-GGA UAC AGC UGG AGU CAG U[dT][dT]-3’ (sense) 
5’-ACU GAC UCC AGC UGU AUC C[dT][dT]-3’ (antisense)  
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siMcl-1 
5’-CAA CUU CCG UAA UUA GGA A[dT][dT]-3’ (sense) 
5’-UUC CUA AUU ACG GAA GUU G[dC][dA]-3’ (antisense) 
The annealed and desalted siRNAs were reconstituted in nuclease-free water 
to a final concentration of 20 µM.  Stealth RNAi negative control duplex 
(Invitrogen) and Silencer Select negative control #1 siRNA (Ambion) were 
transfected in parallel to serve as a control for sequence independent effects of 
siRNA transfection (siControl). 
Huh7.5 cells were seeded without antibiotics in 6 cm dishes to achieve 
about 30% confluency the next day.  Transfection of siRNA was performed 
using Lipofectamine RNAiMAX reagent (Invitrogen) according to the 
manufacturer’s recommendations.  Briefly, 50 nM of Bcl-XL siRNA, 10 nM of 
Mcl-1 siRNA or their respective control siRNA was added to each dish.  At 24 
h post-transfection, the siRNA was removed and the cells were replenished 
with complete medium.  Cells were harvested at 2, 4, 6 and 8 days post-
transfection and the knockdown efficiency was examined by Western blot 
analysis. 
2.11 Cell proliferation assay 
 Huh7.5 cells were seeded in flat-bottomed 96-well microplates at a 
density of 1.0 × 10
4
 cells/well and allowed to attach overnight.  The cells were 
then left untreated or infected with HCV or mock preparation and culture 
medium was replaced every two days.  At specific time points after treatment, 
cell viabilities were determined using the cell proliferation reagent WST-1 
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(Roche), according to the manufacturer’s protocol.  Briefly, 10 µl of WST-1 
reagent was added to each well containing cells in a final culture medium 
volume of 100 µl.  After incubating at 37°C for 1 h, the absorbance of the 
samples was measured using a microplate reader (Tecan, Mannedorf, 
Switzerland) at a wavelength of 440 nm and a reference wavelength of 630 
nm. 
2.12 DNA fragmentation assay 
 This assay measures the degree of apoptosis based on the amount of 
histone-associated DNA fragments detected in the cytoplasm and was 
performed using a Cell Death Detection ELISA
Plus
 kit (Roche) as previously 
described (Deng et al., 2008).  Briefly, Huh7.5 cells cultured in a 96-well 
microplate were spun at 200 × g for 10 min at 4°C to remove the culture 
medium.  The cells were suspended in lysis buffer and centrifuged at 200 × g 
for 10 min.  The supernatant was retained as the cytoplasmic fraction and 20 
µl of supernatant was added to each well of a streptavidin-coated 96-well 
microplate.  A mixture of biotin-labelled anti-histone antibody and peroxidase-
labelled anti-DNA antibody was added to the wells and incubated for 2 h at 
room temperature.  The wells were washed extensively before addition of 
2,2’-azino-diethyl-benzthiazolin substrate and the peroxidase activities were 
measured spectrophotometrically using a microplate reader (Bio-Rad).  
2.13 Detection of caspase enzymatic activities 
 The activation of caspase-3, a hallmark of apoptosis, was measured by 
using a CaspACE fluorometric assay system or a Caspase-Glo 3/7 luminescent 
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assay system (Promega, Madison, WI) according to the manufacturer’s 
instructions.  These assays involve the addition of fluorogenic or luminogenic 
substrates which contain the caspase-3 cleavage site tetrapeptide sequence 
DEVD.  The amount of fluorescence or luminescence produced upon cleavage 
of these substrates is proportional to the amount of caspase activity present in 
the sample. 
 In the CaspACE fluorometric assay, 5 µl of cell lysate were added to 
individual wells of an opaque 96-well microplate and diluted in caspase assay 
buffer before incubation at 30°C for 30 min.  After addition of the substrate 
which is labelled with the fluorochrome 7-amino-4-methyl coumarin (AMC), 
the plate was incubated at 30°C for 1 h.  The yellow-green fluorescence of 
liberated AMC was measured at an excitation wavelength of 360 nm and an 
emission wavelength of 465 nm using a microplate reader (Tecan). 
 The Caspase-Glo 3/7 assay employs a direct lysis method.  An equal 
volume of Caspase-Glo reagent, which contains cell lysis buffer and substrate, 
was added to cells cultured in an opaque 96-well microplate.  The plate was 
incubated at room temperature for 1 h.  Caspase cleavage of the substrate 
releases aminoluciferin which is utilized in the luciferase reaction to produce 
light.  Luminescence was measured in relative light units (RLU) using a 
microplate luminometer (Promega). 
2.14 Viruses 
 The pFL-J6/JFH-1 plasmid encoding the entire viral genome of a 
chimeric strain of HCV genotype 2a, J6/JFH-1 (Lindenbach et al., 2005) , was 
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kindly provided by C. M. Rice.  To generate mutant virus possessing a core 
protein mutation (V119L), a nucleotide substitution was introduced into pFL-
J6/JFH-1 by site-directed mutagenesis using a QuikChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA).  All PCR-amplified DNA 
fragments were verified extensively using an ABI PRISM 3100-Avant Genetic 
Analyzer (Applied Biosystems, Foster City, CA).  Each of the plasmids was 
linearized by XbaI digestion and in vitro transcribed by using T7 RiboMAX 
(Promega) to generate the full-length viral genomic RNA.  The in vitro-
transcribed RNA (10 μg) was transfected into Huh7.5 cells by means of 
electroporation (975 μF, 270 V) using a Gene Pulser (Bio-Rad).  The cells 
were then cultured in complete medium and the supernatant was propagated as 
a virus stock. 
 The J6/JFH-1-P47 virus (Bungyoku et al., 2009), an adapted strain of 
the J6/JFH-1 virus that possesses enhanced infectivity, was kindly provided by 
H. Hotta, Division of Microbiology, Kobe University Graduate School of 
Medicine, Hyogo, Japan.  The adapted virus was obtained by passaging the 
J6/JFH-1-infected cells 47 times and contains 10 amino acid mutations (K78E, 
T396A, T416A, N534H, A712V, Y852H, W879R, F2281L, M2876L and 
T2925A) and a single nucleotide mutation in the 5’-UTR (U146A). 
2.15 Virus titration 
 Virus infectivity was measured by indirect immunofluorescence 
analysis as described (Deng et al., 2008).  Briefly, culture supernatants 
containing HCV were serially diluted 10-fold in complete DMEM and used to 
infect 1.9 × 10
5 
Huh7.5 cells seeded on glass coverslips in a 24-well plate.  
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The inoculum was incubated with cells for 5 h at 37°C and then replaced with 
fresh complete DMEM.  At 24 h post-infection, the cells were fixed with 4% 
paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 for 15 
min and blocked with PBS containing 1% bovine serum albumin (BSA; 
Sigma) for 30 min.  The cells were then incubated with the serum of an HCV-
infected patient (1:200) for 1 h and washed with PBS three times before 
incubating with a fluorescein isothiocyanate (FITC)-conjugated goat anti-
human IgG antibody (1:200; Sigma) for 1h.  After three washes with PBS, the 
coverslips were mounted on glass slides using Vectashield mounting medium 
with 4',6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame, CA) 
and examined under a fluorescence microscope (BX51; Olympus, Center 
Valley, PA).  All incubations and washes were performed at room 
temperature.  The viral titre was determined by the average number of HCV-
positive foci observed at the highest dilutions according to a previously 
described method (Zhong et al., 2005) and expressed as cell-infecting units 
(CIU) or focus-forming units (ffu) per millilitre of supernatant.  
2.16 HCV infection 
 For infection studies, Huh7.5 cells were seeded in either 96-well 
microplates at a density of 1.0 × 10
4
 cells per well, 24-well plates at a density 
of 6.0 × 10
4
 cells per well or 6-well plates at a density of 3.0 × 10
5
 cells per 
well and cultured overnight.  For infection with J6/JFH1 or J6/JFH-1(V119L), 
the cells were infected at a multiplicity of infection (MOI) of 0.1 ffu/cell.  
Infections with the J6/JFH-1-P47 virus were performed at an MOI of 2.0 
ffu/cell.  Control cells were treated with a mock preparation.  The inoculum 
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was incubated with cells for 5 h at 37°C and then replaced with fresh complete 
DMEM.  The culture medium was replenished every two days and the infected 
cells were assayed at different time points post-infection. 
2.17 Isolation of total cellular RNA 
 Huh7.5 cells in 24-well plates were infected with HCV or mock 
preparation and total RNA was isolated at 2, 4 and 6 days post-infection 
(d.p.i.).  Following removal of culture medium, the cells were rinsed twice in 
PBS and RNA was extracted using an RNeasy Mini Kit with an on-column 
DNase treatment step (Qiagen, Valencia, CA) according to the manufacturer’s 
protocol.  The concentration and quality of RNA were determined using a 
NanoDrop spectrophotometer (Thermo Scientific, Rockford, IL).  RNA 
samples with an OD260 nm/OD280 nm absorbance ratio between 1.8 and 2.0 were 
used. 
2.18 Reverse transcription 
 Total RNA was reverse transcribed into complementary DNA (cDNA) 
using the QuantiTect Reverse Transcription (RT) kit (Qiagen).  Briefly, 400 
ng of RNA was incubated with the gDNA Wipeout Buffer for 2 min at 42°C 
to eliminate any contaminating genomic DNA.  The RT master mix was 
prepared by mixing the Quantiscript Reverse Transcriptase, Quantiscript RT 
Buffer and RT Primer Mix containing an optimized blend of oligo-dT and 
random primers.  Template RNA was added to the RT master mix and the RT 
reaction was performed at 42°C for 15 min.  The reaction was then incubated 
at 95°C for 3 min to inactivate the reverse transcriptase. 
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 For PCR array analysis, total RNA was reverse transcribed into cDNA 
using the RT
2
 First Strand Kit (SABiosciences, Frederick, MD) according to 
the manufacturer’s instructions.  In brief, genomic DNA elimination buffer 
was added to 700 ng of RNA in 10 µl reactions and incubated at 42°C for 5 
min.  An equal volume of the reverse transcription cocktail containing primers 
(random hexamers and oligo-dT), nucleotides and reverse transcriptase was 
added to each reaction and incubated at 42°C for 15 min.  The enzyme was 
then immediately inactivated by heating at 95°C for 5 min. 
2.19 Viral RNA quantification 
 To measure intracellular HCV RNA replication levels, cDNA was 
subjected to quantitative real-time PCR analysis using the SYBR Green-based 
detection system.  The cDNA was diluted in water and added in triplicates to 
individual wells of a MicroAmp optical 96-well reaction plate (Applied 
Biosystems) containing the RT
2
 SYBR Green/ROX quantitative PCR (qPCR) 
master mix (SABiosciences) and gene-specific primers.  One primer set 
amplifies a region in NS5A of the HCV genome while another probes the 
expression levels of human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which was used as an internal control.  The primer sequences were 
as follows: 
 HCV primers 
 5’-AGA CGT ATT GAG GTC CAT GC-3’ (sense) 
 5’-CCG CAG CGA CGG TGC TGA TAG-3’ (antisense)  
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 GAPDH primers 
 5’-CAT GAG AAG TAT GAC AAC AGC CT-3’ (sense) 
 5’-AGT CCT TCC ACG ATA CCA AAG T-3’ (antisense) 
The plate was subjected to a two-step cycling program on an ABI 7900HT 
Fast Real-Time PCR System (Applied Biosystems).  HCV and GAPDH 
transcript levels were determined relative to standard curves derived from 
serial dilutions of plasmids containing either the HCV J6/JFH-1 cDNA or the 
human GAPDH gene. 
2.20 Gene expression profiling using PCR arrays 
  Template cDNA was mixed with RT
2
 SYBR Green/ROX qPCR 
master mix (SABiosciences) and 25 µl of this mixture was added to each well 
of the 96-well PCR array containing specific primer sets.  The Human 
Apoptosis RT
2
 Profiler PCR Array (SABiosciences) examines 84 genes 
involved in the apoptotic pathway.  These genes include members of the 
caspase, Bcl-2, IAP, TRAF, CARD, CIDE, death domain, death effector 
domain, and TNF receptor and ligand families, as well as genes involved in 
the p53 and DNA damage pathways.  The array also contains primer sets for 
five housekeeping genes and three RNA and PCR quality controls (Appendix 
1). 
The PCR cycling program was performed using an ABI 7500 Fast 
Real-Time PCR System (Applied Biosystems).  Expression profiles of HCV-
infected and mock-infected cells at the different time points were obtained 
from three independent experiments.  The threshold cycle (Ct) values of each 
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gene were used to calculate the fold changes in gene expression using the RT
2
 
Profiler PCR Array Data Analysis software 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
2.21 Quantitative real-time PCR 
 Gene expression changes observed with the PCR arrays were 
confirmed by quantitative real-time PCR using TaqMan chemistry.  Probes 
and primers specific to the host genes that were identified by the PCR arrays 
to be up-regulated or down-regulated in response to HCV infection were 
obtained from Applied Biosystems.  GAPDH was selected as the reference 
gene for normalization.  Each reaction was performed in triplicates and no 
template controls were included for each primer/probe set.  Amplification was 
monitored on an ABI 7900HT Fast Real-Time PCR System (Applied 
Biosystems).  The difference in Ct values (ΔCt) between the gene of interest 
and GAPDH control was used to calculate the fold changes in gene expression 
(2
-ΔΔCt
) between HCV-infected and mock-infected Huh7.5 cells.  Results were 
obtained from at least three independent experiments. 
2.22 Statistical analysis 
 The two-tailed Student’s t test or one-way analysis of variance was 
applied to evaluate the statistical significance of differences measured from 
the data sets.  A P value of less than 0.05 was considered to be statistically 
significant.  
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CHAPTER 3: HCV CORE PROTEIN CONTAINS A BH3 DOMAIN 
THAT REGULATES APOPTOSIS THROUGH SPECIFIC 
INTERACTION WITH HUMAN MCL-1 
3.1 A BH3-like domain is present in the core protein 
 The family of Bcl-2 proteins constitutes one of the biologically 
important gene products in the regulation of apoptosis [reviewed by (Adams 
and Cory, 2007; Danial, 2007; van Delft and Huang, 2006; Youle and Strasser, 
2008)].  Members of the Bcl-2 protein family are defined by the presence of 
up to four Bcl-2 homology domains (BH1 to BH4) in their protein sequence.  
These Bcl-2 proteins may be classified broadly into three classes: prosurvival 
members containing multiple Bcl-2 homology domains, proapoptotic members 
containing multiple Bcl-2 homology domains and proapoptotic members 
containing only the BH3 domain. 
 The function of Bcl-2 family proteins in regulating cell survival is 
highly conserved in species ranging from nematodes and flies to humans 
(Colin et al., 2009).  A number of viruses have also evolved to encode 
homologues of Bcl-2 family proteins so as to modulate the apoptotic pathways 
of the host in favour of viral propagation.  Several large DNA viruses, 
including adenoviruses, herpesviruses and poxviruses, are known to encode 
prosurvival viral Bcl-2 proteins (vBcl-2s) [reviewed by (Cuconati and White, 
2002; Galluzzi et al., 2008; Polster et al., 2004)].  It has been widely 
hypothesized that these vBcl-2s function to inhibit premature apoptosis of 
infected cells, thus allowing completion of the viral replication cycle.  
Inhibition of apoptosis may also contribute to the establishment of or 
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reactivation from latency and the development of a chronic, persistent 
infection.  In contrast, only one viral homologue of proapoptotic BH3-only 
proteins has been identified thus far.  Lu and colleagues demonstrated that 
HBSP, a spliced hepatitis B viral protein, contains a functional BH3 domain 
(Lu et al., 2006). 
 In the case of HCV, only NS5A has been previously identified as a 
potential vBcl-2 that inhibits apoptosis via direct interaction with Bax (Chung 
et al., 2003).  Therefore, to determine if HCV encodes other homologues of 
Bcl-2 family proteins, we examined the amino acid sequence of other HCV 
proteins for the presence of BH domains.  An examination of the amino acid 
sequence of the core protein revealed that there is a BH3-like domain near the 
C-terminus.  An alignment of this domain with BH3 domains of the Bcl-2 
family of proteins is shown in Figure 3.1A.  The four hydrophobic amino 
acids that are responsible for making critical contacts with residues in the BH3 
recognition grooves present on the surfaces of the prosurvival Bcl-2 family 
proteins are indicated as h1 to h4.  The BH3-like domain of the core protein 
contains L (residue 119) and D (residue 124) separated by four residues, as 
observed in other known BH3 domains.  This region within the core protein is 
highly conserved among the major HCV genotypes, with the exception of 
genotypes 2a and 6k, which have V and M residues at position 119, 
respectively (Figure 3.1B).  
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Fig. 3.1.  Identification of a BH3-like domain in HCV core protein.  (A) Alignment of 
the BH3 domain of the genotype 1b core protein with the BH3 domains of members 
of the Bcl-2 family.  Numbers in parentheses represent the positions of amino acid 
residues of the respective proteins.  The four hydrophobic amino acids that make 
critical contacts with residues in the BH3 recognition grooves present on the surfaces 
of the prosurvival Bcl-2 family proteins are shaded and indicated as h1 to h4.  (B) 
Alignment of the core protein (residues 109 to 132) of different HCV genotypes.  The 
consensus sequences for these genotypes were obtained from 
http://hcv.lanl.gov/content/hcv-index.  The highly conserved L and D residues found 
at positions 119 and 124 of the genotype 1b core protein are boxed.  
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3.2 Role of the BH3 domain in the HCV core protein 
3.2.1 The BH3 domain of the core protein is essential for the induction 
of apoptosis 
 To characterize the putative BH3 domain, plasmid-liposome complex-
mediated overexpression of the core protein was first performed.  The 
expression of the core protein (with a flag epitope at the N terminus) in Huh7 
cells was achieved through the transient transfection of a cDNA expression 
plasmid containing the genotype 1b core protein gene.  Overexpression of the 
core protein induced significant levels of apoptosis as determined by the 
activation of caspase-3, which is a hallmark of apoptosis (Figure 3.2A).  The 
deletion of the BH3 domain in the flag-tagged core protein (designated 
coreΔ115-128aa) abolished its proapoptotic property, indicating that this 
domain is essential for the induction of apoptosis.  Consistently, the cleavage 
of endogenous PARP, a substrate of activated caspase-3, was clearly observed 
in Huh7 cells expressing the wild-type core protein but not in those expressing 
coreΔ115-128aa (Figure 3.2B).  The activation of caspase-3 and cleavage of 
endogenous PARP caused by the overexpression of Bax, a classical potent 
inducer of apoptosis, are shown as positive controls.  
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Fig. 3.2.  Induction of apoptosis by the overexpression of core protein in Huh7 cells.  
(A) A CaspACE fluorometric assay system was used to measure the activation of 
caspase-3, which is a hallmark of apoptosis, in Huh7 cells that were transfected with 
vector only, a classical apoptosis inducer (Bax), the wild-type core protein and a core 
protein mutant lacking the putative BH3 domain (coreΔ115-128aa).  All experiments 
were performed in triplicate and the average values with standard deviations are 
plotted.  (B) Western blot analysis was also performed to determine the cleavage of 
endogenous PARP, which is a substrate of activated caspase-3, from 116 to 83 kDa 
(top).  Similarly, the expression levels of the different proteins were determined using 
anti-flag antibody (middle).  The amounts of total cell lysates loaded were verified by 
















































































3.2.2 The BH3 domain of the core protein mediates specific interaction 
with human Mcl-1 
 To understand how the core protein modulates the function of the Bcl-
2 family of proteins, coimmunoprecipitation experiments were performed in 
Huh7 cells to determine if the core protein can interact with representative 
prosurvival members of the Bcl-2 family.  As shown in the top panel of Figure 
3.3, Mcl-1 was specifically coimmunoprecipitated by the core protein (lane 8) 
but not by an irrelevant protein, glutathione S-transferase (GST) (lane 7).  The 
BH3 domain of the core protein is essential for its interaction with Mcl-1, as 
the coreΔ115-128aa mutant failed to coimmunoprecipitate Mcl-1 (lane 9).  In 
contrast, no significant interaction was observed between the core protein and 
two other prosurvival Bcl-2 family members, Bcl-XL and Bcl-w (lanes 1 to 6).  
These results suggest that the core protein induces apoptosis by interfering 
directly and specifically with the prosurvival function of Mcl-1. 
 The interaction between the core protein and endogenous Mcl-1 was 
determined by overexpressing the core protein in Huh7 cells and performing 
coimmunoprecipitation experiments.  As shown in Figure 3.4A, the wild-type 
core protein was coimmunoprecipitated with endogenous Mcl-1 (lane 3).  In 
contrast, the core protein was not coimmunoprecipitated when an irrelevant 
antibody (anti-HA) (lane 4) was used for IP.  Similar to the results in Figure 
3.3, only a small amount of the coreΔ115-128aa mutant was 
coimmunoprecipitated with endogenous Mcl-1 (lane 5).  CoreΔ115-128aa was 
also not coimmunoprecipitated when anti-HA was used for IP. 
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 To compare the degree of binding between endogenous Mcl-1 and the 
wild-type core protein or the coreΔ115-128aa mutant, an imaging 
densitometer was used to quantify the intensities of specific bands on the 
autoradiographs obtained in three independent coimmunoprecipitation 
experiments (representative data is shown in Figure 3.4B).  The ratios of 
signals for the expression of flag-tagged core proteins, endogenous Mcl-1 and 
actin (internal control) are all close to 1 (0.94 to 1.14), indicating that the 
expression levels of these proteins in the two sets of cells (either transfected 
with cDNA construct for expressing flag-core or flag-coreΔ115-128aa) were 
similar.  From the three independent experiments, the average amount of 
coreΔ115-128aa coimmunoprecipitated specifically by the Mcl-1 antibody is 
14.2% (± 10.7%) of the amount of wild-type core protein 
coimmunoprecipitated.  This implies that the deletion of the BH3 domain does 
not completely abolish the interaction between the core protein and 
endogenous Mcl-1 but reduces this interaction greatly.  Since binding of the 
coreΔ115-128aa mutant to Mcl-1 was not completely abrogated, this 
interaction may also be mediated by other minor interaction domains.  
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Fig. 3.3.  Interaction of core protein with prosurvival members of the Bcl-2 family 
determined by coimmunoprecipitation experiments.  Huh7 cells were transfected with 
cDNA constructs for expressing flag-GST (negative control), flag-core or flag-
coreΔ115-128aa and myc-tagged prosurvival members of the Bcl-2 family (myc-Bcl-
XL [lanes 1 to 3], myc-Bcl-w [lanes 4 to 6] and myc-Mcl-1 [lanes 7 to 9]).  The cells 
were harvested at ~16 h post-transfection, lysed and subjected to IP with anti-flag 
monoclonal antibody conjugated to sepharose beads.  The amount of myc-tagged 
proteins that coimmunoprecipitated (IP) with the flag-tagged proteins was determined 
by Western blot analysis (WB) with an anti-myc rabbit polyclonal antibody (top).  
The amounts of myc-tagged and flag-tagged proteins in the lysates before IP were 
determined by subjecting aliquots of the lysates to Western blot analysis (middle).  
The protein marked with an asterisk represents the heavy chain of the antibody used 
for IP (top) and the amounts of total cell lysates loaded were verified by measuring 

































































































Fig. 3.4.  Interaction of the wild-type core protein or the coreΔ115-128aa mutant with 
endogenous Mcl-1 in Huh7 cells.  (A) Huh7 cells were transfected with cDNA 
constructs for expressing flag-core or flag-coreΔ115-128aa.  Immunoprecipitation 
(IP) was then performed using anti-Mcl-1 or anti-HA rabbit polyclonal antibodies and 
protein A agarose beads.  The amounts of flag-tagged core protein in the lysates 
before IP (lanes 1 and 2) or coimmunoprecipitated (lanes 3 to 6) were determined by 
Western blot analysis with an anti-flag monoclonal antibody (top).  Similarly, the 
amounts of endogenous Mcl-1 in these samples were detected using an anti-Mcl-1 
monoclonal antibody (middle).  The protein marked with an asterisk represents the 
heavy chain of the antibody used for IP (top) and the amounts of total cell lysates 
loaded were verified by measuring the levels of endogenous actin (bottom).  (B) An 
imaging densitometer was used to quantify the intensity of specific bands on the 
autoradiographs.  For the amount of proteins in the lysates before IP (lanes 1 and 2), 
the ratio of the signals for samples transfected with coreΔ115-128aa to that for 
samples transfected with wild-type core protein is plotted.  For the amounts of flag-
tagged core protein co-immunoprecipitated (lanes 3 to 6), the signal for samples co-IP 
by HA antibody (unspecific binding) was subtracted from the signal for samples co-
IP by Mcl-1 antibody.  Then, the ratio of subtracted signals for samples transfected 
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3.3 Overexpression of Mcl-1 or Bcl-XL prevents core protein-induced 
apoptosis 
Although the prosurvival Bcl-2 proteins show significant sequence and 
structural similarity, their functions and interaction profiles are not exactly the 
same (Certo et al., 2006; Chao and Korsmeyer, 1998).  In particular, their 
abilities to protect cells against apoptosis can vary between different cell types 
and death stimulus (He et al., 2003; Memon et al., 1995; Panickar et al., 2005).  
Hence, we first overexpressed several prosurvival Bcl-2 proteins in Huh7 cells 
and measured the level of apoptosis (Figure 3.5A and B).  The transient high-
level expression of Bcl-2 caused apoptosis in Huh7 cells (lane 1), which is 
consistent with studies done using other cell lines (Cheng et al., 1997; 
Uhlmann et al., 1998).  Interestingly, the overexpression of Bcl-w also 
induced a significant level of apoptosis in Huh7 cells (lane 3) and this 
phenomenon has not been reported previously.  Cells overexpressing Bcl-XL 
(lane 2), but not Mcl-1 (lane 4), also displayed a slightly higher level of 
apoptosis than that of the vector-transfected control cells (lane 5).  However, 
the level of apoptosis in the cells overexpressing Bcl-XL is much lower than 
those overexpressing Bcl-2 or Bcl-w.  This suggests that Bcl-2 and Bcl-w are 
not likely to have prosurvival function in Huh7 cells, which is consistent with 
a previous report that described Bcl-XL and Mcl-1 as the major prosurvival 
Bcl-2 proteins in the liver (Hikita et al., 2009).   
 Subsequently, the abilities of Bcl-XL and Mcl-1 to protect against core-
induced apoptosis in Huh7 cells were examined by cotransfection with 
plasmids for expressing myc-Mcl-1 and flag-core or myc-Bcl-XL and flag-
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core.  As shown in Figures 3.5C and 3.5D, the level of apoptosis was 
significantly reduced in cells expressing both myc-Mcl-1 and flag-core (lane 
3) compared to cells expressing the core protein only (lane 2).  When the same 
experiment was repeated using Bcl-XL, the level of apoptosis was reduced to a 
lesser extent (lane 5).  This may be due to the low level of apoptosis induced 
solely by the overexpression of Bcl-XL (lane 6).  The level of the core protein 
expressed in the presence of Bcl-XL also was decreased greatly but the smaller 
amount of the core protein present still induced a high level of apoptosis (lane 
5).  However, when a broad caspase inhibitor (z-VAD-fmk) was used, the core 
protein level in cells coexpressing Bcl-XL increased (Figures 3.6A and 3.6B), 
indicating that the transfection efficiencies were similar in the different 
samples.  To resolve this uncertainty, the coexpression experiment was 
repeated with a smaller amount of Bcl-XL plasmid (0.5 µg).  Under this 
condition, the overexpression of Bcl-XL alone did not induce apoptosis (lane 
8).  The level of apoptosis was also reduced in cells expressing both Bcl-XL 
and the core protein (lane 7) compared to those expressing the core protein 
only (lane 2).  Thus, the results show that the overexpression of either Mcl-1 
or Bcl-XL protects against core protein-induced apoptosis.  
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Fig. 3.5.  Effects of Mcl-1 and Bcl-XL overexpression on the proapoptotic property of 
the core protein.  (A) A CaspACE fluorometric assay system was used to measure the 
activation of caspase-3 in Huh7 cells that were transfected with Bcl-2, Bcl-XL, Bcl-w, 
Mcl-1 or vector only.  All experiments were performed in triplicate and the average 
values with standard deviations are plotted.  (B) Western blot analysis was performed 
to determine the cleavage of endogenous PARP (top) and expression levels of the 
myc-tagged prosurvival members of the Bcl-2 family (middle).  The amounts of total 
cell lysates loaded were verified by measuring the levels of endogenous actin 
(bottom).  (C) A CaspACE fluorometric assay system was used to measure the 
activation of caspase-3 in Huh7 cells that were singly transfected with vector, the 
wild-type core protein, Mcl-1 or Bcl-XL, or that were cotransfected with wild-type 
core protein and Mcl-1 or Bcl-XL.  The amounts of flag-core and myc-Mcl-1 or myc-
Bcl-XL plasmid used in each transfection are indicated in micrograms.  In each 
transfection, the total amount of DNA was normalised to 3 µg with the addition of 
empty vector if necessary.  All experiments were performed in triplicate and the 
average values with standard deviations are plotted.  (D) Western blot analysis was 
performed to determine the cleavage of endogenous PARP (top) and expression 
levels of myc-tagged Mcl-1 and Bcl-XL and flag-tagged core protein (middle).  The 
amounts of total cell lysates loaded were verified by measuring the levels of 










Fig. 3.6.  Effects of apoptosis inhibition on the expression level of HCV core protein.  
(A) A CaspACE fluorometric assay system was used to measure the activation of 
caspase-3 in Huh7 cells that were singly transfected with vector, Bcl-XL or wild-type 
core or co-transfected with wild-type core and Bcl-XL in the presence of z-FA-fmk 
(an irrelevant peptide) or z-VAD-fmk (a pan-caspase inhibitor).  All experiments 
were performed in triplicate and the average values with standard deviations are 
plotted.  (B) Western blot analysis was performed to determine the expression levels 
of the myc-tagged Bcl-XL and flag-tagged core protein (top and middle).  The 
amounts of total cell lysates loaded were verified by measuring the levels of 















































































3.4 Functional complementation between Bad and the core protein 
3.4.1 Bad enhances the ability of the core protein to release cytochrome 
c from isolated mitochondria 
 Next, plasmid-liposome complex-mediated overexpression of the core 
protein was performed in 293T cells to determine if it also induces apoptosis 
in these cells.  As shown in Figure 3.7, overexpression of the wild-type core 
protein in 293T cells induced significant levels of apoptosis in the same 
manner as that in Huh7 cells (lane 5).  Consistent with the observations made 
in Huh7 cells, the coreΔ115-128aa mutant which lacks the BH3 domain of the 
core protein did not induce apoptosis in 293T cells (lane 6).  The ability of 
Noxa, a known BH3-only protein that binds specifically to Mcl-1 and A1 but 
not to the other prosurvival members of the Bcl-2 family (Chen et al., 2005), 
to induce apoptosis in Huh7 and 293T cells is also demonstrated (lanes 3 and 
7).  Hence, the ability of a core protein peptide, which contains residues 118 to 
149 of the genotype 1b core protein, to release cytochrome c from 
mitochondria was tested using 293T cells instead of Huh7 cells, as the method 
for the isolation of mitochondria from 293T cells is well established. 
 Isolated mitochondria from 293T cells were incubated with different 
concentrations of core protein, Bad or Noxa BH3 peptides and the amount of 
cytochrome c released into the supernatant of the treated mitochondria was 
determined by Western blot analysis.  An alignment of the three peptide 
sequences shows that the core protein BH3 peptide lacks the h1 residue of the 
BH3 domain (Figure 3.8A).  As shown in Figure 3.8B, both the Bad and core 
protein BH3 peptides alone were inefficient in inducing the release of 
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cytochrome c, as only a small amount of cytochrome c was detected in the 
supernatant when 200 µM of either peptide was used.  However, when Bad 
and core protein BH3 peptides were used in combination, the release of 
cytochrome c was observed at a much lower total peptide concentration of 50 
µM (consisting of 25 µM Bad BH3 peptide and 25 µM core protein BH3 
peptide).  Furthermore, the release of cytochrome c from isolated 
mitochondria increased in a dose-dependent manner.  The amount of 
cytochrome c left in the treated mitochondria (i.e., pellet) also decreased 
correspondingly, while the amount of mitochondrial protein Hsp-60 (used as a 
loading control) was not affected. 
 The same experiment was repeated using the Noxa BH3 peptide 
instead of the core protein BH3 peptide (Figure 3.8C).  Consistent with a 
previous study (Chen et al., 2005), the Noxa BH3 peptide alone was 
inefficient in inducing the release of cytochrome c from isolated mitochondria 
but when it was used in combination with the Bad BH3 peptide, the 
cytochrome c release was significantly enhanced.  The total peptide dosage 
that induced the release of cytochrome c was similar to the amount required 
for the core protein and Bad BH3 peptides, indicating that the 
complementation between the core protein and Bad is similar to the 
complementation between Noxa and Bad.  The results also suggest that the h1 
residue in the BH3 domain of the core protein, a non-hydrophobic R residue, 
is not essential for the induction of mitochondrial cytochrome c release.  
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 Fig. 3.7.  Induction of apoptosis through the overexpression of core protein or Noxa 
in Huh7 and 293T cells.  A CaspACE fluorometric assay system was used to measure 
the activation of caspase-3, which is a hallmark of apoptosis, in (A) Huh7 cells that 
were transfected with vector only, wild-type core protein and human Noxa or (C) 
293T cells that were transfected with vector only, wild-type core protein, a core 
protein mutant lacking the putative BH3 domain (coreΔ115-128aa) and human Noxa.  
A flag epitope is fused to the N termini of the proteins as this allows comparison of 
protein expression levels with an anti-flag antibody.  All experiments were performed 
in triplicate and the average values with standard deviations are plotted.  Western blot 
analysis of the transfected Huh7 (B) and 293T cells (D) was also performed to 
determine the cleavage of endogenous PARP (top).  Similarly, the expression levels 
of the different proteins were determined using an anti-flag antibody (middle).  The 
amounts of total cell lysates loaded were verified by measuring the levels of 
































































































































Fig. 3.8.  Release of cytochrome c from isolated mitochondria by a combination of 
core-BH3 and Bad-BH3 peptides or Noxa-BH3 and Bad-BH3 peptides.  (A) Protein 
sequence alignment of the core protein (residues 118 to 149), Bad (residues 103 to 
127) and Noxa (residues 67 to 91) BH3 peptides.  The four hydrophobic amino acids 
of the BH3 domain are shaded and indicated as h1 to h4.  The highly conserved D 
residue between the h3 and h4 positions is highlighted in bold.  (B) Mitochondria 
isolated from 293T cells were incubated with either Bad peptide, core protein peptide 
or a combination of the two peptides in equimolar concentrations.  The total amount 
of peptide used in each experiment is indicated.  Following centrifugation, the 
supernatants and pellets were subjected to Western blot analysis with anti-
cytochrome c (cyt c) or anti-Hsp-60 antibodies.  (C) The same experiment was 
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3.4.2 Coexpression of the core protein and Bad resulted in enhanced 
apoptosis 
 Next, we investigated the synergistic proapoptotic activity of the core 
protein and Bad, a cellular BH3-only protein, using an overexpression system.  
This system allows us to examine apoptosis induction in intact transfected 
cells, instead of just isolated mitochondria.  As shown in Figure 3.9, the 
overexpression of the core protein, Noxa or Bad singly induced similar levels 
of apoptosis in Huh7 cells as determined by the level of caspase-3 activation 
and the amount of PARP cleavage (lanes 2 to 4).  However, when Bad was 
coexpressed with the core protein, the level of apoptosis was significantly 
enhanced (lane 5), indicating that Bad can potently cooperate with the core 
protein to induce high levels of apoptosis.  A similar observation was made 
when Bad and Noxa were coexpressed (lane 6).  These findings are consistent 
with the functional complementation between the core protein or Noxa BH3 
peptides and the Bad BH3 peptide previously shown using the in vitro 
cytochrome c release assay (Figures 3.8B and 3.8C).  
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Fig. 3.9.  Coexpression of core protein and Bad enhanced apoptosis in Huh7 cells.  
(A) A CaspACE fluorometric assay system was used to measure the activation of 
caspase-3 in Huh7 cells that were transfected with vector only, core protein, Noxa, 
Bad or a combination of core protein and Bad or Noxa and Bad.  In each transfection, 
the total amount of DNA was normalised to 0.95 μg with the addition of empty vector 
if necessary.  A flag epitope is fused to the N terminus of core and Noxa while a myc 
epitope is fused to that of Bad.  All experiments were performed in triplicate and the 
average values with standard deviations are plotted.  (B) Western blot analysis was 
also performed to determine the cleavage of endogenous PARP (top).  Similarly, the 
expression levels of the different proteins were determined using anti-flag or anti-myc 
antibodies (middle).  The amounts of total cell lysates loaded were verified by 
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3.5 Core protein-induced apoptosis is dependent on the expression of 
Bax 
 If the overexpression of the core protein affects the stoichiometry of 
the prosurvival and BH3-only Bcl-2 family members, this will lead to the 
activation of the proapoptotic multidomain Bcl-2 family members such as Bax 
and Bak, which are essential effectors of the mitochondrial outer membrane 





 cells to core protein-induced apoptosis 
were compared (Figures 3.10A and 3.10B).  HCT116-Bax
+/−
 cells are 
colorectal cancer cells containing one intact Bax allele while the HCT116-
Bax
−/−
 cells have two mutant alleles.  Studies using these cells have provided 
direct evidence that Bax plays an essential role in mediating apoptosis induced 
by the BH3-only protein Bik and certain anticancer drugs (Gillissen et al., 
2003; Prokop et al., 2003; Zhang et al., 2000). 
 As shown in Figure 3.10, the overexpression of the core protein 
induced apoptosis in HCT116-Bax
+/−
 cells but not in HCT116-Bax
−/−
 cells, 
indicating that core protein-induced apoptosis is dependent on Bax.  Although 
the HCT116 cell lines express significant levels of Bak (Gillissen et al., 2003), 
they were insufficient to confer sensitivity to core protein-induced apoptosis in 
HCT116-Bax
−/−
 cells.  Bak has been reported to be sequestered by Bcl-XL and 
Mcl-1 under normal conditions (Willis et al., 2005).  We postulate that while 
the core protein can displace Bak from Mcl-1, Bak is still held in check by 
Bcl-XL, which does not interact with the core protein (Figure 3.3).  This is 
analogous to the Mcl-1-mediated sequestration of Bak that leads to the Bax 
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dependency of Bik-induced apoptosis (Gillissen et al., 2007).  Thus, the data 
suggest that core protein-induced apoptosis is mediated via a primarily Bax-
dependent mitochondrial pathway. 





 cells.  (A) A CaspACE fluorometric assay system was 





cells that were transfected with vector only or wild-type core protein.  All 
experiments were performed in triplicate and the average values with standard 
deviations are plotted.  (B) Western blot analysis was also performed to determine the 
cleavage of endogenous PARP (top) and expression level of flag-tagged core protein 
(middle).  The differential expression of Bax in the two cell lines was demonstrated 
using an anti-Bax antibody (middle).  The amounts of total cell lysates loaded were 



























































3.6 The three hydrophobic residues in the BH3 domain of the core 
protein are important for apoptosis induction 
3.6.1 Effects of alanine substitutions on the proapoptotic property of the 
core protein 
 Site-directed mutagenesis and structural studies of the interactions 
between the prosurvival Bcl-2 proteins and BH3-only proteins have revealed 
the mechanism by which BH3 domains are bound to the hydrophobic grooves 
present on the surface of the prosurvival Bcl-2 proteins [see reviews by (Petros 
et al., 2004; Walensky, 2006)].  In particular, the BH3 domain usually 
contains four hydrophobic residues (h1 to h4) that make contacts with 
conserved hydrophobic residues at the base of the groove and these 
interactions are critical for the stability of the complex.  Interestingly, the core 
protein also contains hydrophobic residues at the h2, h3, and h4 positions 
(Figure 3.1A).  An alanine substitution experiment was performed to 
determine if these residues are essential for the proapoptotic property of the 
core protein (Figure 3.11A and 3.11B).  The results showed that substitution 
of L119, V122 or L126 with A completely abolishes the proapoptotic property 
of the core protein. 
 In addition to the hydrophobic interactions, the invariant solvent-
exposed D residue in the BH3 domain forms an important ionic interaction 
with a conserved R in the BH1 domain of the prosurvival protein (Hinds and 
Day, 2005).  As such, it was surprising that replacement of the highly 
conserved D124 residue with A seems to increase the proapoptotic property of 
the core protein slightly.  The levels of caspase-3 activation induced by the 
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wild-type core protein and the D124A substitution mutant in six independent 
experiments were compared using the two-tailed Student’s t test and the 
difference was found to be statistically significant (Figure 3.11C).  This 
phenomenon has not been reported for other BH3-only proteins and only a few 
known functional BH3 domains do not contain D at this position (Inohara et 
al., 1998; Tan et al., 2001).  
 78 
Fig. 3.11.  Effects of alanine substitutions on the proapoptotic property of the core 
protein.  (A) A CaspACE fluorometric assay system was used to measure the 
activation of caspase-3 in Huh7 cells that were transfected with vector only, wild-type 
core protein or alanine-substituted core mutants.  All experiments were performed in 
triplicate and the average values with standard deviations are plotted.  (B) Western 
blot analysis also was performed to determine the cleavage of endogenous PARP 
(top) and expression levels of the core proteins (middle).  The amounts of total cell 
lysates loaded were verified by measuring the levels of endogenous actin (bottom).  
(C) The levels of activated caspase-3 induced by the wild-type core protein and the 
D124A mutant in six independent experiments were compared using the two-tailed 
Student’s t test, and the difference was found to be statistically significant (P < 0.05).  
The values from each of the experiments are plotted as open triangles and the average 
































































































































3.6.2 Effects of alanine substitutions on the binding of the core protein 
to Mcl-1 
 Coimmunoprecipitation experiments were performed to test whether 
the alanine substituted core proteins can still bind Mcl-1.  As shown in Figure 
3.12A, the L119A, V122A and L126A substitution mutants displayed reduced 
binding to Mcl-1.  Similar results were obtained in four independent 
experiments and the percentages of binding by the substitution mutants 
compared to that of the wild-type core protein were estimated by using an 
imaging densitometer to measure the intensity of the core protein signals after 
coimmunoprecipitation.  For each experiment, three different autoradiographs 
(with different exposure times) were used for quantitation and the average 
values are shown in Table 3.1.  The average percentages in binding of Mcl-1 
to the L119A, V122A and L126A mutants are 33%, 62% and 9% of the 
binding to the wild-type core protein, respectively.  For all three mutants, the 
reductions in interaction with Mcl-1 compared to the interaction between wild-
type core protein and Mcl-1 are statistically significant (Table 3.1). 
 As the D124A substitution mutant induced a slightly higher level of 
apoptosis than the wild-type core protein (Figure 3.11), a 
coimmunoprecipitation experiment was also performed to determine if this 
mutant retains full ability to bind Mcl-1.  Two different amounts of flag-
tagged plasmids (0.5 and 1.0 µg) were used and the results showed that the 
D124A substitution mutant binds Mcl-1 to an extent similar to that of the 
wild-type core protein under both conditions (Figure 3.12B).  When 1.0 µg of 
core (D124A) plasmid was used, the expression level of myc-tagged Mcl-1 
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was slightly reduced, probably due to increased apoptosis in this sample 
(Figure 3.11).  As a result, lesser Mcl-1 was immunoprecipitated when more 
core (D124A) protein was expressed.  
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Fig. 3.12.  Effects of alanine substitutions on the binding of the core protein to Mcl-1.  
(A) Huh7 cells were transfected with cDNA constructs (1.0 µg) for expressing flag-
GST (negative control), flag-tagged wild-type core protein or single-alanine-
substitution mutants (L119A, V122A and L126A).  All cells were cotransfected with 
myc-tagged Mcl-1 (1.5 µg).  (B) Huh7 cells were transfected with cDNA constructs 
for expressing flag-GST (negative control, 0.5 µg), flag-tagged wild-type core protein 
(0.5 or 1.0 µg) or single-alanine-substitution mutant D124A (0.5 or 1.0 µg).  All cells 
were cotransfected with myc-tagged Mcl-1 (1.5 µg).  Coimmunoprecipitation then 
was performed as described in the legend to Fig. 3.3.  The amount of myc-tagged 
proteins that coimmunoprecipitated (IP) with the flag-tagged proteins was determined 
by Western blot analysis (WB) with an anti-myc rabbit polyclonal antibody (top).  
The amounts of myc-tagged and flag-tagged proteins in the lysates before IP were 
determined by subjecting aliquots of the lysates to Western blot analysis (middle).  
The amounts of total cell lysates loaded were verified by measuring the levels of 
endogenous actin (bottom).  The protein marked with an asterisk represents the heavy 
chain of the antibody used for IP (top).  Similar results were obtained in four 












 Exp 1 Exp 2 Exp 3 Exp 4   
L119A 26 21 40 43 33 (± 11) 0.001 
V122A 64 63 66 55 62 (± 5) 0.001 
L126A 3 3 10 18 9 (± 7) 0.0001 
a
The percentage in binding to Mcl-1 for each of the mutants when compared to wild-
type core protein was estimated by using an imaging densitometer to measure the 
intensity of core protein signals after co-immunoprecipitation (Fig. 3.13.).  Four 
independent experiments were performed (Exp 1 to Exp 4).  For each experiment, 3 
different autoradiographs (with different exposure times) were used and the signals 
were normalised to the signal for wild-type core protein.  Then, the average value was 
computed and shown. 
b
The mean value of the results from 4 independent experiments was computed and 
shown.  The standard deviations are shown in parentheses. 
c
The difference between mutant and wild-type core in binding to Mcl-1 was 
compared using the 2-tailed Student’s t test and the P-value is shown.  
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3.6.3 Proapoptotic properties of the core proteins of HCV genotypes 1b 
and 2a 
 Sequence comparison of the core proteins from different HCV 
genotypes revealed that while the V122 and L126 residues, at the h3 and h4 
positions respectively, are highly conserved, the core proteins from genotype 
2a strains typically have V instead of L at the h2 position (Figure 3.1B).  In 
order to determine the impact of this variation on the apoptotic property of 
core, two substitution mutants were generated.  For the first mutant, named 
core (L119V) (genotype 1b), the L119 in genotype 1b core was substituted 
with the corresponding V residue in genotype 2a.  For the second mutant, 
named core (V119L) (genotype 2a), the V119 in genotype 2a core was 
substituted with the corresponding L residue in genotype 1b. 
 As shown in Figures 3.13A and 3.13B, substitution of the L119 of the 
genotype 1b core protein with V reduced the proapoptotic property of the core 
protein dramatically (lanes 2 and 3).  This is similar to the reduction in the 
proapoptotic property of the genotype 1b core protein when the L119 residue 
was substituted with A, although the alanine substitution appeared to be more 
potent as it completely abolished core protein-induced apoptosis (Figure 3.11).  
Interestingly, in all known BH3-only proteins, this position is usually an L 
residue that is essential for the proapoptotic properties of these proteins 
(Figure 3.1A).  The reverse experiment was performed by determining if the 
core protein of a genotype 2a strain (JFH-1 isolate) can induce apoptosis 
(Figure 3.13).  The overexpression of the genotype 2a core protein induced a 
significantly lower level of apoptosis than the genotype 1b core protein (lane 
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4).  However, replacing the V119 of the genotype 2a core protein with L 
resulted in a considerable increase in apoptosis induction, to a level similar to 
that induced by the genotype 1b core protein (lane 5).  These results suggest 
that the dramatic difference in the apoptosis inducing ability of genotype 1b 
and 2a core proteins is due to the amino acid difference at position 119. 
Fig. 3.13.  Comparison of the proapoptotic properties of the core proteins of 
genotypes 1b and 2a.  (A) A CaspACE fluorometric assay system was used to 
measure the activation of caspase-3 in Huh7 cells that were transfected with vector 
only, wild-type core proteins of genotype 1b or 2a or their substitution mutants.  All 
experiments were performed in triplicate and the average values with standard 
deviations are plotted.  (B) Western blot analysis also was performed to determine the 
cleavage of endogenous PARP (top) and expression levels of the core proteins 
(middle).  The amounts of total cell lysates loaded were verified by measuring the 
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3.7 A single substitution from V to L at residue 119 in the core protein 
of the HCV J6/JFH-1 strain is associated with increased abilities to 
induce apoptosis 
 Since the core proteins of HCV genotypes 1b and 2a displayed varying 
abilities to induce apoptosis in transfected cells due to an amino acid 
difference at residue 119, we sought to examine if this is also true in HCV-
infected cells and the possible consequences of this difference.  The pFL-
J6/JFH-1 plasmid encoding the entire viral genome of an intragenotypic 
chimeric strain of HCV genotype 2a (J6/JFH-1) can be used to generate 
infectious HCV (Lindenbach et al., 2005).  In the J6/JFH-1 clone, the core 
protein contains V at residue 119, just like the JFH-1 clone.  A mutant virus, 
J6/JFH-1(V119L), was generated successfully by replacing the V119 residue 
with L so that its core protein contains a genotype 1b-like BH3 domain.  At 
the time of this experiment, we have yet to complete a Material Transfer 
Agreement needed to acquire the J6/JFH-1 infectious clone.  Hence, the 
infection experiments described in this chapter were performed by our 
collaborators from the Division of Microbiology, Kobe University Graduate 
School of Medicine, Hyogo, Japan. 
 Parental J6/JFH-1 and mutant J6/JFH-1(V119L) viruses were used to 
infect naïve Huh7.5 cells and cell viabilities were measured at different time 
points after infection (Figure 3.14A).  From day 2 post-infection (p.i.), cells 
infected by either virus have lower viabilities than mock-infected cells, 
indicating that the viruses have induced cytopathic effects (CPE).  This is 
consistent with recent observations made by us and other researchers (Deng et 
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al., 2008; Mateu et al., 2008).  Results from days 6 and 8 p.i. showed that the 
mutant J6/JFH-1(V119L) virus induced higher levels of CPE and thus, lower 
levels of cell viability compared to the parental J6/JFH-1 virus (Figure 3.14A), 
which is in agreement with the findings of the overexpression studies shown in 
Figure 3.13.  The CPE is mediated primarily through apoptosis, as indicated 
by the levels of caspase-3 activation (Figure 3.14B) and DNA fragmentation 
(Figure 3.14C).  The production of cell-free infectious virus particles by the 
J6/JFH-1(V119L) virus was also significantly higher than that produced by the 
parental J6/JFH-1 virus (Figure 3.14D).  On the other hand, there was no 
significant difference in the percentage of HCV-infected cells in the cultures 
(Figure 3.14E) or the level of HCV RNA replication in the cells between the 
two viruses (Figure 3.14F). 
 We next analyzed the possible interaction between endogenous Mcl-1 
and the core proteins of either J6/JFH-1 or J6/JFH-1(V119L) in virus-infected 
cells.  As shown in Figure 3.14G, the core protein of J6/JFH-1(V119L) was 
coimmunoprecipitated with Mcl-1 (lane 6).  In contrast, Mcl-1 interaction of 
the core protein of J6/JFH-1 was not detected under the same experimental 
conditions (lane 4).  These results collectively imply the possibility that the 
V119L mutation of the core protein of the J6/JFH-1(V119L) virus promotes 
its interaction with Mcl-1 and is responsible for the increased ability of the 
virus to induce apoptosis, which favours a higher degree of infectious progeny 
virus release from the host cell at the late time points of infection compared to 
that of the parental J6/JFH-1 virus.  
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Fig. 3.14.  Comparison of parental J6/JFH-1 and mutant J6/JFH-1(V119L) 
recombinant viruses.  Huh7.5 cells were infected with recombinant HCV at MOI 0.1 
or with a mock preparation and various assays were performed at different days post-
infection (d.p.i.).  (A) Cell viabilities were determined.  (B) Caspase-3 activity per 
cell was determined.  (C) The amount of DNA fragmentation per cell was 
determined.  (D) The production of cell-free infectious virus particles was 
determined.  (E) Virus spread in the culture was quantitated.  (F) HCV RNA 
replication was determined by quantitative real-time PCR analysis.  (G) Interaction of 
the core protein with Mcl-1 was determined by coimmunoprecipitation experiments 
at 3 d.p.i.  IP was performed using anti-Mcl-1 or anti-HA rabbit polyclonal antibodies 
and protein A agarose beads.  The amount of core protein in the lysates before (lanes 
1 and 2) and after IP (lanes 3 to 6) was determined by Western blot analysis with an 
anti-core monoclonal antibody (top).  Similarly, the amounts of endogenous Mcl-1 in 
the samples were determined using an anti-Mcl-1 monoclonal antibody (bottom).  
Statistical analysis was performed using the one-way analysis of variance and 
differences between parental and mutant viruses with P values of <0.05 (marked by 
asterisks) are considered to be statistically significant.  Data were obtained from three 
independent experiments, each with triplicate cultures.  





 Besides playing important roles in maintaining homeostasis in healthy 
cells through the regulation of apoptosis, members of the Bcl-2 family are also 
involved in viral infections.  Indeed, several viruses have been shown to 
encode homologues of prosurvival Bcl-2 proteins and these viral proteins 
serve to inhibit apoptosis in infected cells and prevent the premature death of 
these cells [see reviews by (Cuconati and White, 2002; Hardwick and 
Bellows, 2003; Polster et al., 2004; White, 2006)].  Other viral proteins, which 
can be proapoptotic, prosurvival or both, do not share any sequence homology 
with members of the Bcl-2 family but can also modulate apoptosis in the host 
cells by interfering at different apoptotic checkpoints [see reviews by (Boya et 
al., 2004; Galluzzi et al., 2008; Hay and Kannourakis, 2002; McLean et al., 
2008)]. 
 Unlike the multi-BH domain members, the BH3-only members of the 
Bcl-2 family contain a single BH3 domain.  Although all BH3-only proteins 
can bind to the hydrophobic groove on the surface of the prosurvival 
members, recent quantitative measurements have revealed that the affinities of 
association between different pairs of BH3-only and prosurvival members 
vary greatly (Chen et al., 2005; Kuwana et al., 2005).  For example, Bim and 
Puma bind all prosurvival members tested, while Noxa binds strongly only to 
Mcl-1 and A1.  On the other hand, Bad binds more strongly to Bcl-2, Bcl-XL 
and Bcl-w than to Mcl-1.  Taken together with results from successive studies, 
it becomes clear that the BH3-only members can be classified into subclasses 
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[see reviews by (Fletcher and Huang, 2008; Hacker and Weber, 2007; Shibue 
and Taniguchi, 2006; Willis and Adams, 2005)].   
 In this study, we demonstrate that the HCV core protein is a BH3-only 
viral homologue of the Bcl-2 family and its BH3 domain is essential for the 
induction of apoptosis (Figures 3.1 and 3.2).  In coimmunoprecipitation 
experiments, the core protein interacts specifically with the prosurvival Mcl-1 
protein but not with prosurvival proteins Bcl-XL and Bcl-w (Figure 3.3), 
suggesting that its property is most similar to that of Noxa (Chen et al., 2005).  
Consistently, the overexpression of Mcl-1 protects against core protein-
induced apoptosis (Figure 3.5).  However, the overexpression of Bcl-XL also 
protects against core protein-induced apoptosis (Figure 3.5).  This may be due 
to the ability of a high level of Bcl-XL to prevent the complementation 
between the core protein and endogenous Bad protein, which binds strongly to 
Bcl-XL (Chen et al., 2005), as we have observed that a combination of the core 
protein and Bad peptide mimetics caused efficient cytochrome c release from 
the mitochondria (Figure 3.8).  The complementation between Bad and the 
core protein is similar to that observed between Bad and Noxa, which act in 
combination to neutralize the two classes of prosurvival proteins, one 
containing Bcl-2, Bcl-XL and Bcl-w and the other Mcl-1 and A1 (Chen et al., 
2005).  Similarly, in the overexpression studies, the core protein and Noxa 
induced comparably low levels of apoptosis when expressed individually and 
the induction of apoptosis increased substantially when they were coexpressed 
with Bad (Figures 3.7 and 3.9).  Last but not least, core protein-induced 
apoptosis is dependent on the expression of Bax (Figure 3.10), which is one of 
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the proapoptotic effectors of the mitochondrial outer membrane 
permeabilization acting downstream of activated BH3-only proteins.  Taken 
together, these findings suggest that the core protein can mimic Noxa and 
interfere directly with the prosurvival function of Mcl-1. 
 A comparison of the BH3 domain of the core protein with the 
corresponding domains of other BH3-containing proteins (Figure 3.1A) 
revealed that it contains three out of the four hydrophobic residues that can be 
accommodated within the hydrophobic pockets of previously described BH3 
binding grooves [see reviews by (Petros et al., 2004; Walensky, 2006)].  
Alanine substitution experiments revealed that all three hydrophobic residues 
in the BH3 domain of the core protein are essential for apoptosis induction 
(Figure 3.11).  In coimmunoprecipitation experiments, these alanine 
substitution mutants bound Mcl-1 to a lesser extent than the wild-type core 
protein (Figure 3.12A).  Although these alanine substitution mutants still bind 
Mcl-1, albeit at a lower level than that of the wild-type core protein, it appears 
that these interactions are not sufficient to induce apoptosis.  In several 
mutagenesis studies, the interaction between Bcl-2 family members and 
apoptosis regulation have been observed to be discordant.  For example, two 
mutants of the BH3-only protein Bik, Bik-(43-94) and Bik-(43-120), 
heterodimerized with prosurvival Bcl-2 and Bcl-XL but were unable to induce 
efficient cell death (Elangovan and Chinnadurai, 1997).  A Bad mutant 
containing an alteration of a critical residue within its BH3 domain, E113 to 
K, also was found to have significantly reduced apoptotic activity compared to 
that of wild-type Bad, despite binding to Bcl-2 and/or Bcl-XL to the same 
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extent as wild-type Bad (Lee et al., 2004).  Therefore, the induction of 
apoptosis by the core protein may be controlled by a critical threshold affinity 
of binding between the core protein and Mcl-1 or there are contributions from 
a yet-to-be characterized pathway(s).   
 Two of the hydrophobic residues (V122 and L126) in the BH3 domain 
of the core protein are conserved in the major genotypes of HCV but residue 
119 is a V in genotype 2a instead of an L (Figure 3.1B).  When L119 of the 
genotype 1b core protein was replaced with V, its ability to induce apoptosis 
was greatly reduced (Figure 3.13).  Conversely, when V119 of the genotype 
2a core protein was replaced with L, its ability to induce apoptosis was greatly 
enhanced.  Thus, the results suggest that the genotype 1b core protein induces 
apoptosis efficiently via its BH3 domain, while the genotype 2a core protein is 
comparatively less efficient.  Another highly conserved residue in the BH3 
domain of the core protein is D124.  However, the replacement of D124 with 
A did not reduce the proapoptotic function of the core protein (Figure 3.11).  
To date, there are only a few known functional BH3 domains that do not 
contain D at this position (Inohara et al., 1998; Tan et al., 2001).  Unlike most 
BH3-only proteins, the core protein has a charged residue (R115) at the h1 
position (Figure 3.1A).  This residue does not appear to play a role in core 
protein-induced apoptosis as the core protein BH3 peptide lacking this residue 
is capable of complementing the Bad BH3 peptide to cause more efficient 
release of cytochrome c from isolated mitochondria (Figure 3.8).  
Interestingly, the second BH3 domain of mouse Noxa (mNoxaB) also has a 
charged residue (E74) at this position.  Indeed, the nuclear magnetic resonance 
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structure of the complex between mouse Mcl-1 and a peptide mimetic of 
mNoxaB shows that E74 is tolerated at the h1 position because its charged 
carboxyl group is coordinated by another charged residue, K215, in mouse 
Mcl-1 (Czabotar et al., 2007).  However, R115 of the core protein is basic 
instead of acidic, and how this residue can be accommodated in the 
hydrophobic groove of human Mcl-1 is unclear.  Interestingly, replacing the 
residue at the h1 position (I58) of a novel BimBH3 variant, Bims2A, with A 
had little effect on its interaction with Mcl-1 (Lee et al., 2008).  Thus, it 
appears that the residue in the h1 position is not always involved in the 
interaction between BH3-only proteins and Mcl-1 but further biophysical and 
biochemical studies are required to delineate the precise structure-function 
relationship for the interaction between the HCV core protein and Mcl-1. 
 To determine if the results from the overexpression studies are relevant 
to the modulation of apoptosis in host cells during HCV infection, the J6/JFH-
1-based (genotype 2a) cell culture infection system was used to generate HCV 
carrying a substitution at residue 119 of the core protein.  While both the 
parental wild-type and mutant viruses replicated efficiently in Huh7.5 cells, 
the J6/JFH-1(V119L) virus (which expresses the core protein with L at the h2 
position of the BH3 domain) caused a significantly higher level of apoptosis in 
the infected cells than the parental J6/JFH-1 virus (which expresses the core 
protein with V at the h2 position of the BH3 domain) (Figures 3.14A to 
3.14C).  This is in good agreement with the overexpression studies and 
indicates that the BH3 domain of the core protein contributes to the induction 
of apoptosis in HCV-infected cells.  Thus, it appears that core protein-
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mediated apoptosis during infection by HCV of genotype 2a is less efficient 
than that of the other genotypes having L at residue 119 of the core protein 
(Figure 3.1B).  Coimmunoprecipitation experiments revealed that the core 
protein of J6/JFH-1(V119L), but not that of J6/JFH-1, interacted with Mcl-l in 
virus-infected cells (Figure 3.14G).  This result is consistent with the 
overexpression studies and suggests the possibility that the core protein 
induces apoptosis, at least in part, through interaction with Mcl-1 in HCV-
infected cells.  Interestingly, more progeny virus is released from cells 
infected with the J6/JFH-1(V119L) virus than by those infected with the 
parental J6/JFH-1 virus, while there is no difference in the efficiency of 
infection or amount of HCV replication inside the cells (Figures 3.14D to 
3.14F). 
 We further examined the importance of residue 119 of the core protein 
in HCV replication.  In multiple independent transfection experiments, we 
observed that the J6/JFH-1 mutant virus possessing A at position 119 [J6/JFH-
1(V119A)] barely replicated in the cells and did not produce any infectious 
virus particles in the culture supernatants (data not shown).  This result 
suggests the possibility that this single point mutation impairs the interaction 
of the core protein with other viral and/or cellular proteins that is required for 
HCV RNA replication and infectious virion production.  Similarly, the J6/ 
JFH-1 mutants each possessing A at positions 122 [J6/JFH- 1(V122A)], 124 
[J6/JFH-1(D124A)] or 126 [J6/JFH-1(L126A)] barely replicated in the cells 
and did not produce any infectious virion in the culture supernatants (data not 
shown), thus suggesting an important role for these residues as well as for 
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position 119.  In this connection, the essential role for the HCV core protein in 
infectious virion production has been confirmed recently and numerous 
residues required for this role have been identified (Murray et al., 2007). 
 By using the JFH-1 infectious clone, recent studies have revealed that 
association of the core protein with lipid droplets (LDs) is critical for the 
production of infectious virus particles (Boulant et al., 2007; Miyanari et al., 
2007).  Boulant and co-workers reported that there are two amphipathic α-
helices in the so-called D2 domain of the core protein (~118 to 179 aa) 
(Boulant et al., 2006; Boulant et al., 2005) and the hydrophobic residues 
within this domain are critical for the efficient attachment of the core protein 
to LDs (Boulant et al., 2006).  Our results showed that residues L119, V122 
and L126 of the core protein are essential for the induction of apoptosis and 
these residues are found on the hydrophobic face of the first α-helix of the D2 
domain.  Interestingly, the replacement of L119 with E did not affect LD 
association, while the replacement of L126 with E significantly reduced LD 
association (Boulant et al., 2006).  The contribution of V122 to LD association 
was not investigated.  Consistently, the J6/JFH-1(V119L) virus, but not the 
J6/JFH-1(L126A) virus, replicated efficiently to produce infectious virus 
particles.  Since L119 of the genotype 1b core protein, which occupies the 
crucial h2 position in the BH3 domain, is essential for its proapoptotic 
property but not for its association with LDs, it is clear that the BH3 domain of 
the core protein is an independent motif that partially overlaps with the LD 
association domain. 
 95 
 Recently, Makes caterpillars floppy 1 (Mcf1), a bacterial toxin, was 
reported to contain a BH3-like domain (Dowling et al., 2007).  In addition, 
HBSP, a spliced hepatitis B viral protein, also contains a BH3-like domain (Lu 
et al., 2006).  Here, we show that the HCV core protein is another BH3-like 
viral homologue and it contributes directly to the induction of apoptosis during 
HCV infection.  Our results also reveal that it is a bona fide BH3-only protein 
that appears to interfere with the prosurvival property of Mcl-1 in a manner 
similar to that of Noxa.  As many viruses have adopted strategies to prevent 
apoptosis in infected cells so as to facilitate viral replication and the packaging 
of progeny genomes, our observation that the enhanced apoptotic activity of 
the J6/JFH-1(V119L) virus correlates with an increase in infectious progeny 
HCV release seems to be counterintuitive (Cuconati and White, 2002; 
Hardwick and Bellows, 2003; Polster et al., 2004; White, 2006).  However, 
enhanced releases of virus from infected cells that are undergoing apoptosis 
have also been reported for other viruses, such as the infectious bursal disease 
virus, adenovirus and Aleutian mink disease parvovirus (Best et al., 2002; Mi 
et al., 2001; Yao and Vakharia, 2001), indicating that apoptosis can be 
advantageous for viral spreading at the late stages of infection. 
 Besides the genotype 1b core protein, the properties of the genotype 1a 
core protein have been examined in various studies (Hahn et al., 2000; Kang et 
al., 2009; Moorman et al., 2003; Saito et al., 2006).  Although previous studies 
have attributed both prosurvival and proapoptotic properties to the genotype 
1a core protein, these have yet to be verified using the JFH-1-based infectious 
clone system.  Similar observations have also been described in 
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overexpression studies using the genotype 1b core protein and appear to be 
dependent on the death stimuli and types of cells used (Benali-Furet et al., 
2005; Cao et al., 2004; Chang et al., 2008; Lee et al., 2007; Otsuka et al., 
2002; Realdon et al., 2004; Sacco et al., 2003; Takamatsu et al., 2001; Zhu et 
al., 2001).  Several studies have identified domains or regions within the core 
protein that interfere with specific apoptosis pathways.  For instance, the N-
terminal domain (residues 1 to 75) of the genotype 1a core protein interacts 
with Hsp60, leading to the production of reactive oxygen species and 
enhancement of tumour necrosis factor alpha-mediated apoptosis (Kang et al., 
2009), while its C-terminal domain (residues 153 to 192) facilitates Fas 
oligomerization and is required for apoptosis induction in Jurkat cells 
(Moorman et al., 2003).  The genotype 1b core protein (residues 1 to 153) 
binds to the death domain of FADD, resulting in enhanced apoptosis (Zhu et 
al., 2001).  However, an overlapping domain spanning the first 46 aa of the 
core protein mediates interaction with a p53-binding protein, ASPP2, which 
leads to the inhibition of p53-mediated apoptosis (Cao et al., 2004).  These 
findings suggest that multiple domains present in the core protein contribute to 
the modulation of apoptosis via diverse pathways.  Therefore, the net 
apoptotic effect of the core protein may be dependent on the relative strength 
of its prosurvival and proapoptotic properties.  Unlike the genotype 2a core 
protein, the BH3 domains of the genotype 1b core protein and the genotype 1a 
core protein share an identical sequence (Figure 3.1B) and are expected to 
function in a similar manner.  However, we cannot rule out the possibility that 
there may be differences in the manner in which the core proteins of 
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genotypes 1a and 1b modulate apoptosis during infection.  For example, they 
may be involved in different virus-virus or virus-host interactions. 
 It is apparent that the parental J6/JFH-1 virus also induces a high level 
of apoptosis in the infected cells and for the early time points, there was no 
significant difference in the levels of apoptosis induced by the parental 
J6/JFH-1 virus and the J6/JFH-1(V119L) mutant virus (Figures 3.14A to 
3.14C).  This implies that since the BH3 domain of the genotype 2a core 
protein is not a major contributing factor, there are other viral factors that 
contribute to the induction of apoptosis during J6/JFH-1 infection.  For 
example, several non-structural HCV proteins such as NS3, NS4A, NS5A and 
NS5B have been shown to induce apoptosis when they are overexpressed in 
certain types of cells [see reviews by (Aweya and Tan, 2011; Fischer et al., 
2007; Herzer et al., 2007)].  In addition, other domains in the core protein have 
been shown to bind host proteins and may contribute to apoptosis regulation 
by interfering with different cellular pathways [see reviews by (Lai and Ware, 
2000; McLauchlan, 2000; Ray and Ray, 2001)].  However, the relative 
contribution of these various factors to apoptosis induction during HCV 
infection remains to be determined.  Hence, using the J6/JFH-1 HCVcc 
system, we investigated other pathways that are modulated during HCV-
induced apoptosis and this is discussed in the following chapters.  
 98 
CHAPTER 4: APOPTOSIS IN HCV-INFECTED HUH7.5 CELLS 
4.1 Efficient expression of HCV proteins in Huh7.5 cells infected with 
HCV J6/JFH-1-P47 strain 
 The recent development of an in vitro HCV cell culture (HCVcc) 
infection system facilitates further understanding of the HCV life cycle and 
pathogenesis (Lindenbach et al., 2005; Lindenbach et al., 2006; Wakita et al., 
2005; Zhong et al., 2005).  In Chapter 3, we demonstrated that the HCV 
J6/JFH-1 strain induces apoptosis in infected Huh7.5 cells, which is consistent 
with previous reports (Deng et al., 2008; Mateu et al., 2008; Walters et al., 
2009).  However, the mechanisms underlying this induction of apoptosis are 
poorly understood.  Therefore, in order to further characterize HCV-induced 
apoptosis, we infected Huh7.5 cells with a tissue culture-adapted HCV strain, 
J6/JFH-1-P47, and investigated the possible effects of HCV infection on 
cellular apoptotic pathways.   
 Compared to the parental J6/JFH-1 virus, the J6/JFH-1-P47 strain 
exhibits higher expression of HCV proteins and produces a much higher titre 
of infectivity in Huh7.5 cell cultures.  Growth curve analysis of cells 
transfected or infected with the wild-type and adapted viral RNA or virus 
showed that the adaptive mutant possesses advantages at the entry level, rather 
than the replication or translation level (Bungyoku et al., 2009).  This is 
consistent with previous studies using the HCV replicon system which showed 
that replication-enhancing mutations impair virus release (Blight et al., 2003; 
Bukh et al., 2002).  Furthermore, recent infection studies using JFH-1-based 
recombinants demonstrated that cell culture adaptive mutations largely 
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increase virus titres without affecting replication (Delgrange et al., 2007; 
Gottwein et al., 2009; Kaul et al., 2007; Pokrovskii et al., 2011; Yi et al., 
2007).  Owing to its high infectivity, the J6/JFH-1-P47 infection system is 
more convenient for our study which requires cells to be infected at a 
relatively high MOI of 2.  Furthermore, since the J6/JFH-1-P47 strain was 
previously reported to exert a stronger cytopathic effect than the parental 
virus, the adapted virus may provide a more efficient system for studying 
HCV-induced apoptosis (Deng et al., 2008). 
 To confirm successful HCV infection, we first examined the 
expression of HCV proteins in infected and mock-treated Huh7.5 cells.  Serum 
from a HCV-infected patient was used in indirect immunofluorescence 
experiments to visualize HCV-positive cells.  At 2 days post-infection (d.p.i.), 
HCV antigens were detected in the infected cells, but not in the mock-treated 
cells, and displayed both diffuse and punctate cytoplasmic distribution (Figure 
4.1A).  More than 95% of the cells were infected with HCV by 2 d.p.i.  
Western blot analysis was also performed to determine the expression levels 
of two HCV proteins, NS3 and core, in HCV-infected cells.  As shown in 
Figure 4.1B, expression of NS3 and core was only observed in the HCV-
infected cells and high expression levels were detected over at least 8 days 
after infection.  These data show that J6/JFH-1-P47 (henceforth referred to as 
“HCV”) can successfully infect Huh7.5 cells in our system.  Under these 
conditions, majority of the cells were infected 2 days after inoculation and this 





Fig. 4.1.  Expression of HCV proteins in Huh7.5 cells infected with J6/JFH-1-P47 
virus.  (A) Huh7.5 cells infected with mock preparation (top row) or HCV (bottom 
row) at MOI 2 were subjected to indirect immunofluorescence analysis 48 h after 
infection.  HCV antigens were detected using HCV-infected patient’s serum and 
FITC-conjugated goat anti-human IgG (green staining) and cell nuclei were 
counterstained with DAPI (blue staining).  (B) Whole cell lysates were prepared from 
mock-infected and HCV-infected Huh7.5 cells at 2, 4, 6 and 8 days post-infection 
(d.p.i.) and analyzed by Western blotting to determine the expression levels of HCV 
NS3 (first panel) and core (third panel).  The amounts of total cell lysates loaded were 
verified by measuring the levels of endogenous GAPDH (second panel) or actin 
(fourth panel).  Specific bands are indicated by arrows on the right and molecular 
masses of markers are indicated on the left.  














































2 d.p.i. 4 d.p.i. 6 d.p.i. 8 d.p.i.
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4.2 Kinetics of viral RNA replication and virus production in HCV-
infected Huh7.5 cells 
 In addition to viral protein expression, HCV RNA replication and the 
production of progeny virus were also monitored.  The HCV RNA content in 
the infected cells was analyzed by quantitative real-time PCR and a steady-
state level of viral RNA replication was observed from 2 to 6 d.p.i. (Figure 
4.2A).  The virus titres in the culture supernatant of infected cells peaked and 
reached a plateau at 4 d.p.i. (Figure 4.2B), as determined by indirect 
immunofluorescence analysis.  These results confirm that HCV can replicate 
efficiently in the culture to produce high titres of infectious progeny virus. 
Since this system supports the complete HCV life cycle, it can be used to 
study the impact of a productive HCV infection on host cell function. 
Fig. 4.2.  HCV RNA replication and production of cell-free infectious virus particles.  
(A) Total RNA was isolated from HCV-infected Huh7.5 cells at 2, 4 and 6 days post-
infection (d.p.i.) and reverse transcribed.  HCV RNA replication levels were 
determined by quantitative real-time PCR analysis and normalised to endogenous 
GAPDH levels.  (B) Culture supernatants of HCV-infected cells were collected at 2, 4 
and 6 d.p.i. and used to inoculate naive Huh7.5 cells.  Virus infectivity was 
determined by indirect immunofluorescence analysis at 24 h post-infection and 
expressed as focus forming units per ml (ffu/ml).  Data shown are representative of 





























































4.3 HCV infection modulates cell viability and apoptosis in Huh7.5 
cells 
 To investigate the effect of HCV infection on host cell growth, the 
viabilities of HCV-infected and mock-treated Huh7.5 cells were measured 
using WST-1 assay at 0, 2, 4 and 6 d.p.i.  As shown in Figure 4.3A, HCV-
infected cells showed significantly lower viabilities than mock-treated cells, 
indicating that the virus has induced cytopathic effects (CPE).  To further 
characterize the CPE observed in HCV-infected cells, the activation of 
caspase-3, a hallmark of apoptosis, in these cells was determined.  At 2 and 4 
d.p.i., cells infected with HCV exhibited higher levels of caspase-3 activity 
than mock-treated cells, indicating that the CPE was mediated largely through 
apoptosis (Figure 4.3B).  Interestingly, at 6 d.p.i., the level of caspase-3 
activity in HCV-infected cells was significantly lower compared to that in 
mock-treated cells (Figure 4.3B).  This decrease in apoptosis correlates with a 
higher percentage of viable HCV-infected cells at 6 d.p.i. (61%) than at 4 
d.p.i. (49%) (Figure 4.3A).  However, this was not observed in previous 
studies of apoptosis related to acute HCV infection (Deng et al., 2008; Mohd-
Ismail et al., 2009), which showed increasingly higher levels of both CPE and 
apoptosis in HCV-infected cells than in mock-treated cells at 6 and 8 d.p.i.  A 
possible reason for this disparity is the extensive cell death observed in the 
mock-treated samples due to overgrowth at the later time points in our 
infection system.  
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Fig. 4.3.  Cell viability and caspase-3 activity of Huh7.5 cells infected with HCV.  
(A) Cell viability/proliferation was measured using WST-1 assay at 0, 2, 4 and 6 days 
post-infection (d.p.i.).  The viability of HCV-infected cells (open symbols) is 
expressed as a percentage of the mock control cells (closed symbols) at each time 
point.  (B) A Caspase-Glo 3/7 luminogenic assay system was used to measure the 
activation of caspase-3 in HCV-infected (filled columns) and mock-treated (empty 
columns) cells.  The caspase-3 activity of mock control cells at each time point was 
arbitrarily expressed as 1.0.  Data shown is representative of three independent 
experiments and statistically significant differences between mock and HCV-infected 





































































4.4 Temporal expression of members of the Bcl-2 protein family in 
HCV-infected Huh7.5 cells 
4.4.1 Western blot analysis of Bcl-2 family protein expression 
 The members of the B cell lymphoma-2 (Bcl-2) protein family play a 
central role in the mitochondrial pathway of apoptosis through the tight 
regulation of outer mitochondrial membrane integrity [see recent reviews by 
(Chipuk et al., 2010; Tait and Green, 2010)].  To investigate the possible 
involvement of these proteins in HCV-associated apoptosis, we first examined 
differences in the endogenous expression of prosurvival members, Bcl-XL and 
Mcl-1, and proapoptotic members, Bax and Bak, in response to HCV 
infection.  As shown in Figure 4.4A, HCV-infected Huh7.5 cells expressed 
significantly higher levels of Bcl-XL protein from 2 to 8 days d.p.i. compared 
to the mock-treated control.  The amount of Bcl-XL protein detected in HCV-
infected cells increased 1.5-fold within 2 days of infection and steadily 
increased to approximately 6-fold by 8 d.p.i. (Figure 4.4B).  In contrast, the 
expression of Bak was slightly decreased in HCV-infected cells compared to 
the mock-treated control (Figure 4.4A).  This small reduction in Bak protein 
level was consistently observed at later time points of infection (Figure 4.4C).  
On the other hand, the protein levels of Mcl-1 and Bax were not significantly 
altered by HCV infection of Huh7.5 cells (Figure 4.4A).  The expression of 
the core protein indicated infection by HCV.  These results suggest that HCV 
possibly disrupts the balance of Bcl-2 family members in the infected cells, 
which may in turn have an impact on apoptotic signalling.  
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Fig. 4.4.  Protein expression of Bcl-2 family members in HCV-infected Huh7.5 cells.  
(A) Whole cell lysates were prepared from HCV-infected cells and mock-treated 
control at 2, 4, 6 and 8 days post-infection (d.p.i.) and analyzed by Western blotting 
using antibodies against Bcl-XL, Mcl-1, Bax, Bak, core and actin.  The amounts of 
total cell lysates loaded were verified by measuring the levels of endogenous actin.  
Specific bands are indicated by arrows on the right and molecular masses of markers 
are indicated on the left.  The intensity of Bcl-XL (B) and Bak (C) protein bands in 
HCV-infected cells (filled column) and mock-treated control (empty column) was 
quantified using Image J.  The intensity of the mock-treated control was arbitrarily 
expressed as 1.0.  Data represent means ± SD of three independent experiments.  *P 






































































































4.4.2 HCV infection upregulates Bcl-XL mRNA levels in Huh7.5 cells 
 Since the Bcl-XL protein levels dramatically increased in response to 
HCV infection, the mechanism underlying this upregulation was investigated.  
In order to determine if the elevated Bcl-XL protein levels observed in HCV-
infected cells were due to increased gene transcription, quantitative real-time 
PCR analysis was performed using total mRNA obtained from HCV-infected 
and mock-treated samples.  As shown in Figure 4.5, Bcl-XL mRNA levels 
were upregulated in HCV-infected cells by 1.7 to 4.5-fold from 2 to 6 d.p.i.  
The fold change in Bcl-XL mRNA increased in a time-dependent manner and 
mirrored the increasing trend observed at the protein level (Figures 4.4A and 
4.4B).  Taken together, these results show that HCV upregulates the 
expression of Bcl-XL by enhancing its gene transcription in infected Huh7.5 
cells. 
Fig. 4.5.  HCV infection induces upregulation of Bcl-XL mRNA in Huh7.5 cells.  
Cells were infected with HCV (MOI 2) and incubated for 2, 4 or 6 days post-infection 
(d.p.i.) before RNA extraction.  Fold changes in Bcl-XL gene expression were 
determined by quantitative real-time PCR.  Data shown is representative of three 
independent experiments and statistically significant differences between mock-
treated (empty columns) and HCV-infected (closed columns) cells are indicated by 



























4.4.3 Identifying HCV factors that upregulate Bcl-XL expression 
 Previous studies have demonstrated upregulation of Bcl-XL in cells 
expressing either HCV core protein or NS5A (Hara et al., 2006; Otsuka et al., 
2002; Sarcar et al., 2004; Yoshida et al., 2002).  It has been suggested that the 
core protein and NS5A enhance Bcl-XL levels through the activation of the 
STAT3 signalling pathway.  However, the core protein and NS5A examined 
in these studies were derived from HCV genotype 1b strains while our 
previous experiments were performed using the HCV genotype 2a infectious 
clone.  Therefore, to determine whether the core protein and NS5A of the 
genotype 2a virus can induce Bcl-XL upregulation in a similar manner, 
liposome-mediated transfection of cDNA expression plasmids containing the 
core protein gene or the NS5A gene was performed in Huh7.5 cells and the 
endogenous Bcl-XL protein levels were analyzed by Western blotting. 
 As shown in Figure 4.6, cells expressing flag-tagged genotype 2a core 
protein or NS5A expressed comparable amounts of Bcl-XL protein as the 
vector-transfected control cells (lanes 1 to 3).  In contrast, the expression of 
flag-tagged genotype 1b core protein or NS5A enhanced Bcl-XL protein levels 
slightly (lanes 4 and 5), which is consistent with the previous studies.  These 
results suggest that in the case of HCV genotype 2a infection, other viral 
factors aside from the core protein and NS5A may contribute to the Bcl-XL 
upregulation observed.  Thus, further experiments are required to identify this 
viral factor(s) and delineate the mechanism(s) underlying this upregulation.  
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Fig. 4.6.  Effects of HCV core protein and NS5A expression on the endogenous Bcl-
XL levels.  Huh7.5 cells were transfected with vector only (lane 1) or cDNA 
constructs for expressing flag-core (lanes 2 and 4) or flag-NS5A (lanes 3 and 5) 
derived from HCV genotypes 2a and 1b.  Western blot analysis using a specific 
antibody against Bcl-XL was performed to determine the expression level of the 
endogenous protein (top).  Similarly, the expression levels of the core protein and 
NS5A were determined using an anti-flag antibody (middle two).  The amounts of 
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4.5 Apoptotic gene expression profiling of HCV-infected Huh7.5 cells 
4.5.1 Real-time PCR array analysis of apoptosis-related genes in HCV-
infected Huh7.5 cells 
 Gene expression profiling using pathway-focused real-time PCR arrays 
provides an alternative approach for the identification of host genes that may 
be involved in HCV-associated apoptosis.  Here, the human apoptosis RT
2
 
Profiler PCR array was used to profile and compare the expression of 84 
apoptotic genes in HCV-infected and mock-treated Huh7.5 cells.  These genes 
include members of the caspase, Bcl-2, IAP, TRAF, CARD, CIDE, death 
domain, death effector domain and TNF receptor and ligand families, as well 
as genes involved in the p53 and DNA damage pathways.  Previously, we 
demonstrated the induction of apoptosis in HCV-infected cells from 2 d.p.i. 
(Figure 4.3B).  To further examine HCV-induced apoptosis during the early 
acute phase of infection, HCV-infected and mock control samples from 2 to 6 
d.p.i. were subjected to PCR array analysis.  Since each host gene is only 
represented by one well in the array, three independent experiments were 
performed to achieve reliability, thus providing three biological replicates.   
 In the three experiments, the Ct values of the five housekeeping genes 
were relatively similar in the HCV-infected and the mock-treated samples at 
all time points.  This indicated that the expression of these genes were not 
altered by HCV infection and thus, can be used to normalize the expression of 
the assayed genes.  As shown in Figure 4.7, the population size and intensity 
of differentially expressed apoptotic genes were relatively similar at 2 and 4 
d.p.i. and then increased substantially at 6 d.p.i.  Next, dissociation curve 
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analysis of the PCR products showed that 19 out of the 84 genes had multiple 
peaks in their melting curve, instead of a single sharp peak which indicates a 
specific PCR product (Appendix 2).  This is rather surprising as the PCR array 
contains primer pairs that have been experimentally validated to ensure gene 
specificity.  This could be due to non-specific binding of primers to the cDNA 
template or the presence of splice variants of the gene in liver cells, which 
might be different from the cells used for primer validation.  As a result, the 
observed expression changes of these genes were likely to be inaccurate and 
thus, were excluded from subsequent analysis.  The significance of the gene 
expression changes was determined using a Student’s t-test and P values less 
than 0.05 were considered to be statistically significant.  Out of the remaining 
65 genes, the number of genes that showed statistically significant changes in 
expression of at least 2-fold or 3-fold at each time point is summarized in 
Table 4.1.  Similar to the preliminary data shown in Figure 4.7, a higher 
proportion of the genes were differentially regulated at 6 d.p.i. than at 2 and 4 
d.p.i., suggesting temporal regulation of host apoptotic genes by HCV. 




No. of differentially expressed genes
a
 
≥ 2-fold ≥ 3-fold 
2 d.p.i. 2 (3.1%) 2 (3.1%) 
4 d.p.i. 4 (6.2%) 1 (1.5%) 
6 d.p.i. 10 (15.4%) 6 (9.2%) 
a
 Only genes that gave rise to a specific PCR product and showed statistically 
significant expression changes (P <0.05) were considered.  The percentage of 

























































































































































Fig. 4.7.  3D profiles of the gene expression changes in the PCR array analysis.  Data 
obtained at (A) 2 d.p.i., (B) 4 d.p.i. and (C) 6 d.p.i. are presented in the 96-well 
format of the PCR array (x and y-axes) and the corresponding genes are listed in 
Appendix 1.  Columns pointing up (with z-axis values > 1) indicate an upregulation 
of gene expression and columns pointing down (with z-axis values < 1) indicate a 
downregulation of gene expression in the HCV-infected sample relative to the mock 
control sample.  Gene expression changes of between 2- and 3-fold are represented 
by blue columns and changes of more than 3-fold are represented by red columns.  








4.5.2 Quantitative real-time PCR validation of gene expression changes 
 Various selection criteria can be applied to the PCR array data in order 
to shortlist differentially expressed host apoptotic genes for further validation.  
Using one possible selection criteria, five genes were identified to be 
consistently up- or down-regulated by more than 3-fold at the same time point 
post-infection in all three experiments (Table 4.2).  At 6 d.p.i., the expression 
of BIK and FAS was upregulated while that of BNIP3 was downregulated.  In 
contrast, GADD45A mRNA levels displayed only an initial increase at 2 d.p.i.  
The expression of HRK exhibited the most significant change in response to 
HCV infection and was highly upregulated at all time points post-infection. 
 To validate the PCR array results, quantitative real-time PCR (qPCR) 
analysis was performed using pre-designed primers and probes based on 
TaqMan chemistry.  BIK mRNA expression increased 5-fold within 2 days of 
infection and steadily increased 33-fold by 6 d.p.i. (Figure 4.8A).  In contrast, 
BNIP3 mRNA expression decreased almost 3-fold by 4 d.p.i. (Figure 4.8B).  
An increase in the expression of FAS mRNA by 4-fold was only observed at 6 
d.p.i. (Figure 4.8C) while GADD45A mRNA expression increased 3-fold by 2 
d.p.i. and this upregulation was maintained until 6 d.p.i. (Figure 4.8D).  Out of 
the five differentially expressed host genes that were selected for further 
validation, HRK mRNA expression was altered most dramatically, increasing 
22-fold at 2 d.p.i. and almost 60-fold by 6 d.p.i. (Figure 4.8E). 
 In general, the results of the validation experiments were consistent 
with the expression changes observed in the PCR array analysis.  As shown in 
Table 4.2 and Figure 4.8, the expression of BIK, FAS, GADD45A and HRK 
 113 
were all upregulated at least 3-fold while the expression of BNIP3 was 
downregulated almost 3-fold in HCV-infected cells compared to the mock-
treated control.  However, several differences in trend were observed for the 
expression of BNIP3 and GADD45A.  In the PCR array analysis, BNIP3 
expression showed the biggest decrease at 6 d.p.i. while this was observed 
earlier at 4 d.p.i. in the validation experiment (Figure 4.8B).  Similarly, the 
upregulation of GADD45A peaked at different times, 2 d.p.i. in the PCR array 
analysis and 6 d.p.i. in the validation experiment (Figure 4.8D).  These 
variations may be due to the different sensitivities and specificities of SYBR 
and TaqMan chemistries or the efficiency of priming different target regions 
on the cDNA (Arikawa et al., 2008).  The latter could not be addressed due to 
the lack of access to the proprietary information on the exact sequences of the 
primers and probes used in these two assays. 
Table 4.2.  Fold changes of apoptosis-related genes in HCV-infected Huh7.5 cells as 





Fold Up- or Down-Regulation
b
 
2 d.p.i. 4 d.p.i. 6 d.p.i. 
Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
BIK 1.21 -1.09 2.56 1.36 1.16 4.48 3.19 5.17 5.49 
BNIP3 -1.38 -1.86 1.02 -1.75 -1.60 -2.58 -3.39 -3.07 -3.10 
FAS 2.51 1.09 2.15 2.91 2.04 3.15 53.13 4.93 3.14 
GADD45A 3.88 3.91 4.29 2.49 2.72 2.52 1.94 2.21 1.63 
HRK 21.77 36.46 15.38 12.16 42.36 13.56 124.77 57.41 33.70 
a
 Only genes that were consistently up- or down-regulated by more than 3-fold are 
listed in the table. 
b
 Fold changes of more than 3-fold that were observed at a specific time point in all 
three experiments (sets 1 to 3) are indicated in red (upregulated) or blue 
(downregulated).  
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Fig. 4.8.  Validation of mRNA fold changes in HCV-infected Huh7.5 cells by 
quantitative real-time PCR.  Cells were infected with HCV (MOI 2) and incubated for 
2, 4 and 6 days post-infection (d.p.i.).  Fold changes in gene expression were 
determined by real-time PCR using specific primers to (A) BIK, (B) BNIP3, (C) 
FAS, (D) GADD45A and (E) HRK and normalised to GAPDH expression.  Data 
shown is representative of three independent experiments and statistically significant 
differences between mock (empty columns) and HCV-infected (closed columns) cells 




















































































































4.5.3 Expression of HRK in HCV-infected Huh7.5 cells 
 Since quantitative real-time PCR analysis using both SYBR-based and 
TaqMan-based detection showed that HRK is the most strongly upregulated 
gene at all time points post-infection, Western blot analysis was performed 
using a specific antibody against human HRK in order to determine if the 
upregulation of HRK mRNA expression by HCV infection translates to an 
increase in HRK protein level.  Interestingly, the HRK protein level in HCV-
infected cells was comparable to that in the mock-treated control during the 
first 6 days after infection (Figure 4.7A).  At 8 d.p.i., the HRK protein level in 
HCV-infected cells increased by 1.2-fold (Figure 4.7B).  However, this 
increase in HRK protein level is small compared to the extent of HRK mRNA 
upregulation (Figure 4.6E), suggesting that there may be other factors 
regulating the synthesis and/or stability of the HRK protein. 
Fig. 4.9.  Expression of HRK in HCV-infected Huh7.5 cells.  (A) Whole cell lysates 
were prepared from HCV-infected cells and mock-treated control at 2, 4, 6 and 8 days 
post-infection (d.p.i.) and the expression of HRK, HCV core and actin was 
determined by Western blot analysis.  The amounts of total cell lysate loaded were 
verified by measuring the levels of endogenous actin.  Specific bands are indicated by 
arrows on the right and molecular masses of markers are indicated on the left.  The 
intensity of HRK in HCV-infected cells (filled column) and mock-treated control 
(empty column) at 8 d.p.i. was quantified using Image J.  The intensity of the mock-
treated control was arbitrarily expressed as 1.0.  Data represent means ± SD of two 





























































 HCV-induced liver injury is thought to be the result of both direct 
cytopathic effects of the virus and host immune responses [reviewed by 
(Mengshol et al., 2007)].  Apoptosis is a common feature of these processes 
and might be mediated directly by HCV replication and/or gene products or 
through the actions of cytotoxic lymphocytes (Bantel and Schulze-Osthoff, 
2003; Fischer et al., 2007).  Enhanced hepatocyte apoptosis has been observed 
in the liver of patients chronically infected with HCV and correlates with liver 
damage (Bantel et al., 2001; Calabrese et al., 2000).  Apoptosis of hepatocytes 
may also contribute to liver injury through the induction of hepatic 
fibrogenesis (Bantel et al., 2004; Canbay et al., 2004).  Given its central role in 
HCV-associated liver injury, it is important to understand the cellular 
mechanisms underlying HCV-mediated apoptosis.  The HCVcc infection 
system provides a convenient tool for characterizing the direct cytopathic 
effects of HCV in cultured hepatocytes, without the complication of immune-
mediated responses.  In this study, by using the HCVcc system, we have 
identified several apoptotic genes that are differentially expressed in response 
to acute HCV infection, suggesting a role for them in HCV-associated 
apoptosis.  
 In common with other studies, we showed that acute in vitro HCV 
infection of cultured hepatocytes induced cytopathic effects, which were 
characterized by an increase in apoptosis induction (Figure 4.3).  The 
intragenotypic J6/JFH-1 chimera has previously been shown to induce higher 
levels of apoptosis compared to the parental JFH-1 strain (Mateu et al., 2008) 
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while the tissue culture-adapted  J6/JFH-1-P47 virus used in this study exerts 
an even stronger cytopathic effect than the J6/JFH-1 chimera (Deng et al., 
2008).  Increased abilities of the virus to induce apoptosis appeared to 
correlate with increased viral replication and virion production (Bungyoku et 
al., 2009; Mateu et al., 2008).  The search for host factors that may be 
involved in HCV-associated apoptosis has thus far identified two members of 
the Bcl-2 protein family, Bax and Bcl-XL, which act in the mitochondrial 
apoptosis pathway.  HCV-induced activation of proapoptotic Bax triggered 
apoptosis in Huh7.5 cells infected with the J6/JFH-1-P47 virus (Deng et al., 
2008).  The genotype 1a infectious clone H77c sensitized hepatocytes to 
apoptosis in chimeric SCID/Alb-uPA mice by inducing Bax activation and 
downregulating prosurvival NF-κB and Bcl-XL (Joyce et al., 2009).  More 
recent studies have linked HCV-induced apoptosis to cell cycle perturbations.  
Consistent with previous reports (Kannan et al., 2011; Timpe et al., 2008), we 
observed that proliferation of HCV-infected cells was slower than naive cells 
(Figure 4.3A).  This delay in cell cycle progression has been attributed to cell 
cycle arrest at the G1 phase and/or at the interface of G2 and mitosis, 
accompanied by differential expression of cell death genes and higher levels 
of apoptotic markers (Kannan et al., 2011; Marshall et al., 2005; Walters et al., 
2009). 
 By examining the expression of a subset of the Bcl-2 protein family, 
we demonstrated that HCV infection significantly upregulates Bcl-XL gene 
transcription (Figure 4.5) and protein expression (Figures 4.4A and 4.4B).  
Our finding is consistent with earlier studies that reported increased levels of 
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Bcl-XL in the presence of HCV core or NS5A.  Overexpression of the core 
protein enhanced the expression of Bcl-XL mRNA and protein and resulted in 
the inhibition of apoptosis (Hara et al., 2006; Otsuka et al., 2002).  Yoshida 
and colleagues demonstrated that the activation of STAT3 by the core protein 
upregulates Bcl-XL expression and leads to cellular transformation (Yoshida et 
al., 2002).  Similarly, activation of the STAT3 pathway by NS5A also 
enhanced Bcl-XL expression (Sarcar et al., 2004).  Conversely, inhibition of 
core protein expression in immortalized hepatocytes decreased Bcl-XL protein 
levels (Meyer et al., 2005).   
 However, we showed that the expression of the core protein or NS5A 
derived from the JFH-1 clone (genotype 2a) did not significantly alter the 
endogenous Bcl-XL levels in transfected Huh7.5 cells (Figure 4.6).  This may 
be due to genotypic differences as the previous studies were done using HCV 
genotype 1b proteins and thus, implies that other HCV genotype 2a factors 
may contribute to enhanced Bcl-XL expression in infected cells.  In agreement 
with this, a very recent report showed that HCV E2-CD81 engagement is 
sufficient to induce the upregulation of Bcl-2 and Bcl-XL expression in human 
B lymphocytes treated with purified genotype 1a E2 protein or infected with 
the J6/JFH-1 virus (Chen et al., 2011).  Since this experiment was performed 
using B cells, further experiments are needed to determine if the E2 
glycoprotein contributes to the Bcl-XL upregulation observed in Huh7.5 cells 
infected with HCV genotype 2a.  Alternatively, the differences observed 
between viral proteins derived from HCV genotypes 1b and 2a may be due to 
the low efficiency of liposome-mediated transfection.  The core protein and 
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NS5A of genotype 2a may be less potent inducers of Bcl-XL upregulation than 
their genotype 1b counterparts and thus, their effects on cellular Bcl-XL 
protein levels may not be observable using this expression system.  Hence, 
more efficient gene delivery systems such as viral vectors or more sensitive 
techniques such as promoter reporter assays may be used to examine the roles 
of the core protein and NS5A in HCV-induced Bcl-XL upregulation. 
 It is intriguing that HCV-induced apoptosis occurs in this background 
of high Bcl-XL expression.  Bcl-XL is one of two major prosurvival Bcl-2 
proteins expressed in the liver and plays an important protective role against 
apoptotic stimuli (Hikita et al., 2009; Takehara et al., 2004).  Nevertheless, it 
is possible that the level of Bcl-XL is insufficient to completely inhibit 
apoptosis or that HCV-induced apoptosis is mediated by alternative pathways.  
Also, it is unclear at this point if the upregulation of Bcl-XL is driven by the 
virus in order to moderate apoptosis levels in favour of viral replication or by 
the host in order to protect itself against massive viral-induced cell death.  
Joyce and colleagues reported that although the overall levels of NF-κB and 
Bcl-XL in the liver of HCV-infected chimeric SCID/Alb-uPA mice were 
increased, both NF-κB and Bcl-XL levels were lower in infected cells 
compared to adjacent uninfected cells (Joyce et al., 2009).  This explains 
sensitization of infected hepatocytes to apoptosis and suggests that Bcl-XL 
upregulation in the surrounding cells is a host response to HCV infection.  
However, this is unlikely to be the case in our system as the cultures which 
showed Bcl-XL upregulation were inoculated at a sufficiently high MOI to 
infect all the cells (Figure 4.1A).  Therefore, to further understand the 
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involvement of Bcl-XL in HCV pathogenesis, we investigated the possible 
role(s) of Bcl-XL during the early acute phase of HCV infection and this is 
discussed in Chapter 5. 
 Unlike Bcl-XL, the expression of Mcl-1, the other major prosurvival 
Bcl-2 protein in the liver, was not significantly altered by HCV infection 
(Figure 4.4).  Similarly, HCV infection did not modulate the levels of key 
proapoptotic mediators, Bax and Bak, to a large extent but their proapoptotic 
activity is also dependent on their conformation and/or subcellular localization 
(Westphal et al., 2011).  In agreement with this, previous studies showed that 
HCV-induced apoptosis was accompanied by the activation of Bax, as 
characterized by its conformational change and mitochondrial accumulation, 
with minimal variation in its expression level (Deng et al., 2008; Joyce et al., 
2009). 
 PCR array analysis of HCV-infected cells during the early acute phase 
of infection showed that host apoptotic genes were differentially regulated 
from 2 d.p.i., which corresponds with the HCV-induced apoptosis observed at 
this time point (Figures 4.3 and 4.7).  Five host apoptotic genes were identified 
to be consistently differentially regulated by more than 3-fold in HCV-infected 
cells (Table 4.2).  The changes in gene expression were independently verified 
by quantitative real-time PCR (Figure 4.8).  These genes provide an insight as 
to which apoptotic pathways may be specifically modulated by HCV.  Three 
out of the five shortlisted genes encode proapoptotic BH3-only members of 
the Bcl-2 protein family (BIK, BNIP3 and HRK) which generally act via the 
intrinsic, mitochondria-mediated apoptosis pathway.  The remaining two 
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genes are Fas, a member of the tumour necrosis factor receptor (TNFR) gene 
superfamily that causes cell death via the extrinsic apoptosis pathway, and 
GADD45A, a protein that is involved in cell cycle arrest.  These genes and 
their protein products are discussed in greater detail below. 
 One of the host genes that were upregulated by HCV infection is BCL-
2 interacting killer (BIK) which is a proapoptotic BH3-only member of the 
Bcl-2 protein family (Figure 4.8A).  In addition to binding cellular prosurvival 
proteins Bcl-2 and Bcl-XL, BIK can also interact with viral anti-apoptosis 
proteins such as Epstein-Barr virus BHRH1 and adenovirus E1B-19K (Boyd 
et al., 1995; Han et al., 1996).  Although it has not been extensively studied in 
relation to HCV infection, BIK has been shown to play an important role in 
adenovirus-induced apoptosis.  Bik
−/−
 mice infected with an apoptogenic 
adenovirus mutant did not display the apoptotic cytopathic effect (Shimazu et 
al., 2007).  Furthermore, transcriptional activation of BIK was observed in 
adenovirus-infected human cells undergoing apoptosis (Subramanian et al., 
2007).  In a recent study, global transcriptional profiling of HCV J6/JFH-1-
infected Huh7.5 cells by microarray analysis also detected BIK upregulation 
within the subset of cell death-related genes (Walters et al., 2009). 
 Out of the five shortlisted host genes, only the expression of Bcl-
2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) was downregulated 
(Figure 4.8B).  BNIP3 is an atypical BH3-only protein that can induce 
apoptosis via Bax/Bak activation and/or necrosis via opening of the 
mitochondrial permeability transition pore (Kubli et al., 2007; Quinsay et al., 
2010; Vande Velde et al., 2000).  BNIP3 is also a potent inducer of autophagy, 
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which may confer protection against cell death or contribute to autophagic cell 
death depending on the experimental conditions (Azad et al., 2008; Hamacher-
Brady et al., 2007; Kanzawa et al., 2005).  Due to its multiple roles, it is 
difficult to predict if the HCV-induced downregulation of BNIP3 expression 
has protective or detrimental effects on host cells and further investigations are 
needed to address this.  Interestingly, downregulation of BNIP3 has also been 
observed in astrocytes infected with the murine coronavirus mouse hepatitis 
virus and is postulated to promote viral persistence by inhibiting the host 
antiviral apoptotic response (Cai et al., 2003). 
 Fas, another cell-death related gene found to be upregulated by HCV 
infection (Figure 4.8C), is a death domain-containing cell surface receptor for 
Fas ligand (FasL).  Upon FasL binding and recruitment of cellular adaptor 
proteins, a death-induced signalling complex is formed and apoptosis is 
initiated via the extrinsic apoptosis pathway (Zhang et al., 2005).  Consistent 
with our finding, immunohistochemical studies have previously shown 
upregulation of hepatic Fas expression in chronic hepatitis C patients 
(Hiramatsu et al., 1994; Okazaki et al., 1996).  Enhanced Fas expression in 
hepatocytes and FasL expression in infiltrating T lymphocytes may contribute 
to HCV-induced hepatocyte apoptosis.  However, inhibition of the Fas/FasL 
system was observed in HCC, possibly as a mechanism to evade the host 
immune response (Bortolami et al., 2008).  This suggests that HCV might 
regulate Fas expression differently during early and late stages of infection. 
 Upregulation of growth arrest and DNA damage-inducible alpha 
(GADD45A) was observed in HCV-infected cells (Figure 4.8D).  GADD45A 
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plays a regulatory role in various cellular processes, including maintenance of 
genomic stability, DNA repair, cell cycle arrest and apoptosis (Hollander and 
Fornace, 2002; Tong et al., 2005).  Several studies have reported cell cycle 
arrest in HCV-infected cells, which may be accompanied by apoptosis 
induction (Kannan et al., 2011; Marshall et al., 2005; Sarfraz et al., 2008; 
Walters et al., 2009).  Furthermore, analysis of cell cycle arrest-related gene 
expression revealed that GADD45A is one of several upregulated genes in 
both HCV-infected hepatoma cells and chronic HCV infection, which is in 
agreement with our observation (Sarfraz et al., 2009; Walters et al., 2009).  
Therefore, GADD45A upregulation may contribute to the delayed cell 
proliferation and apoptosis observed in our infection system. 
 Harakiri (HRK), another proapoptotic BH3-only protein, was found to 
be significantly upregulated in response to HCV infection (Figure 4.8E).  
HRK regulates Bax-dependent apoptosis through specific interaction with Bcl-
2 and Bcl-XL (Harris and Johnson, 2001; Inohara et al., 1997).  Enhanced 
HRK expression was also observed in the same genome-wide transcriptional 
profiling study that showed BIK and GADD45A upregulation in the early 
acute phase of HCV infection (Walters et al., 2009).  Hence, enhanced HRK 
expression may be another contributing factor to HCV-induced apoptosis.  
Recently, apoptotic gene expression profiling of HepG2 cells infected with 
dengue virus, another member of the Flaviviridae virus family, showed a 
dramatic increase in HRK expression as well (Morchang et al., 2011).   
 Taken together, the PCR array data suggest that HCV infection 
generally promotes apoptosis induction via both the intrinsic and extrinsic 
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pathways by increasing the expression of proapoptotic genes involved in these 
pathways.  However, since proteins, and not mRNA, are the major effectors of 
cellular function, the corresponding changes in protein level have to be 
confirmed before the contribution of these genes to HCV-induced apoptosis 
can be determined.  For example, in the case of HRK, although there was a 
striking increase in its mRNA expression, this large increase was not observed 
at protein level (Figure 4.9).  Translation of the HRK mRNA might have been 
blocked or the HRK protein may be too short-lived to be detectable by 
Western blot analysis.  Thus, the enhanced expression of HRK mRNA is 
unlikely to have a profound impact in HCV infection.   
 In addition to these five genes, there may be several other differentially 
expressed genes that were unintentionally excluded from the list due to the 
strict selection criteria (at least 3-fold difference in gene expression observed 
in all three experiments).  We showed in Table 4.1 and Figure 4.7 that 
increasing the stringency of selection resulted in fewer shortlisted genes.  This 
also probably explains the absence of Bcl-XL in the list, even though we have 
previously shown that its expression was significantly increased in response to 
HCV infection (Figures 4.4 and 4.5).  The genes that were found to be 
differentially expressed to a lesser extent may also contribute to HCV-induced 
apoptosis.  Six additional genes that showed at least a 2-fold difference in their 
expression at 6 d.p.i. are listed in Appendix 3.  Among them, a homologue of 
BNIP3, BNIP3-like (BNIP3L), was also observed to be downregulated.  Since 
BNIP3 and BNIP3L have similar functions including roles in cell death and 
autophagy (Zhang and Ney, 2009), the data suggest that concerted inhibition 
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of these functions may be important for HCV infection.  Although CIDEB and 
TNFSF10 were not observed to be consistently regulated more than 3-fold in 
all three experiments, they showed an average downregulation of more than 3-
fold at 6 d.p.i., which was nevertheless statistically significant.  Interestingly, 
both TNFSF10 (also known as TRAIL or Apo-2L) and Fas, one of the five 
validated genes, belong to the superfamily of TNF- and TNF receptor-like 
molecules (Tansey and Szymkowski, 2009).  In addition, two other receptors 
of the same family, namely TNFRSF21 and TNFRSF25, were also 
differentially regulated during HCV infection (Appendix 3).  A subset of 
genes was also excluded from the analysis as they displayed multiple peaks in 
the dissociation curve and thus, did not give reliable results (Appendix 2).  It 
might be worth to reanalyse the expression of these genes using different 
primers or other methods if they are known to be involved in specific 
apoptotic pathways that are modulated by HCV. 
 In this study, two different methods were employed to identify host 
factors that may be involved in HCV-induced apoptosis.  Bcl-XL was 
identified by Western blot analysis while BIK, BNIP3, FAS, GADD45A and 
HRK were identified by quantitative real-time PCR array analysis.  There are 
advantages and disadvantages associated with both techniques.  While 
Western blot analysis allows for direct visualization of changes in protein 
levels, screening a large number of proteins is a tedious process and the scope 
of candidate proteins that can be screened is dependent on the availability of 
good antibodies.  In contrast, gene expression profiling by pathway-focused 
PCR arrays enables simultaneous screening of a large number of genes but the 
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changes in mRNA expression require further validation, especially on the 
protein level.  Similar to the disparity observed between HRK mRNA and 
protein levels in this study, a poor correlation between selected mRNA and 
protein abundances in the liver has been previously demonstrated (Anderson 
and Seilhamer, 1997).  Therefore, in this study, the modulation of Bcl-XL 
expression by HCV infection is most convincing and the role of Bcl-XL in 
HCV-induced apoptosis is further investigated in the next chapter.  
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CHAPTER 5: OVEREXPRESSION AND KNOCKDOWN OF BCL-XL 
AND MCL-1 AND THEIR IMPACT ON HCV INFECTION 
5.1 Stable overexpression of Bcl-XL and Mcl-1 in Huh7.5 cells 
 Bcl-XL and Mcl-1 are two major prosurvival Bcl-2 family members in 
the liver which are important for its development and homeostasis (Hikita et 
al., 2009).  As discussed in Chapter 4, HCV may interfere with apoptotic 
signalling in infected cells by modulating the expression levels of host cell 
death proteins.  We demonstrated that HCV infection induced the upregulation 
of Bcl-XL in infected Huh7.5 cells but did not affect Mcl-1 levels (Figure 
4.4A).  The results suggest that Bcl-XL may play a more significant role than 
Mcl-1 in regulating HCV infection.  Therefore, to investigate the possible 
role(s) of Bcl-XL in HCV infection, we examined the effects of Bcl-XL 
overexpression and knockdown during the early acute phase of infection.  
Similarly, the effects of Mcl-1 overexpression and silencing on HCV infection 
were also examined and compared to that of Bcl-XL. 
 Huh7.5 cells stably overexpressing Bcl-XL or Mcl-1 were generated by 
electroporation of the expression plasmids followed by multiple rounds of 
G418 selection.  For ease of detection, exogenously expressed proteins were 
tagged with a c-myc epitope at the N-terminus.  Cells transfected with the 
empty vector were used as controls (clones V4 and V11) as they express only 
endogenous levels of Bcl-XL and Mcl-1 (Figures 5.1A and 5.2A).  Since these 
cells were selected with the same amount of antibiotics as the Bcl-XL and Mcl-
1 stable cells, cellular changes due to the selection process may be ruled out 
when these cells are used as the control cells.  For the Bcl-XL stable cells, 
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clones B60 and B69, expressing approximately 2.8-fold and 3.7-fold more 
Bcl-XL than the control cells respectively, were selected for use in subsequent 
experiments (Figures 5.1A and 5.1B).  Similarly for the Mcl-1 stable cells, 
clone M34, which expresses about 1.7-fold more Mcl-1 than the V4 control 
cells, was selected for the infection experiments (Figures 5.2A and 5.2B).   
 The random integration of the transfected DNA into the cell’s 
chromosomes and the high levels of Bcl-XL or Mcl-1 expression may have an 
effect on cellular proliferation.  Thus, the proliferative abilities of the stable 
clones were determined by WST-1 assay and compared to determine if there is 
substantial difference in their growth rates.  As shown in Figure 5.1C, the 
proliferation rates of the Bcl-XL stable and vector control cells varied slightly.  
However, statistical analysis revealed that these differences were insignificant 
(data not shown).  Likewise, the proliferation rates of M34 and V4 cells were 
comparable (Figure 5.2C).    
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Fig. 5.1.  Stable overexpression of Bcl-XL in Huh7.5 cells.  (A) Cells were 
electroporated with pXJ41neo-myc-Bcl-XL plasmid or empty vector and cultured 
under G418 selection.  Whole cell lysates were prepared from clones stably 
overexpressing Bcl-XL (B60 and B69) and vector control cells (V4 and V11).  Protein 
expression levels were confirmed by Western blot analysis using a primary antibody 
against Bcl-XL (top).  The amounts of total cell lysates loaded were verified by 
measuring the level of endogenous actin (bottom).  Specific bands are indicated by 
arrows on the right and molecular masses of markers are indicated on the left.  (B) 
The intensity of total Bcl-XL in stable clones B60 and B69 (filled columns) and 
control cells V4 and V11 (empty columns) was quantified using Image J.  The 
intensity of Bcl-XL in V4 cells was arbitrarily expressed as 1.0.  (C) Cell proliferation 
of the stable clones was measured using WST-1 assay at days 0, 2, 4 and 6 after cell 
seeding.  Proliferation of V4 at day 0 was arbitrarily expressed as 1.0.  Data represent 

































































Fig. 5.2.  Stable overexpression of Mcl-1 in Huh7.5 cells.  (A) Cells were 
electroporated with pXJ41neo-myc-Mcl-1 plasmid or empty vector and cultured 
under G418 selection.  Whole cell lysates were prepared from cells stably 
overexpressing Mcl-1 (M34) and vector control cells (V4).  Protein expression levels 
were confirmed by Western blot analysis using a primary antibody against Mcl-1 
(top).  The amounts of total cell lysates loaded were verified by measuring the level 
of endogenous GAPDH (bottom).  Specific bands are indicated by arrows on the right 
and molecular masses of markers are indicated on the left.  (B) The intensity of total 
Mcl-1 in stable clone M34 (filled column) and control cells V4 (empty column) was 
quantified using Image J.  The intensity of Mcl-1 in V4 cells was arbitrarily expressed 
as 1.0.  (C) Cell proliferation of M34 and V4 was measured using WST-1 assay at 
days 0, 2, 4 and 6 after cell seeding.  Proliferation of V4 at day 0 was arbitrarily 





























































5.2 Silencing of Bcl-XL and Mcl-1 expression in Huh7.5 cells by RNA 
interference 
 To achieve efficient knockdown of gene expression in Huh7.5 cells, 
transient transfection of small interfering RNA (siRNA) specifically targeting 
Bcl-XL or Mcl-1 mRNA was performed.  Cells transfected with the 
corresponding negative control siRNA (siControl) were used for comparison.  
Preliminary experiments were performed to determine the optimal 
concentration of siRNA for knockdown (data not shown) and subsequently, 50 
nM of siBcl-XL and 10 nM of siMcl-1 were used in all experiments.  The 
efficiency of knockdown was analyzed by Western blotting every 48 h after 
transfection, up to 8 days post-transfection.  As shown in Figure 5.3A, the 
expression of Bcl-XL was completely silenced by 2 days post-transfection and 
this level of knockdown was maintained for the duration of the experiment.  
As for the siMcl-1-treated cells, substantial reduction in Mcl-1 expression was 
also observed by 2 days post-transfection (Figure 5.3B).  Although the Mcl-1 
level in the knockdown cells appeared to recover slightly 8 days after 
transfection, the level of Mcl-1 was considerably lower in siMcl-1-treated 
cells compared to the control throughout the experiment.  The expression of 
prosurvival Bcl-XL and Mcl-1 in the siControl-treated samples gradually 
decreased probably due to cell overgrowth and the subsequent onset of 
confluence-induced cell death (Chang et al., 2007). 
 Proliferation of the knockdown cells was determined as previously 
described.  As shown in Figures 5.3C and 5.3D, the growth rates of the Bcl-XL 
and Mcl-1 knockdown cells did not differ significantly from that of the control 
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cells.  Collectively, the stable clones and knockdown cells are suitable for 
examining the role of Bcl-XL and Mcl-1 in HCV-infected cells.  
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Fig. 5.3.  Efficient siRNA-mediated knockdown of Bcl-XL and Mcl-1 in Huh7.5 cells.  
The siRNAs directed against Bcl-XL (siBcl-XL) or Mcl-1 (siMcl-1) or their respective 
negative control siRNA (siControl) were transfected into Huh7.5 cells using 
Lipofectamine RNAiMAX reagent.  Cells were harvested at 2, 4, 6 and 8 days post-
transfection and the knockdown efficiency was examined by Western blot analysis 
using antibodies against (A) Bcl-XL and (B) Mcl-1.  The amounts of total cell lysates 
loaded were verified by measuring the level of endogenous actin.  Specific bands are 
indicated by arrows on the right and molecular masses of markers are indicated on the 
left.  Proliferation of the Bcl-XL (C) and Mcl-1 (D) knockdown cells (filled columns) 
was measured using WST-1 assay at 2, 4, 6 and 8 days post-transfection.  
Proliferation of siControl cells (empty columns) at day 2 was arbitrarily expressed as 




















































































































































































5.3 Role of Bcl-XL in HCV infection of Huh7.5 cells 
5.3.1 Overexpression of Bcl-XL confers protection against HCV-induced 
apoptosis and inhibits virus replication and production 
 Cells stably overexpressing Bcl-XL and control cells were infected 
with HCV and the proliferation and apoptosis status of the cells were 
examined up to 6 days post-infection (d.p.i.).  As shown in Figure 5.4A, the 
Bcl-XL stable cells exhibited more proliferation than the controls at 4 and 6 
d.p.i.  This increase in cell proliferation was preceded by a decrease in 
caspase-3 activation in the Bcl-XL stable cells compared to the control samples 
at 2 and 4 d.p.i. (Figure 5.4B).  Taken together, the data suggest that increased 
Bcl-XL expression can protect cells against HCV-induced apoptosis, at least in 
the very early stages of an acute HCV infection, and this led to increased cell 
proliferation/viability. 
 The effects of Bcl-XL overexpression on viral replication and virus 
production were also examined.  Quantitative real-time PCR analysis showed 
that the HCV RNA content was significantly reduced in the Bcl-XL stable 
cells compared to the controls from 2 to 6 d.p.i. (Figure 5.5A).  This suggests 
that Bcl-XL may regulate HCV RNA replication in a negative manner.  The 
Bcl-XL stable cells also produced considerably less progeny virus than the 
control cells in the same time frame post-infection (Figure 5.5B).  The 
decrease in virus production is probably due to reduced viral replication in the 
Bcl-XL stable cells.  However, it is tempting to speculate that the inhibition of 
HCV-induced apoptosis by Bcl-XL overexpression may also result in less 
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progeny virus since apoptosis has been postulated to be a mechanism for virus 
release. 
 To rule out the possibility of clonal variation, two different Bcl-XL 
stable clones (B60 and B69) and two control clones (V4 and V11) were used 
in these experiments.  As shown in Figures 5.4 and 5.5, B60 and B69 cells 
behaved in a similar manner in response to HCV infection, as did the V4 and 
V11 cells.  This implies that the observed differences between the Bcl-XL 
stable cells and the control cells were most likely due to the differential 
expression of Bcl-XL in these cells.    
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Fig. 5.4.  Cell proliferation and caspase-3 activity of Bcl-XL stable cells infected with 
HCV.  (A) Cell viability/proliferation was measured using WST-1 assay at 0, 2, 4 and 
6 days post-infection (d.p.i.).  (B) A Caspase-Glo 3/7 luminogenic assay system was 
used to measure the activation of caspase-3 in HCV-infected and mock-treated cells.  
Luminescence readings were normalised to cell numbers, as determined by WST-1 
assay.  Proliferation/caspase-3 activity of HCV-infected cells is expressed relative to 
the proliferation/caspase-3 activity of mock-treated cells (HCV/Mock) at each time 
point.  The proliferation/caspase-3 activity of V4 cells at 0 d.p.i. was arbitrarily 
expressed as 1.0 (data not shown).  Data shown are representative of three 
independent experiments and statistically significant differences between Bcl-XL 
stable clones (B60 and B69) and vector control cells (V4 and V11) at each time point 
































































































Fig. 5.5.  Viral RNA replication and virus production in HCV-infected Bcl-XL stable 
cells.  (A) Total RNA was isolated from HCV-infected cells at 2, 4 and 6 days post-
infection (d.p.i.) and reverse transcribed.  HCV RNA replication levels were 
determined by quantitative real-time PCR analysis and normalised to endogenous 
GAPDH levels.  (B) Culture supernatants of HCV-infected cells were collected at 2, 4 
and 6 d.p.i. and used to inoculate naive Huh7.5 cells.  Virus infectivity was 
determined at 24 h post-infection by indirect immunofluorescence analysis to detect 
HCV antigens using HCV-infected patient’s serum and FITC-conjugated goat anti-
human IgG.  Data shown are representative of three independent experiments and 
statistically significant differences between Bcl-XL stable clones (B60 and B69) and 








































































5.3.2 Depletion of Bcl-XL sensitizes cells to HCV-induced apoptosis and 
modulates virus replication and production 
 The expression of Bcl-XL in siBcl-XL-treated cells was monitored by 
Western blot analysis up to 6 d.p.i. (Figure 5.6A).  Consistent with our 
findings in Chapter 4.4, Bcl-XL expression was increased in HCV-infected 
cells compared to mock-treated cells.  This was true for both siBcl-XL and 
siControl-treated cells and was apparent at 4 and 6 d.p.i.  Despite the HCV-
induced upregulation of Bcl-XL, the level of Bcl-XL in the knockdown cells 
was still considerably lower than that in the control cells.  Hence, RNA 
interference can effectively suppress the HCV-induced upregulation of 
endogenous Bcl-XL.  Following HCV infection, the proliferation of the Bcl-XL 
knockdown cells was significantly lower than the control cells from 2 to 6 
d.p.i. (Figure 5.6B).  A corresponding increase in apoptosis induction was also 
observed in the Bcl-XL knockdown cells (Figure 5.6C).  In agreement with the 
findings of the Bcl-XL overexpression experiments, Bcl-XL appears to play a 
protective role against apoptosis in HCV-infected cells and thus, HCV-
induced apoptosis was enhanced in the absence of Bcl-XL.   
 Depletion of Bcl-XL reduced HCV RNA content slightly in Bcl-XL 
knockdown cells compared to the control (Figure 5.7A).  This inhibition of 
viral replication might be related to the high levels of apoptosis observed in 
Bcl-XL knockdown cells (Figure 5.6C).  Apoptosis is known to induce 
changes in cellular membranes and this possibly affected HCV RNA 
replication which is mainly localized to membranous webs in infected cells 
(Elazar et al., 2004).   An increase in progeny virus production was observed 
 139 
at 2 d.p.i. followed by slightly reduced virus production at 4 and 6 d.p.i. in 
Bcl-XL knockdown cells compared to control cells (Figure 5.7B).  This is 
consistent with our earlier observation that the enhanced apoptotic activity of 
the J6/JFH-1(V119L) mutant virus is correlated with an increase in infectious 
progeny HCV release (see Chapter 3).  As viral-induced apoptosis of the host 
cell may function to facilitate viral egress (Blaho, 2004), we postulate that the 
initial spike in virus production was due to enhanced apoptosis-dependent 
virus release.  Subsequently, the amount of virus released by the Bcl-XL 
knockdown sample was probably limited by the number of viable cells left and 
the reduced level of HCV RNA replication in these cells. 
 To address the difference in viable cell numbers in the Bcl-XL 
knockdown and control samples, the amount of virus produced per cell was 
determined by normalising the total virus infectivity titres to cell proliferation 
levels.  As shown in Figure 5.7C, each Bcl-XL knockdown cell produced more 
progeny virus than the control sample at all time points post-infection, albeit 
to a smaller degree at 4 and 6 d.p.i. than at 2 d.p.i.  These results show that the 
slight decrease in total virus production observed previously at 4 and 6 d.p.i. 
was indeed due to the smaller number of cells left in the Bcl-XL knockdown 
sample following extensive apoptosis (Figure 5.7B).  However despite the 
possibility of enhanced apoptosis-dependent virus release, the Bcl-XL 
knockdown sample only showed a small increase in virus infectivity per cell at 
4 and 6 d.p.i., indicating that viral replication is probably impaired in these 
cells.  This correlates with the lower level of viral RNA replication observed 
in the Bcl-XL knockdown cells (Figure 5.7A).  
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Fig. 5.6.  Protein expression, cell proliferation and caspase-3 activation in Bcl-XL 
knockdown cells infected with HCV.  (A) Whole cell lysates were prepared at 0, 2, 4 
and 6 days post-infection (d.p.i.) and subjected to Western blot analysis using 
antibodies against Bcl-XL and NS3.  The amounts of total cell lysates loaded were 
verified by measuring the level of endogenous GAPDH.  Specific bands are indicated 
by arrows on the right and molecular masses of markers are indicated on the left.  (B) 
Cell viability/proliferation of siBcl-XL-treated (filled columns) and siControl-treated 
(empty columns) cells was measured using WST-1 assay at 0, 2, 4 and 6 d.p.i.  (C) A 
Caspase-Glo 3/7 luminogenic assay system was used to measure the activation of 
caspase-3 in HCV-infected and mock-treated cells.  Luminescence readings were 
normalised to cell numbers, as determined by WST-1 assay.  Proliferation/caspase-3 
activity of HCV-infected cells is expressed relative to the proliferation/caspase-3 
activity of mock-treated cells (HCV/Mock) at each time point.  The 
proliferation/caspase-3 activity of siControl-treated cells at 0 d.p.i. was arbitrarily 
expressed as 1.0 (data not shown).  Data shown are representative of three 
independent experiments and statistically significant differences between siBcl-XL-
treated and siControl-treated cells at each time point are marked by asterisks (*P 


























































































































































































Fig. 5.7.  Viral RNA replication and virus production in HCV-infected Bcl-XL 
knockdown cells.  (A) Total RNA was isolated from HCV-infected siBcl-XL-treated 
(filled columns) and siControl-treated (empty columns) cells at 2, 4 and 6 days post-
infection (d.p.i.) and reverse transcribed.  HCV RNA replication levels were 
determined by quantitative real-time PCR analysis and normalised to endogenous 
GAPDH levels.  (B) Culture supernatants of HCV-infected cells were collected at 2, 4 
and 6 d.p.i. and used to inoculate naive Huh7.5 cells.  Virus infectivity was 
determined at 24 h post-infection by indirect immunofluorescence analysis to detect 
HCV antigens using HCV-infected patient’s serum and FITC-conjugated goat anti-
human IgG.  (C) The amount of virus produced per cell was determined by 
normalising the virus infectivity titres of the culture supernatants to cell proliferation 
levels as determined by WST-1 assay.  Data shown are representative of three 
independent experiments and statistically significant differences between siBcl-XL-









































































































siBcl-XL * * 
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5.4 Role of Mcl-1 in HCV infection of Huh7.5 cells 
5.4.1 Effects of Mcl-1 overexpression on HCV-induced apoptosis, HCV 
RNA replication and virus production 
 Cells overexpressing Mcl-1 (M34) exhibited more proliferation than 
control cells (V4) up to 6 days after HCV infection (Figure 5.8A).  This 
observation correlated with a decrease in caspase-3 activation in M34 cells 
compared to V4 cells at 2 and 4 d.p.i. (Figure 5.8B).  These data show that 
Mcl-1, like Bcl-XL, can confer protection against HCV-induced apoptosis 
during the early stages of infection.  The HCV RNA content was slightly 
lower in M34 cells than in V4 cells, suggesting that high Mcl-1 levels may to 
some extent inhibit viral RNA replication (Figure 5.8C).  A small decrease in 
the production of progeny virus was also observed in the M34 cells compared 
to the V4 cells, probably as a result of decreased viral RNA replication in the 
Mcl-1 stable cells (Figure 5.8D).  Unlike the Bcl-XL stable cells, only one 
suitable Mcl-1 stable clone was obtained in this study.  Thus, it is not possible 
to ascertain if the effects observed here are clone-specific.  
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Fig. 5.8.  Cell proliferation, caspase-3 activation, viral RNA replication and virus 
production in Mcl-1 stable cells infected with HCV.  (A) Cell viability/proliferation 
of Mcl-1 stable (M34; filled columns) and vector control (V4; empty columns) cells 
was measured using WST-1 assay at 0, 2, 4 and 6 days post-infection (d.p.i.).  (B) A 
Caspase-Glo 3/7 luminogenic assay system was used to measure the activation of 
caspase-3 in HCV-infected and mock-treated M34 and V4 cells.  Luminescence 
readings were normalised to cell numbers, as determined by WST-1 assay.  
Proliferation/caspase-3 activity of HCV-infected cells is expressed relative to the 
proliferation/caspase-3 activity of mock-treated cells (HCV/Mock) at each time point.  
The proliferation/caspase-3 activity of V4 cells at 0 d.p.i. was arbitrarily expressed as 
1.0 (data not shown).  (C) Total RNA was isolated from HCV-infected M34 and V4 
cells at 2, 4 and 6 d.p.i. and reverse transcribed.  HCV RNA replication levels were 
determined by quantitative real-time PCR analysis and normalised to endogenous 
GAPDH levels.  (D) Culture supernatants of HCV-infected cells were collected at 2, 
4 and 6 d.p.i. and used to inoculate naive Huh7.5 cells.  Virus infectivity was 
determined at 24 h post-infection by indirect immunofluorescence analysis to detect 
HCV antigens using HCV-infected patient’s serum and FITC-conjugated goat anti-
















































































































































5.4.2 Depletion of Mcl-1 has no significant impact on HCV-induced 
apoptosis, HCV RNA replication and virus production 
 Similar to the observation previously made in wild-type Huh7.5 cells, 
HCV infection did not alter the expression of Mcl-1 in siControl-treated cells 
(Figure 5.9A).  The knockdown of Mcl-1 expression had no effect on cell 
proliferation as well as apoptosis induction in HCV-infected samples (Figures 
5.9B and 5.9C).  This is rather surprising as we previously found that Mcl-1 
overexpression protected HCV-infected cells against apoptosis, suggesting a 
role for it in HCV-induced apoptosis.  A possible explanation for this disparity 
is that while Mcl-1 can contribute to the inhibition of HCV-induced apoptosis, 
other host factors with similar functions may also be involved and they may be 
able to compensate for the loss of Mcl-1 prosurvival activity in the siMcl-1-
treated cells.  As shown in Figure 5.10A, depletion of Mcl-1 did not affect 
viral RNA replication in the infected cells.  Similarly, the production of 
progeny virus in Mcl-1 knockdown and control cells did not vary significantly 
(Figure 5.10B).  Taken together, the findings of Mcl-1 overexpression and 
depletion on HCV infection have shown that aside from its ability to confer 
protection against HCV-induced apoptosis, Mcl-1 does not appear to play a 
major role in the early acute phase of HCV infection. 
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Fig. 5.9.  Protein expression, cell proliferation and caspase-3 activity of Mcl-1 
knockdown cells infected with HCV.  (A) Whole cell lysates were prepared at 0, 2, 4 
and 6 days post-infection (d.p.i.) and subjected to Western blot analysis using 
antibodies against Mcl-1 and core.  The amounts of total cell lysates loaded were 
verified by measuring the level of endogenous actin.  Specific bands are indicated by 
arrows on the right and molecular masses of markers are indicated on the left.  (B) 
Cell viability/proliferation of siMcl-1-treated (filled columns) and siControl-treated 
(empty columns) cells was measured using WST-1 assay at 0, 2, 4 and 6 d.p.i.  (C) A 
Caspase-Glo 3/7 luminogenic assay system was used to measure the activation of 
caspase-3 in HCV-infected and mock-treated cells.  Luminescence readings were 
normalised to cell numbers, as determined by WST-1 assay.  Proliferation/caspase-3 
activity of HCV-infected cells is expressed relative to the proliferation/caspase-3 
activity of mock-treated cells (HCV/Mock) at each time point.  The 
proliferation/caspase-3 activity of siControl-treated cells at 0 d.p.i. was arbitrarily 
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Fig. 5.10.  Viral RNA replication and virus production in HCV-infected Mcl-1 
knockdown cells.  (A) Total RNA was isolated from HCV-infected siMcl-1-treated 
(filled columns) and siControl-treated (empty columns) cells at 2, 4 and 6 days post-
infection (d.p.i.) and reverse transcribed.  HCV RNA replication levels were 
determined by quantitative real-time PCR analysis and normalised to endogenous 
GAPDH levels.  (B) Culture supernatants of HCV-infected cells were collected at 2, 4 
and 6 d.p.i. and used to inoculate naive Huh7.5 cells.  Virus infectivity was 
determined at 24 h post-infection by indirect immunofluorescence analysis to detect 
HCV antigens using HCV-infected patient’s serum and FITC-conjugated goat anti-


































































 In Chapter 4, we demonstrated that HCV induces the upregulation of 
Bcl-XL in infected Huh7.5 cells.  Prosurvival factor Bcl-XL is constitutively 
expressed in the liver and acts as a critical apoptosis antagonist in hepatocytes 
(Takehara et al., 2004).  It has been postulated that apoptosis inhibition may be 
beneficial for viruses as premature host cell death prevents completion of the 
viral replication cycle.  Hence, many viruses have evolved anti-apoptotic 
strategies such as the expression of viral homologues of Bcl-2 in order to 
counteract altruistic host cell suicide, prolong the survival of infected cells and 
maximise progeny virus production [see reviews by (Cuconati and White, 
2002; Hardwick and Bellows, 2003; Polster et al., 2004; White, 2006)].  On 
the other hand, other studies have shown that suppression of virus-induced 
apoptosis through the overexpression of host prosurvival proteins such as Bcl-
2 and Bcl-XL may inhibit the propagation of several other viruses via the 
modulation of NF-κB activity, viral glycosylation or viral release (Carthy et 
al., 2003; Marshall et al., 1999; Olsen et al., 1996; Scallan et al., 1997). 
 In the present study, we investigated the role of HCV-induced Bcl-XL 
upregulation in infected cells.  Using stable overexpression and gene silencing 
systems, we demonstrated that Bcl-XL can modulate HCV-induced apoptosis, 
viral RNA replication and progeny virus production.  Consistent with its 
protective role against apoptosis, high levels of Bcl-XL expression inhibited 
HCV-induced apoptosis in infected stable cells (Figure 5.4B).  Interestingly, a 
decrease in viral RNA replication was also observed in the infected Bcl-XL 
stable cells (Figure 5.5A).  In addition to apoptosis inhibition, Bcl-XL has been 
 148 
reported to inhibit autophagy through direct interaction with Beclin-1, a BH3-
only protein and essential mediator of autophagy (Maiuri et al., 2007a; Maiuri 
et al., 2007b).  Autophagy has been observed in HCV-infected hepatocytes 
and components of the autophagy machinery have been shown to be essential 
for initiating HCV replication (Dreux et al., 2009; Ke and Chen, 2011; Sir et 
al., 2008).  Therefore, enhanced Bcl-XL expression in the stable cells possibly 
impaired viral replication through the inhibition of Beclin-1-mediated 
autophagy.  In addition, the Bcl-XL stable cells also produced less infectious 
progeny virus compared to the control (Figures 5.5B).  Reduced apoptosis-
dependent virus release and impaired viral replication in the Bcl-XL stable 
cells probably contributed to this decrease in virus production.  The two 
independent Bcl-XL stable clones (B60 and B69) that were examined in this 
study gave similar results, implying that the observations were directly due to 
the higher Bcl-XL levels in these cells. 
 In agreement with the inhibition of apoptosis by Bcl-XL 
overexpression, depletion of Bcl-XL enhanced apoptosis induction in HCV-
infected cells (Figure 5.6C).  Collectively, these data provide further evidence 
that HCV-induced apoptosis in vitro is largely mediated via the mitochondrial 
apoptosis pathway, which can be antagonized or potentiated by the 
overexpression or depletion of certain prosurvival Bcl-2 members respectively 
(Wong and Puthalakath, 2008).  Enhanced apoptosis in the HCV-infected Bcl-
XL knockdown cells affected both viral RNA replication and subsequent 
progeny virus production.  Extensive cellular changes during apoptosis 
probably affected the HCV replication sites, thus resulting in decreased viral 
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RNA content in the Bcl-XL knockdown cells (Figure 5.7A).  In addition, high 
apoptosis levels promoted progeny virus release initially but also reduced the 
number of viable cells substantially (Figures 5.6B, 5.6C and 5.7B).  The latter 
probably accounts for the decrease in total virus production observed at 4 and 
6 d.p.i., even as the apoptosis level remained elevated (Figure 5.6C and 5.7B).  
In agreement with this, when cell numbers in the culture were taken into 
account, each Bcl-XL knockdown cell was found to produce more virus than 
the control at all time points post-infection, although virus production at the 
later time points appeared to be limited by other factors such as viral RNA 
replication (Figure 5.7C). 
 Taken together, our findings demonstrate that high levels of Bcl-XL 
expression in HCV-infected cells are unfavourable for virus propagation and 
thus, the upregulation of endogenous Bcl-XL in infected cells may constitute 
an “antiviral” response.  In this connection, Bcl-XL upregulation may also 
serve to protect host cells against extensive HCV-induced apoptosis.  On the 
other hand, HCV-induced upregulation of Bcl-XL in infected cells may be 
beneficial for the virus.  We postulate that Bcl-XL upregulation may function 
to moderate the direct cytopathic effects of HCV in infected cells by blocking 
the intrinsic apoptosis pathway with the aim of maximising progeny virus 
production.  Our data suggest that Bcl-XL may also be involved in regulating 
HCV RNA replication (Figure 5.5A).  This presents a possible additional 
pathway for modulating HCV-induced apoptosis as viral replication is closely 
associated with apoptosis induction (Zhu et al., 2007).  Furthermore, 
prosurvival Bcl-2 members, namely Bcl-2 and Bcl-XL, have been shown to 
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confer protection against Fas-mediated hepatic apoptosis (de la Coste et al., 
1999; Lacronique et al., 1996).  Thus, during an in vivo infection, the elevated 
Bcl-XL levels may serve to protect HCV-infected cells against death receptor-
mediated killing by cytotoxic lymphocytes, leading to evasion of host immune 
responses and viral persistence. 
 Interestingly, Bcl-XL is frequently overexpressed and confers 
resistance to apoptosis in hepatocellular carcinoma (Takehara et al., 2001; 
Watanabe et al., 2002; Zhao et al., 2011).  Although the link between HCV-
induced Bcl-XL upregulation and HCV-related hepatocellular carcinoma 
(HCC) is still unclear, Bcl-XL expression appears to correlate with the 
presence of HCV in tumour cells (Zekri et al., 2011).  Transcriptional 
regulation of Bcl-XL expression has been reported to be mediated by members 
of the STAT, Rel/NF-κB, Ets and AP-1 transcription factor families [reviewed 
by (Grad et al., 2000; Sevilla et al., 2001)].  Modulation of these pathways by 
HCV might contribute to Bcl-XL upregulation since we previously showed 
that Bcl-XL was regulated at the transcriptional level during HCV infection 
(Figure 4.5).  In relation to this, HCV has previously been shown to interfere 
with the Rel/NF-κB and Jak-STAT pathways (Blindenbacher et al., 2003; 
Heim et al., 1999; Tai et al., 2000).  Of particular interest is the modulation of 
the STAT3 signalling pathway by HCV as it has been implicated in both the 
core protein-mediated and NS5A-mediated upregulation of Bcl-XL expression 
(Sarcar et al., 2004; Yoshida et al., 2002). 
 In addition to Bcl-XL, prosurvival Mcl-1 is also expressed in the liver 
and protects differentiated hepatocytes against apoptosis (Hikita et al., 2009).  
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As shown in Chapter 4, unlike Bcl-XL, the expression of Mcl-1 remained 
unchanged in HCV-infected cells, indicating a lack of role for Mcl-1 in HCV 
infection.  However, the overexpression of Mcl-1 conferred protection against 
HCV-induced apoptosis and slightly reduced viral RNA replication and 
progeny virus production, which is similar to the observations made with Bcl-
XL stable cells although to a smaller extent (Figure 5.8).  Unfortunately, the 
effects of Mcl-1 overexpression were examined using only one Mcl-1 stable 
clone, thus the possibility of clone-specific effects cannot be ruled out.  The 
lack of any observable effects of Mcl-1 silencing on host cell apoptosis, viral 
RNA replication and progeny virus production further suggests that the Mcl-1 
overexpression results may be unreliable (Figures 5.9 and 5.10).  Overall, the 
data suggest that, compared to Bcl-XL, Mcl-1 does not play a major role in our 
HCV genotype 2a infection system.  This correlates with the findings 
discussed in Chapter 3 which show that endogenous Mcl-1 does not interact 
with the BH3 domain of the HCV genotype 2a core protein and thus, does not 
contribute to core protein-induced apoptosis. 
 This study highlights the importance of viral-induced apoptosis in 
acute HCV infection.  When host cell apoptosis is suppressed, viral 
propagation is impaired and thus, HCV circumvents this problem by directly 
inducing apoptosis in the infected cells (Deng et al., 2008; Kannan et al., 
2011; Mateu et al., 2008; Walters et al., 2009).  However, rapid and excessive 
host cell death is also unfavourable for the virus as it results in insufficient 
time and opportunities for the virus to complete its replication cycle.  In 
accordance with this, a recent study on the hepatitis B virus (HBV) 
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demonstrated an inverse relationship between the degree of host cell apoptosis 
and the release of infectious virus particles (Arzberger et al., 2010).  
Therefore, a fine balance between cell survival and apoptosis and/or the timing 
of apoptosis induction is critical for HCV infection.  
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CHAPTER 6: CONCLUSION AND FUTURE DIRECTIONS 
 Apoptosis of hepatocytes is a prominent feature of viral hepatitis C and 
is thought to be a major contributing factor towards HCV-induced liver injury.  
Induction of apoptosis in virus-infected cells may be a host response to 
eliminate the virus or a viral strategy to promote virus dissemination.  
Evaluation of liver tissue samples from patients chronically infected with 
HCV has thus far provided most of the in vivo evidence for apoptosis in HCV 
infection (Fischer et al., 2007).  However, due to the lack of adequate animal 
models and the limited availability of biopsy material, the functional role of 
apoptosis during HCV infection and the molecular mechanisms underlying 
apoptosis induction remain unclear. 
 Using overexpression systems, there have been numerous attempts to 
define the potential roles of individual HCV proteins in regulating host cell 
apoptosis.  However, conflicting apoptotic properties have been described for 
most of the viral proteins, probably due to differences in the experimental 
conditions, HCV genotypes, cell types and apoptotic stimuli used [reviewed 
by (Fischer et al., 2007)].  Moreover, the overexpression of proteins in these 
studies is incongruent with the very low levels of viral proteins usually 
expressed in HCV-infected patients.  Taking these into consideration, 
interpretation of the currently available data in relation to possible events 
occurring in a natural infection is restricted. 
 Recently, in vitro infection studies using the JFH-1-based cell culture 
system have demonstrated HCV-induced apoptosis of infected hepatoma cells 
(Deng et al., 2008; Mateu et al., 2008).  Subsequently, this infection system 
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has been used to perform genome-wide analysis of changes in host gene 
expression following HCV infection (Blackham et al., 2010; Liu et al., 2010; 
Walters et al., 2009).  These studies provide a general overview as to which 
cellular pathways are likely to be modulated during acute HCV infection and 
among others, differential expression of apoptosis-related mRNAs and 
miRNAs was observed in HCV-infected cells.  However, specific viral-host 
interactions that are involved in regulating apoptosis have not yet been clearly 
defined.   
 There is increasing evidence to suggest that hepatocyte apoptosis is an 
important mechanism in HCV-induced liver disease [reviewed by (Mengshol 
et al., 2007)].  Therefore, apoptotic signalling pathways may provide new 
targets for the treatment of hepatitis C.  In relation to this, a clinical study 
demonstrated that the administration of ursodeoxycholic acid, an antiapoptotic 
agent, improved the response rate to IFN-α therapy in patients chronically 
infected with HCV who were initially unresponsive to IFN-α treatment alone 
(Fabbri et al., 2000).  Further characterization of the molecular mechanisms 
governing HCV-associated apoptosis may lead to the identification of specific 
targets for potential antiviral therapy and open up challenging possibilities for 
the development of novel pharmacological strategies to eradicate HCV 
infection. 
 The research efforts described in this thesis attempt to gain a better 
understanding of the viral-host interactions that contribute to HCV-associated 
apoptosis.  Our study focused on the identification and characterization of 
interactions between apoptosis-related host proteins and viral factors using 
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both cell culture overexpression and HCVcc systems.  The findings of our 
study are summarized below: 
a) It was demonstrated that the HCV genotype 1b core protein contains a 
functional BH3 domain that is essential for the induction of apoptosis 
in core protein-expressing Huh7 cells. 
b) Coimmunoprecipitation experiments showed that the BH3 domain of 
the genotype 1b core protein mediates specific interaction with human 
Mcl-1. 
c) Genotype 1b core protein-induced apoptosis was demonstrated to be 
dependent on the expression of proapoptotic Bax and inhibited by the 
overexpression of prosurvival Mcl-1 or Bcl-XL.  This provides further 
evidence that the genotype 1b core protein acts via the intrinsic 
apoptosis pathway. 
d) Similar to the complementation between BH3-only proteins Noxa and 
Bad, the genotype 1b core protein was shown to functionally 
complement Bad, resulting in enhanced mitochondrial cytochrome c 
release and apoptosis. 
e) Site-directed mutagenesis analysis showed that the three hydrophobic 
residues in the BH3 domain of the genotype 1b core protein are 
essential for apoptosis induction. 
f) The ability of the genotype 1b core protein to induce more apoptosis 
than the genotype 2a core protein was shown to be due to an amino 
acid difference in one of these hydrophobic residues (residue 119). 
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g) It was demonstrated that a single amino acid substitution from V to L 
at residue 119 in the core protein of the HCV J6/JFH-1 strain 
(genotype 2a) correlates with its ability to interact with endogenous 
Mcl-1 and to induce higher levels of apoptosis in infected cells.  This 
was also accompanied by enhanced progeny virus release. 
h) Using the HCVcc system, HCV J6/JFH-1-P47 strain was shown to 
efficiently induce apoptosis in Huh7.5 cells during acute infection. 
i) Gene expression analysis of apoptosis-related genes revealed that HCV 
J6/JFH-1-P47 infection of Huh7.5 cells induces upregulation of BIK, 
FAS, GADD45A and HRK and downregulation of BNIP3. 
j) The expression levels of Bcl-XL mRNA and protein were shown to be 
elevated in HCV J6/JFH-1-P47-infected Huh7.5 cells. 
k) When the level of Bcl-XL in infected cells was further increased by 
stable transfection, there was a reduction in HCV J6/JFH-1-P47-
induced apoptosis, viral RNA replication and progeny virus release. 
l) When the upregulation of Bcl-XL in infected cells was prevented by 
RNA interference, HCV-J6/JFH-1-P47-infected cells displayed higher 
levels of apoptosis and an initial increase in progeny virus release. 
m) However, enhanced apoptosis also resulted in a reduction in the 
number of viable cells and lower viral RNA replication was observed. 
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n) In contrast to Bcl-XL, the expression of Mcl-1 was not affected by 
HCV J6/JFH-1-P47 infection and the knockdown of Mcl-1 had 
minimal effects on virus-induced apoptosis and viral replication. 
 In this study, we have demonstrated that the genotype 1b core protein 
is a novel BH3-only viral homologue that contributes to the induction of 
apoptosis during HCV infection by mimicking Noxa and interfering with the 
prosurvival function of Mcl-1 (Mohd-Ismail et al., 2009).  These findings 
present one of the mechanisms possibly employed by the virus to regulate 
apoptosis in infected cells.  Comparison of the BH3 domains of the genotype 
1b and 2a core proteins revealed genotypic differences in core protein-induced 
apoptosis.  Consequently, modification of the J6/JFH-1 genotype 2a virus 
through a substitution at residue 119 of the core protein produced a mutant 
virus [J6/JFH-1(V119L)] that induced higher levels of apoptosis and showed 
enhanced release of progeny virus from infected cells, indicating that 
apoptosis can be advantageous for viral spreading at the late stages of 
infection. 
 Despite lacking a functional BH3 domain in the core protein, the 
J6/JFH-1 genotype 2a virus still induced considerable apoptosis, thus 
indicating the presence of alternative pathways of HCV-induced apoptosis.  
Using gene expression analysis, we have identified five host apoptosis-related 
genes (BIK, BNIP3, FAS, GADD45A and HRK) that may be involved in 
these pathways.  Although HRK mRNA level was found to be highly 
upregulated by HCV, this upregulation was not observed at the protein level, 
suggesting that HRK is unlikely to be important in HCV infection.  While the 
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mRNA levels of the other four genes, which are involved in both the intrinsic 
and extrinsic apoptosis pathways, are strongly up- or down-regulated by HCV, 
the corresponding changes at protein level have to be confirmed in further 
studies.  Then, further investigations are needed to determine their role in 
HCV-induced apoptosis and the mechanism of their regulation by viral 
proteins, as well as the specific apoptotic pathways possibly modulated by 
HCV. 
 In addition, we observed that HCV infection also significantly 
upregulates Bcl-XL expression on the mRNA and protein levels in a time-
dependent manner.  The change in Bcl-XL expression during HCV infection 
seems to keep the cells in a finely balanced state as HCV-induced apoptosis is 
consistently antagonized or potentiated by the overexpression or depletion of 
Bcl-XL.  Consistent with the J6/JFH-1(V119L) virus described above, there is 
a direct correlation between the level of apoptosis and release of progeny virus 
from infected cells.  However, the reduction in viable cell number and cellular 
changes that are caused by premature apoptosis negatively impacted viral 
replication and total virus production, which suggests that HCV-induced 
upregulation of Bcl-XL in infected cells may be beneficial for the virus. 
 Future studies are required to identify the viral factor(s) that contribute 
to HCV-induced Bcl-XL upregulation, the molecular mechanisms of Bcl-XL-
mediated regulation of HCV infection and the interplay with other host factors 
such as the apoptosis-related genes that we have identified to be 
transcriptionally regulated by HCV.  It will also be interesting to determine if 
HCV-induced Bcl-XL upregulation is conserved across different HCV 
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genotypes and if it possibly contributes to hepatocarcinogenesis since Bcl-XL 
has been found to be frequently overexpressed in HCC.  Lastly, our findings 
provide interesting insights into HCV subversion of cellular apoptotic 
pathways and suggest that a fine balance between cell survival and apoptosis 
has to be achieved during acute infection.  Further understanding of this 
phenomenon, particularly in relation to chronic infection and clinical 
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Appendix 1: Gene table of the Human Apoptosis RT
2
 Profiler PCR Array 
Position Unigene GeneBank Symbol Description 
A01 Hs.431048 NM_005157 ABL1 C-abl oncogene 1, receptor tyrosine kinase 
A02 Hs.525622 NM_005163 AKT1 V-akt murine thymoma viral oncogene homolog 1 
A03 Hs.552567 NM_001160 APAF1 Apoptotic peptidase activating factor 1 
A04 Hs.370254 NM_004322 BAD BCL2-associated agonist of cell death 
A05 Hs.377484 NM_004323 BAG1 BCL2-associated athanogene 
A06 Hs.523309 NM_004281 BAG3 BCL2-associated athanogene 3 
A07 Hs.194726 NM_004874 BAG4 BCL2-associated athanogene 4 
A08 Hs.485139 NM_001188 BAK1 BCL2-antagonist/killer 1 
A09 Hs.624291 NM_004324 BAX BCL2-associated X protein 
A10 Hs.193516 NM_003921 BCL10 B-cell CLL/lymphoma 10 
A11 Hs.150749 NM_000633 BCL2 B-cell CLL/lymphoma 2 
A12 Hs.227817 NM_004049 BCL2A1 BCL2-related protein A1 
B01 Hs.516966 NM_138578 BCL2L1 BCL2-like 1 
B02 Hs.283672 NM_020396 BCL2L10 BCL2-like 10 (apoptosis facilitator) 
B03 Hs.469658 NM_006538 BCL2L11 BCL2-like 11 (apoptosis facilitator) 
B04 Hs.410026 NM_004050 BCL2L2 BCL2-like 2 
B05 Hs.486542 NM_014739 BCLAF1 BCL2-associated transcription factor 1 
B06 Hs.435556 NM_016561 BFAR Bifunctional apoptosis regulator 
B07 Hs.591054 NM_001196 BID BH3 interacting domain death agonist 
B08 Hs.475055 NM_001197 BIK BCL2-interacting killer (apoptosis-inducing) 
206 
 
Position Unigene GeneBank Symbol Description 
B09 Hs.710305 NM_004536 NAIP NLR family, apoptosis inhibitory protein 
B10 Hs.696238 NM_001166 BIRC2 Baculoviral IAP repeat-containing 2 
B11 Hs.127799 NM_001165 BIRC3 Baculoviral IAP repeat-containing 3 
B12 Hs.356076 NM_001167 XIAP X-linked inhibitor of apoptosis 
C01 Hs.150107 NM_016252 BIRC6 Baculoviral IAP repeat-containing 6 
C02 Hs.348263 NM_033341 BIRC8 Baculoviral IAP repeat-containing 8 
C03 Hs.145726 NM_001205 BNIP1 BCL2/adenovirus E1B 19kDa interacting protein 1 
C04 Hs.646490 NM_004330 BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2 
C05 Hs.144873 NM_004052 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 
C06 Hs.131226 NM_004331 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 
C07 Hs.550061 NM_004333 BRAF V-raf murine sarcoma viral oncogene homolog B1 
C08 Hs.405153 NM_006092 NOD1 Nucleotide-binding oligomerization domain containing 1 
C09 Hs.200242 NM_032587 CARD6 Caspase recruitment domain family, member 6 
C10 Hs.446146 NM_014959 CARD8 Caspase recruitment domain family, member 8 
C11 Hs.2490 NM_033292 CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) 
C12 Hs.5353 NM_001230 CASP10 Caspase 10, apoptosis-related cysteine peptidase 
D01 Hs.466057 NM_012114 CASP14 Caspase 14, apoptosis-related cysteine peptidase 
D02 Hs.368982 NM_032982 CASP2 Caspase 2, apoptosis-related cysteine peptidase 
D03 Hs.141125 NM_004346 CASP3 Caspase 3, apoptosis-related cysteine peptidase 
D04 Hs.138378 NM_001225 CASP4 Caspase 4, apoptosis-related cysteine peptidase 
D05 Hs.213327 NM_004347 CASP5 Caspase 5, apoptosis-related cysteine peptidase 
D06 Hs.654616 NM_032992 CASP6 Caspase 6, apoptosis-related cysteine peptidase 
D07 Hs.9216 NM_001227 CASP7 Caspase 7, apoptosis-related cysteine peptidase 
D08 Hs.599762 NM_001228 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
D09 Hs.329502 NM_001229 CASP9 Caspase 9, apoptosis-related cysteine peptidase 
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Position Unigene GeneBank Symbol Description 
D10 Hs.472860 NM_001250 CD40 CD40 molecule, TNF receptor superfamily member 5 
D11 Hs.592244 NM_000074 CD40LG CD40 ligand 
D12 Hs.390736 NM_003879 CFLAR CASP8 and FADD-like apoptosis regulator 
E01 Hs.249129 NM_001279 CIDEA Cell death-inducing DFFA-like effector a 
E02 Hs.642693 NM_014430 CIDEB Cell death-inducing DFFA-like effector b 
E03 Hs.38533 NM_003805 CRADD CASP2 and RIPK1 domain containing adaptor with death domain 
E04 Hs.380277 NM_004938 DAPK1 Death-associated protein kinase 1 
E05 Hs.484782 NM_004401 DFFA DNA fragmentation factor, 45kDa, alpha polypeptide 
E06 Hs.86131 NM_003824 FADD Fas (TNFRSF6)-associated via death domain 
E07 Hs.244139 NM_000043 FAS Fas (TNF receptor superfamily, member 6) 
E08 Hs.2007 NM_000639 FASLG Fas ligand (TNF superfamily, member 6) 
E09 Hs.80409 NM_001924 GADD45A Growth arrest and DNA-damage-inducible, alpha 
E10 Hs.87247 NM_003806 HRK Harakiri, BCL2 interacting protein (contains only BH3 domain) 
E11 Hs.643120 NM_000875 IGF1R Insulin-like growth factor 1 receptor 
E12 Hs.36 NM_000595 LTA Lymphotoxin alpha (TNF superfamily, member 1) 
F01 Hs.1116 NM_002342 LTBR Lymphotoxin beta receptor (TNFR superfamily, member 3) 
F02 Hs.632486 NM_021960 MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 
F03 Hs.513667 NM_003946 NOL3 Nucleolar protein 3 (apoptosis repressor with CARD domain) 
F04 Hs.499094 NM_013258 PYCARD PYD and CARD domain containing 
F05 Hs.103755 NM_003821 RIPK2 Receptor-interacting serine-threonine kinase 2 
F06 Hs.241570 NM_000594 TNF Tumor necrosis factor (TNF superfamily, member 2) 
F07 Hs.591834 NM_003844 TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 
F08 Hs.521456 NM_003842 TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b 
F09 Hs.81791 NM_002546 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b 
F10 Hs.279594 NM_001065 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 
208 
 
Position Unigene GeneBank Symbol Description 
F11 Hs.443577 NM_014452 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 
F12 Hs.462529 NM_003790 TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 
G01 Hs.355307 NM_001242 CD27 CD27 molecule 
G02 Hs.654459 NM_001561 TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 
G03 Hs.478275 NM_003810 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 
G04 Hs.501497 NM_001252 CD70 CD70 molecule 
G05 Hs.654445 NM_001244 TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 
G06 Hs.654481 NM_000546 TP53 Tumor protein p53 
G07 Hs.523968 NM_005426 TP53BP2 Tumor protein p53 binding protein, 2 
G08 Hs.697294 NM_005427 TP73 Tumor protein p73 
G09 Hs.460996 NM_003789 TRADD TNFRSF1A-associated via death domain 
G10 Hs.522506 NM_021138 TRAF2 TNF receptor-associated factor 2 
G11 Hs.510528 NM_003300 TRAF3 TNF receptor-associated factor 3 
G12 Hs.8375 NM_004295 TRAF4 TNF receptor-associated factor 4 
H01 Hs.534255 NM_004048 B2M Beta-2-microglobulin 
H02 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
H03 Hs.523185 NM_012423 RPL13A Ribosomal protein L13a 
H04 Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
H05 Hs.520640 NM_001101 ACTB Actin, beta 
H06 N/A SA_00105 HGDC Human Genomic DNA Contamination 
H07-H09 N/A SA_00104 RTC Reverse Transcription Control 
H10-H12 N/A SA_00103 PPC Positive PCR Control 
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A11 BCL2 B-cell CLL/lymphoma 2 
B11 BIRC3 Baculoviral IAP repeat-containing 3 
C02 BIRC8 Baculoviral IAP repeat-containing 8 
C11 CASP1 
Caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
D01 CASP14 Caspase 14, apoptosis-related cysteine peptidase 
D08 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
D10 CD40 CD40 molecule, TNF receptor superfamily member 5 
D11 CD40LG CD40 ligand 
E01 CIDEA Cell death-inducing DFFA-like effector a 
E08 FASLG Fas ligand (TNF superfamily, member 6) 
E12 LTA Lymphotoxin alpha (TNF superfamily, member 1) 
F04 PYCARD PYD and CARD domain containing 
F06 TNF Tumor necrosis factor (TNF superfamily, member 2) 
G01 CD27 CD27 molecule 
G02 TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 
G04 CD70 CD70 molecule 
G05 TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 
G08 TP73 Tumor protein p73 
G11 TRAF3 TNF receptor-associated factor 3 
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Appendix 3: Additional differentially expressed apoptosis-related genes 
in HCV-infected Huh7.5 cells 





C06 BNIP3L -2.45 0.04 
D05 CASP5 2.26 0.009 
E02 CIDEB -7.32 0.006 
F11 TNFRSF21 2.17 0.02 
F12 TNFRSF25 -2.26 0.03 
G03 TNFSF10 -3.34 0.004 
a
 Average fold changes of at least 2-fold observed at 6 days post-infection are listed. 
b
 P values of less than 0.05 are considered to be statistically significant. (n = 3) 
